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During	  my	  PhD	  fellowship,	  I	  focused	  on	  the	  role	  of	  Diacylglycerol	  kinase	  alpha	  (DGKα)	  in	  defining	  
the	   cell	   morphology	   [1]	   and	   in	   modulating	   the	   signal	   transduction	   in	   both	   T	   lymphocytes	   and	  
epithelial	  cells.	  Also,	  I	  contributed	  to	  the	  characterization	  of	  the	  antitumoral	  activities	  of	  ICOS	  on	  
transformed	  epithelial	  cells	  [2].	  
In	  this	  thesis	  I	  reported	  my	  main	  PhD	  project,	  which	  was	  a	  part	  of	  an	  international	  collaboration	  
aimed	  to	  understand	  the	  role	  of	  DGKα	   in	  the	  modulation	  of	  TCR-­‐induced	  diacylglycerol	  signaling	  
and	   in	   the	   pathogenesis	   of	   X-­‐linked	   lymphoproliferative	   disease	   1	   (XLP1).	   The	   following	   units	  
contributed	  in	  the	  data	  presented	  in	  this	  thesis:	  i)	  Dr.	  A.L.	  Snow	  (USUSH,	  Bethesda)	  for	  studies	  on	  
XLP1-­‐derived	   T	   lymphocytes,	   ii)	   Dr.	   K.E.	   Nichols,	   MD	   (St.	   Jude	   Children's	   Research	   Hospital,	  
Memphis)	  for	  animal	  model	  of	  XLP1	  and	  iii)	  Dr.	  I.	  Rubio	  (CMB,	  Jena)	  who	  hosted	  me	  to	  carry	  out	  




X-­‐linked	  lymphoproliferative	  disease	  (XLP1)	  is	  a	  rare	  primary	  immunodeficiency	  associated	  with	  an	  
unconstrained,	   life-­‐threatening	   expansion	   of	   CD8+	   T	   cells	   following	   Epstein-­‐Barr	   virus	   (EBV)	  
infection.	  XLP1	  is	  caused	  by	  mutations	  in	  SAP,	  an	  adaptor	  protein	  that	  mediates	  signaling	  through	  
the	  SLAM	  family	  receptors.	  SAP-­‐deficient	  cells	  exhibit	  impaired	  T	  cell	  receptor	  (TCR)	  restimulation-­‐
induced	  cell	  death	  (RICD),	  a	  key	  physiological	  process	  in	  maintaining	  lymphocyte	  homeostasis.	  	  We	  
previously	   showed	   that	   SAP	   has	   a	   critical	   role	   in	   TCR-­‐induced	   inhibition	   of	   diacylglycerol	   kinase	  
alpha	  (DGKα),	  which	  phosphorylates	  diacylglycerol	   (DAG)	  to	  phosphatidic	  acid,	  acting	  as	  a	  major	  
regulator	  of	  T	  cell	  signaling.	  Here,	  we	  show	  that	  in	  SAP-­‐deficient	  Jurkat	  cells,	  DGKα	  activity	  impairs	  
immune	  synapse	  (IS)	  formation,	  MTOC	  reorientation	  and	  affects	  the	  integrity	  of	  DAG	  gradient.	  By	  
taking	   advantage	   of	   confocal	   live-­‐cell	   imaging,	   we	   found	   that	   RNAi-­‐mediated	   silencing	   or	  
pharmacological	  inhibition	  of	  DGKα	  in	  SAP-­‐deficient	  cells	  rescues	  both	  immune	  synapse	  formation	  
and	  MTOC	  repositioning,	  and	  the	  subsequent	  DAG	  accumulation	  at	  the	  IS.	   Inhibition/silencing	  of	  
DGKα	  was	   also	   sufficient	   to	   restore	   PKCθ	   and	  RasGRP1	   recruitment	   at	   the	   immune	   synapse,	   as	  
well	   as	   ERK1/2	   activation	   and	   IL-­‐2	   production/IL-­‐2	   receptor	   membrane	   exposure	   in	   SAP	  
knockdown	  primary	  T	  cells.	  Notably,	  DGKα	  blockade	  specifically	   reestablished	  RICD	   in	  both	  SAP-­‐
silenced	  cells	  and	  XLP1	  patients’	  T	  cells	  by	  restoring	  RSK-­‐mediated	  induction	  and	  phosphorylation	  
of	  the	  pro-­‐apoptotic	  genes	  Nur77	  and	  Nor1.	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Furthermore,	  in	  vivo	  inhibition	  of	  DGKα	  prevented	  aberrant	  CD8+	  T	  cell	  expansion,	  TNFα	  and	  IFNγ	  
production	   as	   well	   as	   tissue	   infiltration	   in	   Lymphocytic	   Choriomeningitis	   Virus-­‐infected	   SAP	   KO	  
mice,	  a	  mouse	  model	  of	  XLP1.	  
Altogether,	  these	  data	  demonstrates	  that	  DGKα	  inhibition,	  by	  increasing	  localized	  DAG	  signaling	  at	  
the	  IS,	  restores	  RICD	  in	  SAP	  deficient	  cells.	  In	  vivo,	  this	  limits	  the	  CD8+	  T	  cell	  expansion	  and	  tissue	  
damage	  that	  characterize	  XLP1.	  	  
Collectively,	  these	  data	  highlight	  the	  key	  role	  for	  the	  SAP-­‐mediated	  DGKα	  inhibition	  in	  regulating	  T	  








	   	  




AICD	   	   	   Activation-­‐induced	  cell	  death	  
APC	   	   	   Antigen	  Presenting	  Cell	   	   	  
cSMAC	  	   	   Central	  supramolecular	  activation	  complex	  
CTLs	   	   	   Cytotoxic	  T	  lymphocytes	  
DAG	   	   	   Diacylglycerol	  
DCs	   	   	   Dendritic	  cells	  
DGKs	   	   	   Diacylglycerol	  kinases	  
dSMAC	  	   	   Distal	  supramolecular	  activation	  complex	  
EBV	   	   	   Epstein-­‐Barr	  virus	  
FIM	   	   	   Fulminant	  infectious	  mononucleosis	  
GAPDH	  	   	   Glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase	  
GAPs	   	   	   GTPase	  activating	  proteins	  	  
GEF	   	   	   Guanine	  nucleotide	  exchange	  factor	  
HLH	   	   	   Hemophagocytic	  lymphohistiocytosis	  
HSC	   	   	   Hematopoietic	  stem	  cell	  
IL	   	   	   Interleukin	  
INF	   	   	   Interferon	  
IS	   	   	   Immunological	  synapse	  
ITAMs	   	   	   Immunoreceptor	  tyrosine-­‐based	  activation	  motifs	  
LCMV	   	   	   Lymphocytic	  Choriomeningitis	  Virus	  
MTOC	   	   	   Microtubule-­‐organizing	  center	  	  
NTB-­‐A	   	   	   NK,	  T,	  and	  B	  cell	  Antigen	  (Ly108	  in	  mice)	  
PA	   	   	   Phosphatidic	  acid	   	   	  
PKC	   	   	   Protein	  kinase	  C	  
PMA	   	   	   Phorbol	  myristate	  acetate	  -­‐	  DAG	  functional	  analogue	  
pSMAC	  	   	   Periferal	  supramolecular	  activation	  complex	  
RasGRP1	   	   RAS	  guanyl-­‐releasing	  protein	  1	  
RICD	   	   	   Restimulation-­‐induced	  cell	  death	   	  
RSK	   	   	   p90	  ribosomal	  protein	  S6	  kinase	  	  
SAP	   	   	   SLAM-­‐associated	  protein	  
SEE	   	   	   Staphylococcal	  enterotoxin	  E	  
SHP-­‐1	   	   	   SH2	  domain-­‐containing	  phosphatase	  1	  
SLAM	   	   	   Signaling	  lymphocyte	  activation	  molecule	  
TCR	   	   	   T	  cell	  receptor	  
XLP1	   	   	   X-­‐linked	  lymphoproliferative	  syndrome	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Introduction	  
1.	  TCR	  signaling	  and	  T	  cell	  activation	  
	  
T	   cells	   are	   key	   effectors	   of	   the	   adaptive	   immune	   response,	   playing	   a	   central	   role	   in	   clearing	  
pathogens’	  infection.	  	  
Activation	  of	  T	  cells	  occurs	  upon	   ligation	  of	  T	  cell	   receptors	   (TCRs)	  with	  peptides	  processed	  and	  
exposed	  by	  antigen-­‐presenting	   cells	   (APCs)	   for	  CD8+	  and	  CD4+	  T	   cells	  on	   class	   I	   or	   class	   II	  MHC	  
molecules,	  respectively	  [3,	  4].	  
This	   interaction	   is	  necessary	  but	  not	  sufficient	   to	   fully	  establish	   lymphocyte’s	  activation:	   indeed,	  
the	  concomitant	  triggering	  of	  several	  accessory	  molecules	  on	  the	  surface	  of	  T	  cell	  as	  well	  on	  APC	  is	  
required.	   The	   engagement	   of	   the	   TCR	   by	   specific	   antigens,	   along	   with	   stimulation	   by	   co-­‐
stimulatory	  receptors	  such	  as	  CD28,	  CD2,	  CD4	  and	  CD8,	  leads	  to	  a	  cascade	  of	  signaling	  events	  that	  
culminate	  in	  T	  cell	  activation,	  which	  causes	  the	  proliferation	  and	  differentiation	  of	  T	  cells	  coupled	  
with	   their	   acquisition	   of	   effector	   functions	   [5].	   Conversely,	   stimulation	   via	   the	   TCR	   alone,	  while	  
partially	   activates	   intracellular	   signaling	   pathways,	   is	   not	   sufficient	   to	   induce	   effector	   functions	  
such	  as	  cytokines	  production	  and	  proliferation	  [6].	  Notably,	  engagement	  of	  TCR	  in	  the	  absence	  of	  
co-­‐stimulation	  results	  in	  a	  weak	  and	  transient	  activation	  of	  both	  Ras	  and	  PKCθ,	  which	  drives	  T	  cells	  
into	  anergy,	  a	  hypo-­‐responsive	  status	  characterized	  by	  the	  inability	  to	  produce	  IL-­‐2	  and	  proliferate	  
[7,	  8].	  
TCR	   is	   multi-­‐molecular	   complex	   composed	   of	   separate	   antigen	   binding	   and	   signal-­‐transduction	  
subunits.	  The	  unique,	  clonotypic	  α	  and	  β	  chains	  are	  responsible	  for	  the	  recognition	  of	  the	  antigen,	  
while	  the	  invariant	  subunits	  of	  the	  CD3	  (heterodimers	  γ-­‐ε/	  ε-­‐δ	  and	  homodimer	  ζ-­‐ζ)	  drive	  the	  signal	  
transduction	   upon	   antigen	   recognition	   [5,	   9].	   On	   the	   invariant	   CD3	   subunits,	   immunoreceptor	  
tyrosine-­‐based	  activation	  motifs	  (ITAMs)	  play	  a	  major	  role	   in	  branching	  out	  signals	  from	  TCR	  [5].	  
Indeed,	  TCR	  has	  no	  intrinsic	  enzymatic	  activity	  and,	  to	  initiate	  the	  signaling,	  activation	  of	  Src	  kinase	  
family	  member	  (SFKs),	  and	  in	  particular	  of	  LCK,	   is	  required.	  LCK	  is	  recruited	  to	  the	  cytoplasmatic	  
domain	  of	   the	  TCR	  co-­‐receptors	  CD4	  and	  CD8,	  which	  serve	  to	  drive	  LCK	   in	  close	  proximity	  of	   its	  
substrates	  ITAMs	  (Figure	  1).	  	  
	   	  




	  Figure	  1.	  Signals	  controlling	  the	  TRC-­‐mediated	  T-­‐cell	  function.	  (Baniyash	  et	  al.,	  2004)	  
	  
	  
For	   conveying	   the	   signal,	   at	   least	   two	   ITAMs	   must	   be	   phosphorylated	   by	   LCK.	   The	   double	  
phosphorylation	  leads	  to	  the	  recruitment	  and	  activation	  of	  zeta	  chain-­‐associated	  protein	  kinase	  70	  
kDa	  (ZAP-­‐70)	  through	  its	  tandem	  SH2	  domains	  [10,	  11].	  	  
Subsequently,	  active	  ZAP-­‐70	  phosphorylates	  the	  membrane-­‐bound	   linker	   for	  activation	   in	  T	  cells	  
(LAT)	  and	  the	  SH2-­‐domain-­‐containing	  leukocyte	  protein	  of	  76	  kDa	  (SLP-­‐76)	  [12,	  13],	  which	  serve	  as	  
scaffolds	  to	  recruit	  many	  other	  adaptor	  and	  effector	  molecules,	  including	  growth	  factor	  receptor-­‐
bound	  protein	  2	  (Grb2),	  phospholipase	  C	  gamma	  (PLCγ)	  and	  phosphatidyl-­‐inositol	  3-­‐kinase	  (PI3K)	  
[14]	   (Figure	   1).	   LAT	   and	   SLP-­‐76	   have	   a	   central	   role	   in	   nucleating	   the	   signal	   complexes,	   and	  
ultimately	  serve	  as	  a	  platform	  to	  recruit	  many	  other	  effector	  molecules:	  among	  them,	  Itk.	  Itk	  is	  the	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prominent	  and	  best	  characterized	  member	  of	  the	  Tec	  family	  in	  T	  cells.	  Through	  its	  PH	  domain,	  Itk	  
is	   recruited	   to	   the	   membrane	   via	   the	   phosphatidylinositol	   3-­‐kinase	   (PI3K)	   lipid	   product	  
phosphatidylinositol-­‐3,4,5-­‐trisphosphate	   (PIP3),	   in	   close	   proximity	   to	   LCK,	  which	   phosphorylates	  
Itk	   in	   its	   activation	   loop	   [15].	   Once	   activated,	   Itk	   interacts	   with	   and	   phosphorylates	   the	  
phospholipase	   C	   gamma	   1	   (PLCγ1)	   (Figure	   1).	  PLCγ1	  hydrolyzes	   phosphatidylinositol-­‐4,5-­‐
bisphosphate	   (PIP2)	   producing	   the	   second	   messengers	   inositol-­‐1,4,5-­‐trisphosphate	   (IP3)	   and	  
diacylglycerol	  (DAG).	  IP3	  generation	  results	  in	  release	  of	  Ca2+	  from	  intracellular	  stores	  [16].	  
Calcium	  release	  is	  an	  important	  trigger	  for	  transcriptional	  activation	  in	  the	  nucleus	  [17,	  18]	  (Figure	  
1).	   	  For	  instance,	  sustained	  calcium	  elevation	  is	  critical	  for	  the	  activation	  of	  the	  IL-­‐2	  promoter	  by	  
the	  calcineurin/NFAT	  pathway	  [17,	  18].	  	  
Besides	   the	   calcium	   flux,	   the	   TCR	   triggering	   induces	   the	   production	   of	  DAG,	  which	   leads	   to	   the	  
activation	   of	   two	   major	   pathways	   involving	   PKCθ	   and	   Ras	   (Figure	   1).	   T	   cells	   express	   multiple	  
functionally	  distinct	  PKC	  isoforms	  that	  can	  be	  classified	   into	  the	  classical	  PKCs	  (α,	  β1,	  β2,	  and	  γ),	  
which	   are	   regulated	   by	   calcium,	   diacylglycerol,	   and	   phospholipids;	   novel	   PKCs	   (δ,	   ε,	    η,	   and	   θ),	  
which	  are	  regulated	  by	  diacylglycerol	  and	  phospholipids;	  and	  atypical	  PKCs	  (ζ	  and	  λ),	  which	   lack	  
calcium	  or	  diacylglycerol-­‐binding	  domains	  [19].	  It	  was	  previously	  thought	  that	  among	  the	  available	  
PKCs,	   only	   the	  θ	   isoform	   is	   recruited	   to	   the	   site	   of	   TCR	  engagement	   [20-­‐22];	   however,	   recently	  
Quann	  et	  al.	  showed	  that	  also	  PKCε	  and	  PKCη,	  but	  not	  the	  δ	   isoform,	  are	  recruited	  at	  the	  IS	  and	  
are	  necessary,	   in	   turn,	   to	   recruit	  PKCθ	   [23].	  Once	   recruited,	  PKCθ	   regulates	  a	  number	  of	   critical	  
pathways,	   i.e.	  NF-­‐κB	  activation,	  which	   leads	   to	   the	  activation	  of	   genes	   involved	   in	   the	   function,	  
survival,	  and	  homeostasis	  of	  T	  cells.	  	  
The	  second	  major	  signaling	  pathway	  regulated	  by	  DAG	  is	  mediated	  by	  Ras.	  Ras	  cycles	  between	  a	  
GTP-­‐associated	   active	   state	   (Ras-­‐GTP)	   and	   GDP-­‐bound	   inactive	   state	   (Ras-­‐GDP).	   The	   activation	  
state	  of	  Ras	  is	  defined	  by	  the	  balance	  of	  two	  regulators	  of	  the	  process:	  in	  the	  one	  hand,	  guanine	  
nucleotide	  exchange	  factor	  (GEFs)	  promotes	  the	  Ras	  GTP-­‐bound	  state	  by	  enhancing	  exchange	  of	  
GDP	  with	  GTP.	  On	  the	  other	  hand,	  GTPase	  activating	  proteins	  (GAPs)	  promote	  the	   inactive	  GDP-­‐
bound	  state	  of	  Ras	  by	  increasing	  the	  rate	  of	  GTP	  hydrolysis	  [24].	  
In	   T	   cells,	   two	   families	   of	   Ras	  GEFs	   are	   expressed:	   Son	  of	   sevenless	   (which	   consist	   of	   SOS1	  and	  
SOS2),	   and	   Ras	   guanine	   nucleotide-­‐releasing	   proteins	   (four	   proteins	   which	   include	   RasGRP1	   to	  
RasGRP4).	   While	   SOS	   proteins	   are	   ubiquitously	   expressed,	   RasGRPs,	   and	   particularly	   RasGRP1,	  
have	  a	  major	  role	  in	  T	  cells	  [24].	  	  Upon	  TCR	  stimulation,	  DAG	  recruits	  RasGRP1	  to	  the	  membrane,	  
where	  it	  can	  activate	  Ras	  [22,	  25].	  However,	  RasGRP1	  can	  also	  be	  activated	  in	  a	  way	  that	  depends	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only	  indirectly	  from	  DAG:	  indeed,	  DAG	  can	  activate	  PKCθ,	  which	  in	  turns	  phosphorylates	  RasGRP1	  
on	   T184,	   thus	   enhancing	   its	   GEF	   activity	   [26,	   27].	   The	   other	   major	   GEF	   of	   Ras	   is	   SOS.	   SOS	   is	  
constitutively	   bound	   to	   the	   adapter	   protein	   GRB2,	   and	   upon	   TCR	   stimulation,	   the	   GRB2	   SH2	  
domain	  is	  recruited	  to	  and	  binds	  phosphorylated	  tyrosines	  on	  LAT,	  thereby	  bringing	  SOS	  into	  the	  
proximal	   signaling	   complex	   where	   it	   can	   facilitate	   the	   localized	   activation	   of	   Ras	   [12].	   The	  
significance	  of	   these	  two	  modes	  of	  Ras	  activation	  was	  unclear	  until	   it	  was	  shown	  that	  RasGRP1-­‐
dependent	   RasGTP	   production	   catalyzes	   SOS	   activity,	   resulting	   in	   a	   positive	   feedback	   loop	   and	  
robust	  TCR-­‐induced	  Ras	  activation	  [27].	  This	  explains	  why	  RasGRP1	  plays	  a	  more	  dominant	  role	  in	  
antigen	   receptor-­‐stimulated	   Ras	   activation	   [24].	   Ras	   is	   then	   responsible	   for	   the	   activation	   of	  
multiple	   effector	   pathways,	   including	   the	   extracellular	   signal-­‐regulated	   kinase	   (ERK),	   as	   well	   as	  
linkage	   to	   Rho	   GTPases	   [28,	   29].	   ERK1/2	   belongs	   to	   the	   mitogen-­‐activated	   protein	   kinases	  
(MAPKs),	   a	   family	   of	   serine/threonine	   kinases	   that	  mediates	   intracellular	   signal	   transduction	   in	  
response	   to	   different	   physiological	   stimuli	   and	   stressing	   conditions.	   MAPKs	   are	   activated	   by	   a	  
cascade	  involving	  a	  MAP3K	  (Raf-­‐1)	  and	  a	  MAP2K	  (MEK-­‐1	  or	  MEK-­‐2)	  [29,	  30].	  Once	  activated,	  ERK	  
plays	  an	  essential	   role	   in	   the	  expression	  of	   the	  activator	  protein	  1	   (AP-­‐	  1)	   transcription	   factor	  c-­‐
Fos,	  as	  well	  as	  c-­‐myc	  [30].	  Beside	   its	  role	   in	  modulating	  proliferation	  and	  differentiation,	  ERK1/2	  
was	  shown	  to	  have	  also	  pro-­‐apoptotic	  effects,	  especially	  in	  thymocytes	  during	  negative	  selection	  
triggered	  by	  high	  affinity	  TCR	  ligands	  [31].	  Particularly,	   it	  has	  been	  shown	  that	  the	  ERK1/2-­‐MAPK	  
pathway	  mediates	   these	   pro-­‐apoptotic	   functions	   by	   phosphorylating	   Nur77,	   an	   orphan	   nuclear	  
receptor	   whose	   expression	   and	   phosphorylation	   are	   strongly	   induced	   after	   TCR-­‐triggering.	   This	  
phosphorylation	  is	  mediated	  by	  both	  ERK2,	  which	  phosphorylates	  Nur77	  at	  threonine	  142	  [32]	  and	  
p90	   ribosomal	   protein	   S6	   kinase	   2	   (RSK2),	   a	   serine/threonine	   kinase	   that	   acts	   as	   downstream	  
effector	  of	  the	  MEK1/2-­‐ERK1/2	  MAPK	  cascade	  [33,	  34].	  RSK2	  is	  known	  to	  phosphorylate	  Nur77	  at	  
serine	  351,	  both	  in	  vitro	  and	  in	  vivo	  [33,	  34].	  Also,	  it	  has	  been	  demonstrated	  that	  phosphorylation	  
of	  Nur77	  on	  this	  specific	  residue	  mediates	  its	  translocation	  from	  the	  nucleus	  to	  the	  mitochondria,	  
where	  activates	  the	  intrinsic	  apoptotic	  pathway	  by	  interacting	  with	  Bcl-­‐2	  [34,	  35].	  Besides	  MAPK	  
cascade,	  also	  PKCs	  were	  shown	  to	  be	  responsible	  for	  the	  Nur77	  mitochondrial	  targeting,	  as	  their	  
inhibition	   prevented	   the	   association	   with	   Bcl-­‐2	   and	   apoptosis	   in	   thymocytes	   induced	   by	   the	  
combination	  of	  PKC	  agonist	  with	  calcium	  ionophore	  [36].	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2.	  The	  immunological	  synapse	  
	  
The	  immunological	  synapse	  (IS)	  refers	  to	  a	  contact	  between	  the	  T	  cell	  and	  the	  APC	  that	  results	  in	  a	  
well-­‐defined	  organization	  of	  the	  membrane	  proteins	  [37,	  38].	  In	  1998,	  Kupfer	  was	  the	  first	  to	  show	  
that	   the	   IS	   formed	   at	   the	   T	   cell	   :	   APC	   interface	   consists	   of	   two	   rings	   according	   to	   the	   spatial-­‐
segregation	  of	  distinct	  molecules.	  Because	  of	  its	  typical	  double-­‐ring	  structure,	  the	  IS	  organization	  
is	  known	  as	  “bull’s	  eye”	  [38].	  Specifically,	  the	  IS	  is	  divided	  in	  peripheral	  supramolecular	  activation	  
complex	  (pSMAC)	  and	  central	  supramolecular	  activation	  complex	  (cSMAC).	  Lymphocyte	  function-­‐
associated	  antigen-­‐1	  (LFA-­‐1,	  also	  known	  as	  αLβ2),	  which	  interacts	  with	  ICAM	  [39],	  localizes	  to	  the	  
pSMAC	   of	   the	   immunological	   synapse	   during	   T-­‐cell	   activation,	   and	   is	   believed	   to	   be	   the	   most	  
important	   integrin	   that	   is	   involved	   in	   conjugate	   formation.	   In	   addition,	   the	   α4β1-­‐integrin	   (also	  
known	   as	   VLA4)	   binds	   to	   vascular	   cell-­‐adhesion	   molecule-­‐1	   (VCAM1)	   to	   facilitate	   the	  
extravasation,	  as	  well	  as	  to	  extracellular	  matrix	  components,	  such	  as	  fibronectin.	  Similar	  to	  LFA-­‐1,	  
α4β1-­‐integrin	  accumulates	  at	  the	  pSMAC	  and	  can	  function	  as	  a	  co-­‐stimulatory	  molecule	  for	  T-­‐cell	  
activation	  [40].	  	  
On	  the	  other	  hand,	  the	  activated	  TCR	  diffuses	   in	  the	  cSMAC,	   in	  the	  center	  of	  the	  IS.	  Outside	  the	  
pSMAC	   is	   another	   domain	   named	   distal	   supramolecular	   activation	   complex	   (dSMAC),	   a	   CD45-­‐
enriched	   region	   characterized	   by	   active	   actin	   movement,	   thereby	   recently	   associated	   to	   the	  
lamellipodia	  of	  epithelial	  cells	  [41]	  (Figure	  2).	  
	  
	  
Figure	  2.	  Structure	   of	   the	   immunological	   synapse.	   The	  basic	   structure	  of	   the	  “bull’s	  eye”	   immunological	  
synapse	   with	   SMACs	   is	   shown	   (left).	   Given	   the	   active	   membrane	   movement	   and	   enrichment	   in	   actin,	  
pSMAC	  and	  dSMAC	  are	  associated	  with	  lamellae	  and	  lamellipodia,	  respectively	  (right)	  (Dustin	  et	  al.,	  2010)	  
	  
Although	  mature	  IS	  formation	  is	  observed	  with	  B	  cells,	  artificial	  bilayers,	  or	  tumor	  cells,	  this	  does	  
not	   apply	   with	   dendritic	   cells	   (DCs).	   Indeed,	   even	   if	   DCs	   are	   capable	   to	   strongly	   induce	   T	   cell	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activation,	  they	  form	  multifocal	  ISs	  rather	  then	  cSMAC	  and	  pSMAC	  structures	  [38].	  Therefore,	  the	  
function	  of	   the	  d-­‐,	   p-­‐	   and	   cSMAC	   is	   still	   debated.	   It	  was	   first	   thought	   that	   the	   cSMAC	   serves	   to	  
convey	  the	  signal	  at	  the	  center	  of	  the	  synapse,	  allowing	  the	  recognition	  of	  low-­‐affinity	  ligands	  for	  
the	  TCR	   [37,	   38].	  Nevertheless,	   further	   studies	   showed	   that	   strong	  peptides	   tended	   to	   result	   in	  
less	  phosphotyrosine	  staining	  at	  the	  cSMAC,	  whereas	  weak	  peptides	  showed	  more	  signals	  at	  the	  
cSMAC	   [42].	   Based	   on	   these	   observations,	   and	   given	   the	   enrichment	   of	   the	   cSMAC	   in	  
lysobisphosphatidic	  acid	  [43],	  a	  marker	  of	  multivesicular	  bodies,	  it	  was	  suggested	  that	  the	  cSMAC	  
ultimately	  might	  serve	  as	  a	  specific	  compartment	  to	  facilitate	  the	  TCR	  internalization/degradation	  
[44,	  45].	  Furthermore,	   it	  has	  been	  proposed	  that	  the	  role	  of	  the	  pSMAC	  might	  be	  to	  contain	  the	  
release	   of	   the	   cytolytic	   granule	   contents	   to	   bystander	   cells,	   thus	   preventing	   their	   non-­‐specific	  
cytolysis	   [46].	   However,	   appears	   to	   be	   clear	   that	   the	   ultimate	   function	   of	   the	   IS	   is	   to	   provide	  
signals	   to	   and	   from	   the	   T	   cell,	   during	   the	   phase	   of	   priming	   and	   the	   ultimate	   effector	   function,	  
respectively	   [41].	   The	   process	   of	   IS	   formation	   is	   extremely	   fast	   –	   it	   takes	   approximately	   2-­‐3	  
minutes	  [47]	  (Figure	  3).	  
	  
Figure	  3.	  Schematic	  diagram	  showing	  the	  transition	  between	  migratory	  and	  synaptic	  polarity	  that	  occurs	  
upon	  antigen	  recognition	  by	  T	  cells.	  (Huse,	  2012)	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First,	  the	  circulating	  T	  cells	  extend	  a	  leading	  edge	  searching	  for	  the	  antigen.	  Once	  encountered	  the	  
antigen,	   they	   stop	   to	   form	   stable	   contacts	   with	   the	   APC,	   and	   the	   leading	   edge	   spreads	   in	   a	  
lamellipodium,	  which	  literally	  embraces	  the	  APC.	  During	  this	  process,	  an	  extensive	  remodeling	  of	  
the	  actin	  takes	  place,	  which	  can	  be	  easily	  followed	  by	  visualizing	  actin	  accumulation	  between	  the	  T	  
and	   the	   APC	   cells	   [47]	   (Figure	   3).	   As	   a	   direct	   consequence,	   the	   TCR	   complex	   is	   activated	   and	  
PLCγ	  generates	  the	  lipid	  DAG,	  which	  accumulates	  in	  a	  polarized	  manner	  at	  the	  IS	  [48].	  DAG	  acts	  as	  
a	  second	  messenger	  by	  recruiting	  and	  activating	  the	  nPKCs	  PKCε	  and	  PKCη	  	  and,	  finally,	  PKCθ.	  [23,	  
49]	  (Figure	  3).	  All	  these	  three	  proteins	  are	  required	  –	  with	  some	  redundancy	  between	  PKCε	  and	  
PKCη	  [23].	  The	  final	  step	  of	  IS	  formation	  is	  the	  reorientation	  of	  the	  microtubule-­‐organizing	  center	  
(MTOC)	  (Figure	  3).	  The	  key	  player	  of	  this	  process	  is	  dynein,	  a	  “microtubule	  motor”	  that	  drives	  the	  
MTOC	   toward	   the	  APC.	   It	  has	  been	  proposed	   that	  microtubules	  directly	   link	   to	   the	   integrin-­‐rich	  
pSMAC	   and	   to	   the	   cortical	   actin	   cytoskeleton,	   thus	   giving	   the	   force	   required	   to	   reposition	   the	  
MTOC	  just	  behind	  the	  nucleus	  [50]	  (Figure	  3).	  
Also,	   the	   IS	   formation	  and	   the	   repositioning	  of	   the	  MTOC	  are	  key	  events	  during	   the	  cytotoxic	  T	  
lymphocytes	   (CTLs)	   killing	   of	   a	   cognate	   target	   cells.	   Cytotoxic	   granules	   (containing	   perforin	   +	  
granzymes)	   move	   along	   microtubules	   and	   then	   cluster	   around	   the	   MTOC,	   juxtaposed	   to	   the	  
plasma	  membrane.	  Then	   the	  granule’s	   content	   is	   released	  between	   the	  CTL	  and	   the	   target	   cell,	  
where	  perforin	  and	  granzymes	  cooperate	  to	   induce	  a	  rapid	  death	  of	  the	  target	  cell	  by	  apoptosis	  
[51].	  	  	  
	  
In	  this	  highly	  controlled	  process	  of	  synapse	  formation,	  the	  generation	  and	  preservation	  of	  a	  stable	  
gradient	  of	  DAG	  at	  the	  IS	  plays	  a	  central	  role.	  Recently,	  this	  mechanism	  has	  been	  clarified	  in	  details	  
by	   the	   work	   of	   Huse’s	   group.	   Diacylglycerol	   kinase	   alpha	   (DGKα),	   by	   consuming	   the	   DAG	   to	  
phosphatidic	  acid	   (PA),	   limits	   the	  diffusion	  of	  DAG	  and	   therefore	  determines	   the	  polarity	  of	   the	  
cell.	   DGKα-­‐deficient	   T	   cells	   exhibit	   an	   uncontrolled	   accumulation	   of	   DAG	   at	   the	   IS,	   and	   the	  
repositioning	  of	   the	  MTOC	   is	   impaired,	   as	   a	   result	   of	   the	  mis-­‐orientation	  of	   the	   cell.	  Moreover,	  
they	  found	  that	  DGKα	  localizes	  at	  the	  pSMAC	  in	  a	  PI3K-­‐dependent	  mechanism,	  while	  is	  excluded	  
from	  the	  cSMAC,	  suggesting	  a	  role	  for	  DGKα	  in	  constraining	  the	  area	  of	  DAG	  accumulation	  at	  the	  
cSMAC.	  Hence,	  DGKα	  acts	  as	  a	  negative	  regulator	  of	  signal	  initiated	  from	  the	  TCR,	  thus	  originating	  
a	  polarized	  and	  fine-­‐tuned	  DAG	  gradient	  [52].	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3.	  SAP	  and	  X-­‐linked	  lymphoproliferative	  disease	  	  
3.1.	  The	  SLAM/SAP	  signaling	  pathway	  
	  
The	  activation	  of	  the	  immune	  cells	  depends	  on	  the	  integration	  of	  multiple	  signals,	  originating	  from	  
multiple	   receptor	  and	   co-­‐receptors	  on	   the	   cell	   surface.	   There	   is	   accumulating	  evidence	   that	   the	  
signaling	   lymphocytic	   activation	   molecule	   (SLAM)	   family	   of	   receptors	   plays	   important	   roles	   in	  
immunity	  [53,	  54].	  	  
The	  SLAM-­‐family	  is	  composed	  by	  a	  group	  of	  transmembrane	  receptors	  that	  include	  SLAM	  (CD150),	  
2B4	   (CD244),	   Ly-­‐9	   (CD229),	  natural	   killer,	   T-­‐	   and	  B-­‐cell	   antigen	   (NTB-­‐A)	  or	   Ly108	   (in	   the	  mouse)	  
(SLAMF6),	  CD84,	  and	  CD2-­‐like	  receptor	  activating	  cytotoxic	  cells	  (CRACC;	  CD319)	  [53,	  54].	  They	  all	  
share	  an	  extracellular	  region	  that	  contains	  two	  immunoglobulin-­‐like	  domains:	  one	  variable	  (V)-­‐like	  
domain	  and	  one	  constant	  2	  (C2)-­‐like	  domain.	  In	  the	  cytoplasmic	  segment	  multiple	  tyrosine-­‐based	  
motifs	  were	  found.	  The	  only	  exception	  is	  Ly-­‐9,	  which	  has	  two	  tandem	  repeats	  of	  the	  basic	  V-­‐like	  
and	  C2-­‐like	  organization	   [53,	   54].	  With	   the	   exception	  of	   2B4,	  which	   interacts	  with	  CD48	  on	   the	  
surface	  of	  other	  hematopoietic	  cells,	  all	  the	  others	  SLAM	  receptors	  are	  self-­‐ligands,	  so	  they	  can	  be	  
triggered	   in	  homotypic	   (all)	  or	  heterotypic	   (2B4)	   interaction.	  For	  example,	  NTB-­‐A	   is	   triggered	  by	  
another	  NTB-­‐A	  located	  on	  the	  APC	  cell	  surface	  [53].	  
SLAM	   receptors	   transduce	   the	   signal	   through	   SLAM-­‐associated	   protein	   (SAP)	   family	   of	   adaptor	  
proteins.	  This	  family	  includes	  three	  members:	  SAP	  (gene	  name	  SH2D1A),	  which	  is	  expressed	  in	  T,	  
NK	  and	  NK-­‐T	  cells,	  EAT-­‐2	   (SH2D1B1),	  which	   is	   found	   in	  NK	  cells,	  DCs	  and	  macrophages,	  and	  ERT	  
(SH2D1B2),	  which	  is	  expressed	  only	  in	  murine	  NK	  cells.	  Among	  them,	  I	  will	  focus	  on	  SAP	  protein,	  
since	  mutations	  on	   its	   gene	  are	   responsible	   for	   the	  X-­‐linked	   lymphoproliferative	  disease	   (XLP1),	  
which	  will	  be	  the	  topic	  of	  the	  next	  section	  of	  this	  thesis.	  
The	   SAP	   (SH2D1A)	   gene	   is	   located	   on	   the	   X	   chromosome	   and	   encodes	   for	   a	   128	   amino	   acid	  
protein,	  which	   is	   composed	   almost	   entirely	   by	   a	   Src	   homology	   2	   (SH2)	   domain.	   Its	   SH2	  domain	  
binds	   immunoreceptor	   tyrosine-­‐based	   switch	  motifs	   (ITSMs)	   on	   the	   cytoplasmic	   domain	   of	   the	  
SLAM-­‐related	  receptors	  [55-­‐59].	  
Because	  of	   the	  “adaptor”	  nature	  of	   the	  SAP	  protein,	   it	  was	  first	   thought	  that	  SAP	  promoted	  cell	  
activation	   through	   an	   anti-­‐inhibitory	   mechanism,	   by	   blocking	   the	   interaction	   of	   SLAM	   family	  
receptors	   with	   SH2	   domain	   containing	   phosphatase	   such	   as	   SHP-­‐1,	   SHP-­‐2	   and	   SHIP-­‐1	   [54,	   59].	  
However,	  SAP	  itself	  was	  later	  found	  to	  have	  a	  crucial	  role	  in	  signal	  transduction.	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One	   of	   the	   best-­‐characterized	   functions	   of	   SAP	   is	   the	   association	   with	   the	   Src-­‐related	   tyrosin	  
kinase	   Fyn,	   through	   an	   arginine	   (R78)	   located	  within	   the	   SAP	   SH2	   domain	   [60-­‐62].	   This	   specific	  
residue	  binds	  to	  the	  Src	  homology	  3	  (SH3)	  region	  of	  Fyn.	  Because	  the	  residue	  involved	  in	  SAP-­‐Fyn	  
interaction	   (R78)	   is	   distinct	   from	   the	   one	   involved	   in	   its	   association	   with	   SLAM	   (R32),	   SAP	   can	  
simultaneously	   associate	   with	   SLAM	   and	   Fyn	   to	   form	   a	   trimolecular	   complex	   [60-­‐63],	   which	  
appears	   to	  be	  critical	   for	   some	   functions	  of	   SAP.	   For	   instance,	   it	  has	  been	   shown	   that	  SAP/Fyn-­‐






Figure	  6.	  SLAM/SAP	  signaling	  pathway	  (Filipovich	  et	  al.,	  2010) 
	  
	  
	   16	  
In	   addition	   to	   the	   binding	   of	   Fyn,	   the	   R78-­‐based	  motif	   of	   SAP	   can	   interact	   also	  with	   other	   SH3	  
domain-­‐containing	  proteins,	  such	  as	  PAK-­‐interacting	  exchange	  factor	  (β-­‐PIX),	  the	  adaptor	  Nck	  and	  
PCKθ	   [65-­‐67].	  Moreover,	   SAP	  was	   recently	   found	   to	   directly	   associate	  with	   the	   phosphorylated	  
CD3ζ	  chain,	  contributing	  to	  the	  activation	  of	  Erk,	  Akt	  and	  PLCγ1	  pathways	  [68].	  
Depending	   on	   the	   cell	   type,	   state	   of	   activation,	   and	   specific	   SLAM	   family	   member	   engaged,	  
multiple	  mechanisms	   exist	   for	   recruitment	   of	   other	   downstream	   proteins.	   Is	   important	   to	   note	  
that	  SAP	  may	  either	  acts	  as	  a	  competitor	  or	  as	  an	  adaptor	   to	  recruit	  Src	  kinases,	  and	  these	  two	  
processes	  may	  not	  be	  mutually	  exclusive	  [63].	  
In	   the	   following	   chapter,	   I	   will	   specifically	   focus	   on	   the	   role	   of	   SLAM	   and	   SAP	   in	   XLP1	   disease,	  
where	  studies	  with	  both	  genetic	  murine	  models	  and	  cells	  from	  XLP1	  patients	  contributed	  to	  clarify	  
this	  complex	  scenario.	  
	  
3.2.	  X-­‐linked	  lymphoproliferative	  disease	  (XLP1)	  and	  cellular	  defects	  
	  
X-­‐liked	  lymphoproliferative	  disease	  type	  1	  (XLP1)	  is	  a	  rare	  primary	  immunodeficiency	  that	  affects	  
both	  innate	  and	  adaptive	  immunity	  of	  male	  patients.	  David	  Purtilo	  originally	  reported	  it	   in	  1975,	  
describing	   a	   big	  American	   family	   –	   the	  Duncan	   kindred	   -­‐	   in	  which,	   out	   of	   18	   boys,	   6	   died	   for	   a	  
lymphoproliferative	   disease	   [69].	   For	   this	   reason,	   XLP1	   is	   also	   known	   as	   “Duncan’s	   disease”	   or	  
“Purtilo	  syndrome”.	  XLP1	  is	  caused	  by	  mutations	  on	  SH2D1A	  (SAP)	  gene,	  which	  is	  located	  on	  the	  
long	  arm	  of	  the	  chromosome	  X	  (Xq25).	  So	  far,	  more	  than	  70	  mutations	  resulting	  in	  XLP1	  have	  been	  
reported	   to	   the	  Human	  Gene	  Mutation	  Database	   (HGMD),	  which	  are	  gross	  deletions,	  nonsense,	  
missense,	  small	   insertion/deletion	  and	  splice-­‐site	  mutations	  [70].	  Even	  in	  patients	  with	  the	  same	  
mutations,	  and	  within	  the	  same	  family,	  there	  are	  no	  well-­‐defined	  correspondences	  in	  most	  of	  the	  
cases	  between	  genotype	  and	  clinical	  phenotype.	  A	   certain	  grade	  of	   correlation	  with	  an	  Epstein-­‐
Barr	  virus	  (EBV)	  infection	  was	  initially	  reported,	  and	  it	  is	  still	  considered	  to	  be	  the	  ultimate	  cause	  
for	  the	  development	  of	  at	  least	  the	  acute	  clinical	  manifestations	  in	  XLP1.	  However,	  some	  patients	  
develop	  the	  disease	  even	  without	  prior	  EBV	  exposure.	  
XLP1	   affects	   1	   to	   3	  million	   boys	  worldwide	   and	  most	   commonly	   arises	   during	   the	   childhood	   or	  
early	   adolescence.	   The	   main	   clinical	   feature	   of	   XLP1	   is	   represented	   by	   a	   fulminant	   infectious	  
mononucleosis	   (often	   triggered	   by	   EBV)	   and	   followed	   by	   hemophagocytic	   lymphohistiocytosis	  
(HLH)	   [71];	   the	   latter	   is	   responsible	  alone	   for	  more	  than	  80%	  of	  mortality	  before	  receiving	  stem	  
cell	   transplantation	   [72].	   In	   the	   individuals	   who	   survived	   these	   initial	   episodes	   or	   who	   are	   not	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infected	   by	   EBV,	   other	   lymphoproliferative	   manifestations	   such	   as	   malignant	   lymphomas	   and	  
lymphoid	   vasculitis,	   dysgammaglobulinemias	   -­‐	   including	   hypo/hyper-­‐gammaglobulinemias	   -­‐	   or	  
syndromes	  related	  to	  common	  variable	  immunodeficiency	  (CVID)	  are	  observed	  [73].	  While	  healthy	  
individuals	  are	  able	  to	  orchestrate	  an	  efficient	   immune	  response	  to	  EBV,	  XLP1	  patients	  exhibit	  a	  
deregulated	  response,	  characterized	  by	  an	  excessive	  accumulation	  of	  CD8	  and	  CD4	  T	  cells,	  NK	  cells	  
and	  macrophages,	  unable	  to	  mount	  a	  response	  to	  EBV,	  and	  a	  consequent	  accumulation	  of	  EBV+	  B	  
lymphocytes.	  
At	   present,	   allogeneic	   hematopoietic	   stem	   cell	   (HSC)	   transplantation	   remains	   the	   only	   curative	  
option	   for	   XLP1	   [70,	   72,	   74].	   Improved	   chemotherapy	   regimes	   for	   lymphoma	   and	  
immunosuppressive	  protocols	  to	  treat	  HLH	  (including	  rituximab)	  may	  reduce	  the	  mortality	  rate	  for	  
XLP1	  patients	  and	  allow	  stabilization	  before	  HSC	  transplant,	  but	  due	  to	  the	  rarity	  of	  the	  cases	  the	  
debate	  on	  the	  right	  procedure	  to	  be	  used	  is	  still	  open.	  
However,	  despite	  of	  the	  new	  improved	  regimens	  of	  conditioning,	  HSC	  transplantation	  still	  displays	  
high	  mortality	  in	  the	  mismatched	  and/or	  unrelated	  donor	  setting	  [74].	  Therefore,	  recently	  a	  first	  
study	   was	   carried	   out	   on	   mice	   models	   of	   XLP1	   to	   investigate	   the	   possibility	   to	   perform	   gene	  
therapy	   on	   XLP1	   patients.	   In	   2013,	   Rivat	   and	   colleagues	   transduced	   murine	   SAP	   -­‐/-­‐	   HSC	   with	  
lentiviral	   vectors	   containing	   either	   SAP	   or	   reporter	   gene	   before	   transplantation	   into	   irradiated	  
recipients.	  They	  found	  that	  NKT-­‐cell	  development	  was	  significantly	  higher	  and	  NK-­‐cell	  cytotoxicity	  
restored	  to	  wild-­‐type	  levels	  in	  mice	  receiving	  the	  SAP	  vector	  compared	  to	  control	  mice.	  Moreover,	  
in	  SAP-­‐transduced	  mice,	  they	  observed	  a	  significant	   increase	  in	  the	  basal	   immunoglobulin	   levels,	  
and	   a	   nearly	   normal	   response	   to	   the	   immunization	   with	   NP-­‐CGG,	   including	   germinal	   center	  
formation	  [75].	  This	  study	  provides	  proof	  of	  concept	  that	  SAP	  gene	  transfer	  into	  HSCs	  can	  correct	  
the	  multiple	  immune	  defects	  seen	  in	  XLP1.	  	  
XLP1	  patients	  have	  a	  great	  number	  of	  cellular	  defects	  that	  are	  implicated	  in	  the	  phenotype,	  and	  to	  
find	  an	  effective	  cure	  for	  at	  least	  one	  of	  them	  might	  be	  a	  successful	  approach	  for	  the	  patients	  to	  
safely	  reach	  the	  time	  of	  the	  transplant.	  
For	   instance,	   they	  exhibit	   impaired	  NK-­‐	  and	  CD8-­‐	  mediated	  killing	  of	  EBV-­‐infected	  B	  cell	   targets,	  
whereas	  cytotoxicity	  against	  non-­‐	  EBV-­‐infected	  cells	  appears	  normal,	  highlighting	  the	  specificity	  of	  
this	   phenotype	   [76-­‐80].	   Specifically,	   SAP	   deficient	   CTLs	   from	   XLP1	   patients	   display	   a	   defective	  
polarization	   of	   2B4	   and	   of	   the	   lytic	   machinery,	   while	   exist	   divergences	   on	   the	   effect	   of	   SAP	  
mutations	  on	  proliferation	  and	  production	  of	  interleukin	  2	  (IL-­‐2),	  IL-­‐4,	  and	  IFNγ	  [76-­‐78].	  In	  NK	  cells	  
from	  XLP1	  patients,	  2B4	  and	  NTB-­‐A	  were	  found	  to	  associate	  to	  CD48	  (their	  ligand	  on	  EBV+	  target	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cells)	   in	   an	   inhibitory	   fashion:	   in	   cells	   lacking	   SAP,	   the	   two	   SLAM	   receptors	   associate	   to	   the	  
phosphatase	  SHP-­‐1	  [79,	  80].	  As	  result,	  in	  both	  cell	  types	  impairment	  in	  cytolytic	  function	  leads	  to	  
the	  accumulation	  of	  virus-­‐infected	  B	  cells	  as	  well	  as	  the	  persistence	  of	  reactive	  inflammatory	  cells,	  
responsible	  for	  the	  exaggerated	  responses	  seen	  in	  XLP1.	  
XLP1	  patients	  also	  have	  impaired	  NKT	  cells	  development;	  NKT	  cells	  differ	  from	  other	  lymphocytes	  
because	  they	  are	  select	  by	  lipid	  antigens	  presented	  on	  other	  DP	  tymocytes,	  express	  invariant	  TCR,	  
and	  rapidly	  secrete	  high	  levels	  of	  cytokine	  following	  stimulation	  [81].	  Strikingly,	  in	  the	  absence	  of	  
SAP,	  the	  development	  of	  NKT	  cells	  is	  severely	  impaired	  both	  in	  mice	  and	  humans	  (a	  process	  SLAM	  
and	  Ly108-­‐mediated)	  [82,	  83].	  	  
Another	   major	   defect	   in	   XLP1	   patients	   is	   the	   hypo-­‐gammaglobulinemia,	   i.e.	   the	   defect	   in	   the	  
production	  of	  Ab	  directed	  against	  the	  antigen.	  Surprisingly,	  despite	  some	  papers	  detected	  SAP	  in	  B	  
cells,	  several	  other	  were	  not	  able	  to	  confirm	  these	  observations,	  and	  is	  now	  accepted	  that	  B	  cell	  
do	  not	  express	  SAP	  [84].	  Thus,	  the	  primary	  role	  of	  SAP	  during	  Ab	  responses	  occurs	  in	  CD4+	  T	  cells	  
carrying	  out	  their	  “helper”	  role	  for	  B	  cells	  [84].	  Indeed,	  it	  has	  been	  demonstrated	  that	  SAP	  has	  a	  
role	  in	  the	  development	  of	  TFH	  cells.	  CD4+	  T	  cells	  isolated	  from	  XLP1	  patients	  showed	  defective	  IL-­‐
10	  production	  in	  vitro	  [85].	  Qi	  and	  colleagues	  provided	  an	  important	  insight	  into	  the	  mechanism	  of	  
defective	  CD4+	  T	  cell	  help	  in	  the	  absence	  of	  SAP.	  Using	  two-­‐photon	  imaging,	  they	  demonstrated	  
that	  SAP-­‐deficient	  CD4+	  T	  cells	  were	  unable	  to	  form	  stable	  and	  prolonged	  interactions	  with	  B	  cells	  
in	  the	  germinal	  center,	  while,	  in	  contrast,	  SAP	  was	  not	  required	  for	  interaction	  between	  T	  cells	  and	  
DCs	  [86].	  	  
Finally,	   loss	   of	   SAP	   has	   been	   implicated	   in	   a	   defect	   of	   restimulation-­‐induced	   cell	   death	   (RICD),	  
which	   is	   responsible	   for	   the	   uncontrolled	   and	   life-­‐threatening	   accumulation	   of	   antigen-­‐specific	  
CD8+	  T	  cells	  post	  EBV	  infection.	  	  This	  defect	  will	  be	  reviewed	  in	  the	  following	  section.	  
	  
3.2.1	  T	  cell	  homeostasis	  and	  RICD	  
	  
In	  normal	   subjects,	   EBV	   infection	  of	  B	   cells	   leads	   to	   a	  massive	  proliferation	  of	  CD8+	   cytotoxic	   T	  
cells	   (CTLs)	   that	   exert	   their	   cytotoxic	   function	   clearing	   the	   infection.	   As	   foreign	   antigens	   are	  
successfully	  eliminated,	  an	  intrinsic	  pathway	  of	  apoptosis	  triggered	  by	  cytokine	  withdrawal	  causes	  
a	  major	   contraction	   phase	   of	   the	   T	   cell	   response,	   leading	   to	   the	   clearance	   of	   all	   but	   the	   small	  
fraction	  of	  T	  lymphocytes	  that	  became	  memory	  T	  cells.	  At	  the	  peak	  of	  the	  immune	  response,	  when	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antigen	   and	   IL-­‐2	   are	   still	   abundant,	   restimulation	   through	   the	   TCR	   also	   deletes	   effector	   T	   cells	  
(Figure	  7).	  
	  
Figure	  7.	  Conceptual	  scheme	  of	  the	  two	  major	  apoptosis	  mechanisms,	  active	  and	  passive	  apoptosis,	  that	  




This	   auto-­‐regulatory	   program	   of	   restimulation-­‐induced	   cell	   death	   (RICD)	   constitutes	   a	   negative	  
feedback	  mechanism	  to	  impair	  over-­‐lymphoproliferation	  and	  to	  maintain	  T	  cells	  homeostasis	  [87],	  
and	   is	   mediated	   by	   the	   induction	   of	   multiple	   cellular	   pathways,	   including	   both	   death	   receptor	  
signals	   (e.g.,	  FAS-­‐FASL)	  as	  well	  as	  pro-­‐apoptotic	  Bcl-­‐2	   family	  proteins	   targeting	   the	  mitochondria	  
(e.g.,	  BIM)	  [88,	  89].	  
Because	  of	  SAP	  deficiency,	  T	  lymphocytes	  of	  XLP1	  patients	  fail	  in	  sensing	  the	  second	  restimulation	  
through	   the	   TCR.	   Thus,	   these	   cells	   became	   resistant	   to	   RICD	   and	   accumulate,	   leading	   to	  
development	  of	  the	  disease	  [90,	  91].	  Chen	  et	  al.	  described	  in	  2007	  a	  survival	  advantage	  of	  SAP	  KO	  
murine	   CD8+	   T	   cells	   48	   hours	   upon	   the	   first	   TCR	   stimulation	   of	   freshly	   isolated	   T	   lymphocytes,	  
which	  they	  identified	  as	  AICD	  defect	  induced	  by	  p73,	  a	  protein	  involved	  in	  the	  mitochondrial	  cell	  
death	  pathway	  [92].	  	  
In	   contrast	   to	   AICD,	   susceptibility	   to	   RICD	   depends	   on	   prolonged	   exposure	   to	   IL-­‐2	   (termed	  
“propriocidal	  regulation”),	  upregulation	  of	  Fas	  and,	  importantly,	  a	  strong	  second	  restimulation	  of	  
the	  TCR	  [93-­‐95].	  In	  2009,	  Andrew	  Snow	  in	  Lenardo’s	  lab	  explored	  the	  role	  of	  SAP	  and	  SLAM	  in	  this	  
process	  for	  the	  first	  time	  [90].	  He	  showed	  that	  T	  cells	  from	  individuals	  with	  XLP1,	  as	  well	  as	  T	  cells	  
in	  which	  SAP	  expression	  was	  reduced	  with	   iRNA,	  are	  specifically	  resistant	  to	  apoptosis	  mediated	  
by	   TCR	   restimulation	   –	   RICD	   –	   and	   both	   SAP	   and	   NTB-­‐A	   are	   required	   for	   the	   apoptosis	   [90].	  
Importantly,	  SAP/NTB-­‐A	  signaling	  augmented	  the	  strength	  of	   the	  proximal	  TCR	  signal	   to	  achieve	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the	  threshold	  required	  for	  RICD,	  since	  restimulation	  with	  a	  stronger	  stimulus	  such	  as	  phorbol	  ester	  
(PMA)	   and	   ionomycin,	   reagents	   that	   bypass	   early	   TCR	   signaling	   events,	   triggered	   equivalent	  
apoptosis	   in	  control	  and	  XLP1	  patient	  T	  cells	   [90].	  Once	  the	  threshold	  has	  been	  reached,	  RICD	  is	  
specifically	  mediated	  by	  the	  expression	  of	  a	  number	  of	  pro-­‐apoptotic	  molecules,	  i.e.	  FASL	  and	  BIM,	  
which	  is	  lost	  in	  T	  lymphocytes	  from	  XLP1	  patients	  [90].	  	  
Recently,	  Katz	  et	  al.	  in	  Snow’s	  lab	  showed	  that	  LCK,	  but	  surprisingly	  not	  Fyn,	  is	  recruited	  to	  NTB-­‐A	  
through	  SAP	  and	  mediate	  RICD	  through	  a	  FASL/BIM	  dependent	  pathway	  [96].	  
4.	  The	  Diacylglycerol	  kinases	  
	  
4.1.	  The	  Diacylglycerol	  kinases	  family	  
	  
The	  Diacylglycerol	   kinases	   (DGKs)	   are	   a	   large	   family	   of	   enzymes	   that	   catalyze	   the	   conversion	  of	  
diacylglycerol	  (DAG)	  to	  phosphatidic	  acid	  (PA).	  Ten	  mammalian	  isozymes	  have	  been	  identified	  so	  
far,	  classified	  in	  five	  subtypes	  according	  to	  their	  primary	  structure	  (Figure	  4).	  
	  
Figure	  4.	  The	  Diacylglycerol	  kinases	  family.	  The	  five	  subtypes	  of	  Diacylglycerol	  kinases	  isoforms.	  All	  share	  
the	   C1	   domains	   and	   a	   catalytic	   domain.	   RVH:	   recoverin	   homology	   domain.	   PH:	   pleckstrin	   homology	  
domain.	  SAM:	  sterile	  α	  motif.	  M:	  MARCKS	  homology	  domain.	  ANK,	  ankyrin	  repeat	  domain;	  PDZ-­‐bind,	  PDZ-­‐
binding	  domain	  (Joshi	  et	  al.,	  2013).	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All	   of	   them	   share	   at	   least	   two	   characteristic	   C1	   (PKC-­‐like)	   domains	   and	   a	   catalytic	   ATP-­‐binding	  
domain,	  while	  differ	  in	  other	  sub-­‐specific	  domains	  [97].	  Interestingly,	  the	  C1	  domains	  do	  not	  show	  
in	  all	  the	  DGK	  family	  members	  high	  affinity	  for	  DAG/phorbol	  esters	  binding;	  indeed,	  the	  disruption	  
of	   the	   C1	   domain	   does	   not	   affect	   the	   enzymatic	   activity	   of	   DGKα	   [98].	   Instead,	   some	   reports	  
indicate	  that	  the	  C1	  domain	  of	  DGKγ,	  θ	  and	  ζ	  serves	  to	  mediate	  the	  membrane	  translocation	  [99-­‐
102].	  
Besides	   the	   differences	   in	   terms	   of	   structural	   features,	   each	   DGK	   shows	   a	   unique	   subcellular	  
localization,	  which	  reflects	  their	  non-­‐redundant	  function	  within	  the	  cells.	  	  
Moreover,	  most	  of	  the	  DGK	  isoforms	  are	  expressed	  in	  multiple	  tissues.	  Particularly,	  DGKα,	  DGKδ,	  
and	   DGKζ	   are	   the	   most	   abundant	   isoforms	   expressed	   in	   lymphocyte-­‐rich	   tissue.	   While	   DGKα,	  
DGKδ,	  and	  DGKζ	  are	  all	  expressed	  in	  T	  cells,	  the	  function	  of	  DGKδ	  remains	  largely	  unknown	  [103,	  
104].	  	  
DGKα,	   together	  with	  β	   and	   γ	   isoforms,	   belongs	   to	   the	   class	   I	   of	   DGKs	   (Figure	   4).	   They	   contain	  
calcium-­‐binding	   EF-­‐hand	  motifs	   and	   a	   recoverin	   homology	  domain	   (RVH).	   The	   EF-­‐hand	  domains	  
bind	  to	  calcium	  and	  the	  lack	  of	  these	  motifs	  causes	  the	  activation	  of	  class	  I	  DGKs,	  indicating	  that	  in	  
absence	   of	   calcium	   EF-­‐hand	   domains	   exert	   an	   auto-­‐inhibitory	   effect	   on	   the	   enzymatic	   activity	  
[105].	   The	   RVH	   domain	   is	   homologous	   to	   the	   N-­‐terminus	   of	   the	   recoverin	   family	   of	   neuronal	  
calcium	  sensors	   and	  deletion	  of	   this	  domain	   causes	   the	   loss	  of	   calcium-­‐dependent	  activation	  of	  
these	  enzymes	  [106].	  The	  other	  prominent	  member	  of	  DGK	  family	  expressed	  in	  T	  lymphocytes	  is	  
DGKζ,	   which	   belongs	   to	   the	   class	   for	   of	   DGKs	   (Figure	   4).	   DGKζ	   has	   a	   MARCKS	   (myristoylated	  
alanine-­‐rich	  C	  kinase	  substrate)	  phosphorylation	  site	  domain	  (PSD),	  which	  functions	  as	  a	  nuclear	  
localization	   signal	   and	   is	   phosphorylated	   by	   conventional	   PKC	   isoforms	   [107].	   Also,	   it	   has	   four	  
ankyrin	  repeats	  and	  carboxy	  terminal	  PDZ-­‐binding	  domains	  [108].	  
Specifically,	  in	  this	  thesis	  I	  will	  discuss	  the	  role	  of	  DGKα	  as	  a	  negative	  regulator	  of	  apoptosis	  during	  
the	   restimulation-­‐induced	   cell	   death	   (RICD)	   in	   primary	   T	   cells.	   This	   work	   provides	   a	   proof	   of	  
concept	  for	  the	  therapy	  of	  the	  life-­‐threatening	  expansion	  of	  T	  cells	  in	  XLP1	  disease.	  
4.2.	  Regulation	  of	  Diacylglycerol	  kinase	  alpha	  in	  T	  lymphocytes	  
	  
As	  previously	  reported,	  DGKα	   is	  particularly	  abundant	   in	  T	   lymphocytes;	  therefore,	  this	  cell	   type	  
represented	   over	   the	   past	   years	   the	   most	   suitable	   and	   interesting	   system	   to	   study	   DGKα	  
physiological	   functions.	   In	   T	   cells,	   DGKα	   is	   regulated	   by	   calcium.	   Strikingly,	   Ca2+	   induces	   DGKα	  
	   22	  
translocation	   to	   the	  plasma	  membrane,	   rather	   then	   its	  activation,	  which	   is	  augmented	  only	   in	  a	  
low	  extent	  [109].	  	  
Besides	  calcium,	  DGKα	  is	  regulated	  by	  the	  cytokine	  IL-­‐2.	  Indeed	  the	  enzyme,	  which	  locates	  in	  the	  
cytosol	  and	  nuclei	  of	  resting	  cells,	  translocates	  outside	  the	  nucleus	  in	  response	  to	  IL-­‐2	  binding.	  IL-­‐2	  
also	   mediates	   the	   activation	   of	   the	   enzyme,	   which	   in	   turns	   promotes	   the	   IL-­‐2-­‐induced	   T	   cells	  
proliferation	  by	  inducing	  G1	  to	  S	  transition	  [110,	  111].	  Nevertheless,	  it	  has	  been	  shown	  that	  those	  
effects	   are	   Ca2+-­‐independent,	   suggesting	   the	   existence	   of	   a	   different	   regulatory	  mechanism	   for	  
DGKα	   activation	   [112].	   In	  2003,	  Merida’s	  group	  demonstrated	   that	  DGKα	   is	   activated	  upon	  TCR	  
engagement	  in	  a	  PI3K-­‐dependent,	  calcium-­‐independent	  manner.	  The	  lipid	  product	  of	  active	  PI3K,	  
PIP3,	  directly	  activates	  and	  mediates	  DGKα	  translocation	  to	  the	  plasma	  membrane	  [102].	  	  
It	   has	   been	   demonstrated,	   in	   non-­‐hematopoietic	   cells,	   that	   DGKα	   is	   positively	   regulated	   by	   Src	  
phosphorylation	  on	  Tyr335,	  located	  at	  the	  hinge	  between	  the	  second	  C1	  domain	  and	  the	  catalytic	  
domain	  in	  the	  human	  sequence	  [113,	  114].	  Similarly,	  in	  T	  lymphocytes	  DGKα	  is	  phosphorylated	  on	  
the	  same	  residue	  by	  the	  Src	  kinase	  family	  member	  LCK	  [115].	  This	  phosphorylation	  leads	  to	  kinase	  
activation	   and	   translocation	   to	   the	  plasma	  membrane,	  where	   it	   can	  negatively	  modulates	  DAG-­‐
dependent	  signals	  derived	  from	  TCR	  [115].	  
Recently,	   our	   research	   group	   also	   identified	   the	   adaptor	   protein	   SAP	   as	   a	   novel	   regulator	   of	  
DGKα	  [116].	   	  Upon	  TCR/CD28	  or	  TCR/SLAM	  co-­‐stimulation,	  DGKα	  exits	   from	  the	  nucleus	  and	   its	  
catalytic	  activity	  is	  suppressed	  in	  a	  PLCγ1-­‐dependent	  manner	  [116].	  The	  knockdown	  of	  SAP	  results	  
in	  a	  rescue	  of	  DGKα	  activity	  and	  impairs	  its	  exit	  from	  the	  nucleus	  upon	  TCR	  co-­‐stimulation	  [116].	  
However,	  SAP	  and	  DGKα	  do	  not	  directly	  interact,	  and	  the	  mechanism	  by	  which	  SAP	  inhibits	  DGKα	  
in	  normal	  T	  cells	  still	  has	  to	  be	  clarified.	  	  
	  
4.3	  Diacylglycerol	  kinases	  as	  negative	  regulators	  of	  T	  cell	  signaling	  
	  
Engagement	  of	  the	  TCR	  by	  peptides	  presented	  on	  APCs	  trigger	  a	  signaling	  cascade	  that	  culminates	  
in	  T	  cells	  activation.	  One	  of	  the	  early	  events	  is	  the	  activation	  of	  PLCγ,	  which	  in	  turn	  is	  responsible	  
for	  DAG	  generation	  and,	  ultimately,	  calcium	  flux.	  DAG-­‐dependent	  proteins,	  i.e.	  PKCs,	  RasGRP1	  and	  
PKD,	  represent	  the	  central	  hub	  of	  the	  TCR	  response.	  	  
Consistent	   with	   their	   catalytic	   activity,	   both	   DGKα	   and	   DGKζ	   have	   a	   crucial	   role	   in	   T	   cells	   by	  
metabolizing	   DAG	   and	   therefore	   terminating	   the	   DAG-­‐activated	   signaling	   cascade.	   It	   has	   been	  
showed	  by	  Merida’s	  group	  that	   in	  T	  cells	  stimulated	  with	  anti-­‐CD3,	  DGKα	   rapidly	  translocates	  to	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the	   plasma	   membrane,	   where	   metabolizes	   DAG	   into	   PA	   [117].	   Importantly,	   overexpression	   of	  
DGKα	   drastically	   reduces	   the	   expression	   of	   CD69,	   a	   well-­‐known	   marker	   of	   T	   cells	   activation,	  
demonstrating	   for	   the	   first	   time	   that	   DGKα	   acts	   as	   an	   integral	   component	   of	   the	   TCR-­‐induced	  
signaling	   cascade	   [117].	   The	   same	   group	   then	   went	   on	   demonstrating	   that	   DGKα-­‐mediated	  
consumption	   of	   DAG	   culminates	   in	   RasGRP1	   release	   from	   the	   plasma	   membrane	   and	  
consequently	   terminates	   the	   RasGRP1-­‐regulated	   signals	   [118,	   119].	   Consistently,	   DGKα	   activity	  
controls	   DAG-­‐mediated	  membrane	   localization	   of	   RasGRP1,	   ERK	   activation	   and	   IL-­‐2	   production	  
upon	  TCR	  engagement	  [8,	  117,	  118,	  120].	  Similarly,	  it	  has	  been	  shown	  that	  DGKζ	  knockout	  T	  cells	  
produce	   less	  PA	  after	  TCR	  stimulation	  compared	  to	  the	  wild	  type	  counterpart	   [121].	   In	  addition,	  
DGKζ-­‐deficient	   T	   cells	   were	   found	   to	   be	   hyper-­‐responsive	   to	   TCR	   stimulation,	   displaying	   an	  
increased	  activation	  of	  MEK,	  ERK	  and	  high	  levels	  of	  the	  activation	  markers	  CD69	  and	  CD25	  [121].	  
Moreover,	  it	  has	  been	  demonstrated	  that	  DGKζ	  plays	  a	  pivotal	  role	  in	  determinating	  the	  threshold	  
of	  T	  cells	  activation,	  acting	  as	  a	  modulator	  of	  the	  analog/digital	  signaling	  [122].	  
In	  2006,	  two	  distinct	  groups	  simultaneously	  reported	  a	  critical	  role	  of	  DGKα	  and	  DGKζ	  in	  defining	  
the	   activation	   status	   versus	   the	   induction	   of	   anergy	   upon	   TCR	   stimulation	   [8,	   123].	   They	   found	  
high	  expression	  levels	  of	  both	  DGK	  isoforms	  in	  anergic	  cells,	  which	  are	  characterized	  by	  a	  state	  of	  
antigen	  unresponsiveness	   induced	  by	  (TCR)	  stimulation	   in	  the	  absence	  of	  a	  co-­‐stimulatory	  signal	  
[8,	  123]	  (Figure	  5).	  	  
	  
	  
Figure	  5.	  DGKα	  expression	  levels	  in	  non-­‐activated	  versus	  cycling	  T	  cells	  (Merida	  et	  al.,	  2009)	  
	  
Anergy	   is	   associated	   with	   DGKα	   overexpression,	   which	   ultimately	   leads	   to	   defective	   RasGRP1	  
translocation	   to	   the	   plasma	  membrane	   [8].	   Accordingly,	   T	   cells	   from	  DGKα	   and	   DGKζ	   KO	  mice	  
proliferate	  and	  produce	  IL-­‐2,	  even	  under	  anergic	  conditions	  [8,	  123].	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Collectively,	  these	  data	  have	  provided	  evidences	  that	  DGKα	  and	  ζ,	  by	  metabolizing	  DAG,	  are	  key	  
enzymes	  in	  the	  induction	  of	  the	  anergy	  state,	  which	  is	  controlled	  by	  signal	  strength,	  co-­‐stimulatory	  
signals	  and	  differentiation	  status	  of	  the	  cells.	  	  
As	  mentioned	  before,	  in	  order	  to	  have	  a	  functional	  immune	  synapse,	  is	  essential	  to	  form	  a	  sharp	  
gradient	  of	  DAG	  in	  the	  contact	  zone	  between	  the	  T	  cell	  and	  the	  APC.	  DGKs	  have	  a	  pivotal	  role	  in	  
the	  formation	  of	  a	  functional	  IS,	  where	  a	  fine	  regulation	  of	  DAG	  production	  is	  absolutely	  required.	  
For	   instance,	   localized	  DAG	  synthesis	  causes	  reorientation	  of	   the	  MTOC	  towards	  the	   IS,	  which	   is	  
required	  for	  transduction	  of	  the	  TCR	  signal	  [124].	  In	  this	  context,	  inhibition	  of	  DGKs	  disrupts	  DAG-­‐
localized	  accumulation	  and	  impairs	  MTOC	  reorientation	  [124].	  
A	   first	   study	   in	   2011	   showed	   that	   although	  both	  DGKα	   and	  ζ	   localize	   at	   the	   IS	   upon	  TRC/CD28	  
engagement,	  DGKζ	  appears	  to	  play	  a	  dominant	  role	  in	  both	  DAG	  consumption	  and	  PA	  production	  
at	  the	  IS	  [125].	  However,	  a	  recent	  work	  from	  Huse’s	  group	  elegantly	  demonstrates	  that	  DGKα,	  but	  
not	  DGKζ,	   localizes	   at	   the	  periphery	  of	   the	   IS,	  where	   is	   required	   for	  optimal	  MTOC	  polarization	  
toward	  the	  APC	  by	  constraining	  the	  area	  in	  which	  DAG	  accumulated	  at	  the	  IS	  [52].	  This	  process	  of	  
DGKα	  compartmentalization	  is	  PI3K-­‐dependent	  [52].	  	  
Collectively,	  these	  evidences	  suggest	  that	  DGKα	  and	  ζ	  share	  overlapping	  and	  complementary	  roles	  
in	  T	   cell	   signaling,	   acting	  as	  negative	   regulators	  of	  TCR	   signaling	  by	   terminating	  DAG-­‐dependent	  
pathways	   and	   inducing	   anergy.	   However,	   although	   no	   direct	   comparison	   of	   the	   relative	  
contribution	  of	  the	  two	  DGK	  isoforms	  in	  the	  regulation	  of	  the	  signaling	  has	  been	  performed	  yet,	  
the	  ζ	   isoform	  appears	   to	   be	   the	  more	   crucially	   involved	   in	   controlling	   the	   TCR-­‐driven	   signaling,	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Material	  and	  Methods	  
	  
Cells	  culture	  and	  reagents	  
Blood	   samples	   were	   obtained	   with	   informed	   consent	   under	   protocols	   approved	   by	   the	  
Institutional	   Review	   Board	   at	   Cincinnati	   Children’s	   Hospital	  Medical	   Center	   or	   according	   to	   the	  
declaration	  of	  Helsinki.	   Peripheral	  blood	  mononuclear	   cells	   (PBMCs)	  were	   isolated	   from	  healthy	  
donors	   or	   XLP1	   patients	   by	   Ficoll-­‐Paque	   PLUS	   (GE	   Health	   Care)	   density	   gradient	   centrifugation,	  
washed,	   and	   resuspended	   at	   2	   x	   106	   cell/mL	   in	   RPMI-­‐GlutaMAX	   (GIBCO,	   Life	   technologies)	  
containing	  10%	  heat	  inactivated	  FCS	  (LONZA)	  and	  antibiotics/antimycotics	  (Sigma-­‐Aldrich).	  T	  cells	  
were	  activated	  with	  1	  μg/mL	  anti-­‐CD3	  (clone	  OKT3)	  and	  anti-­‐CD28	  (clone	  CD28.2)	  antibodies	  for	  3	  
days.	   After	   3	   days,	   activated	   T	   cells	   were	   washed	   and	   cultured	   in	   complete	   RPMI-­‐GlutaMAX	  
supplemented	  with	  100	  IU/mL	  rhIL-­‐2	  (Peprotech)	  at	  1.2	  x	  106	  cells/mL	  for	  ≥7	  days	  before	  all	  the	  
assays	  were	  conducted	  (media	  was	  replaced	  every	  2-­‐3	  days).	  	  
	  
Jurkat	  A3	  cells	  were	  from	  ATCC.	  Cells	  were	  cultured	  in	  RPMI-­‐GlutaMAX	  (GIBCO,	  Life	  Technologies)	  
with	   10%	   FCS	   and	   antibiotics/antimycotics	   (Sigma-­‐Aldrich)	   in	   humidified	   atmosphere	   5%	  CO2	   at	  
37°C.	  	  
	  
The	  DGKα	  inhibitor	  R59949	  (Sigma-­‐Aldrich)	  was	  dissolved	  in	  DMSO;	  equal	  amounts	  of	  DMSO	  were	  
used	   in	  the	  control	  samples.	  All	   reagents	  are	  from	  Sigma-­‐Aldrich	  apart:	  human	  recombinant	   IL-­‐2	  
(Peprotech),	   FR180204	   (ERK	   inhibitor	   II	   #	   328007,	   Calbiochem),	   1,2-­‐dioctanoyl-­‐sn-­‐glycerol	   (DG	  
08:0,	  #	  800800O,	  Avanti),	  SL0101-­‐1	  (Tocris	  Bioscience,	  Cat	  n.	  2250).	  	  
	  
Antibody	   Vendor	   Type	   Catalog	  number	  	  	   clone	  
anti-­‐actin	   Santa	  Cruz	   monoclonal	   sc-­‐8432	   C-­‐2	  
anti-­‐tubulin	   Sigma-­‐Aldrich	   monoclonal	   T0926	   	  
anti-­‐DGKα	   Shaap	   et	   al.,	  
1993	  
monoclonal	  mix	   	   	  
anti-­‐DGKα	   Abcam	   polyclonal	   AB	  64845	   	  
anti-­‐human	  CD3ε	   in	  house	   monoclonal	   	   OKT3	  
anti-­‐human	  CD3	   eBiosciences	   monoclonal	   16-­‐0038-­‐85	   UCHT1	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anti-­‐human	  CD28	   eBiosciences	   monoclonal	   16-­‐0289-­‐85	   CD28.2	  
anti-­‐SAP	   Cell	  Signaling	   polyclonal	   5272S	   	  
anti	  p44/p42	  MAPK	   Cell	  Signaling	   polyclonal	   9102	   	  
anti-­‐phospho	  
T202/Y204	   p44/p42	  
MAPK	  	  
Cell	  Signaling	   polyclonal	   9101S	   	  
anti-­‐S6	   Cell	  Signaling	   polyclonal	   2217	   	  
anti-­‐phospho	  S6	   Cell	  Signaling	   polyclonal	   4856	   	  
anti-­‐RasGRP1	   Santa	  Cruz	   polyclonal	   sc-­‐28581	   	  
anti-­‐PKCθ 	   Santa	  Cruz	   polyclonal	   sc-­‐212	   	  
anti-­‐phospho	   S351	  
Nur77	  	  
Cell	  Signaling	   polyclonal	   5095	   	  





polyclonal	   A-­‐21206	   	  
anti-­‐mouse	  HRP	   Perkin	  Elmer	   polyclonal	   NEF822001EA	   	  
anti-­‐rabbit	  HRP	   Perkin	  Elmer	   polyclonal	   NEF812001EA	   	  
	  
	  
siRNA	  for	  transient	  silencing	  
Activated	  human	  PBLs	  were	  prepared	  as	  described	  above	  and	  transfected	  with	  200	  pmol	  of	  siRNA	  
oligonucleotides	  specific	  for	  the	  target	  protein	  (Stealth	  Select	  siRNA,	  Life	  Technologies)	  or	  a	  non-­‐
specific	   control	   oligo	   (Life	   Technologies).	   Transient	   silencing	  was	   obtained	   by	   transfection	   using	  
the	   Amaxa	   nucleofector	   kit	   “Human	   T	   cell	   nucleofector	   kit”	   (VPA-­‐1002,	   Lonza)	   and	   the	   Amaxa	  
Nucleofector	   II	   system	  (program	  T-­‐20,	  Lonza)	  according	   to	  manufacturer’s	   instructions.	  The	  cells	  
were	   maintained	   in	   culture	   in	   presence	   of	   IL-­‐2	   (100	   IU/ml)	   for	   4	   day	   to	   allow	   target	   gene	  
knockdown.	   siRNA	   sequences	   were:	   SAP	   forward	   UGUACUGCCUAUGUGUGCUGUAUCA,	   reverse	  
UGAUACAGCAGACAUAGGCAGUACA;	  DGKα	  forward	  CGAGGAUGGCGAGAUGGCUAAAUAU,	  reverse	  
AUAUUUAGCCAUCUCGCCAUCCUCG;	   DGKζ	   forward	   GCCGCUUUCGGAAUAAGAUtt,	   reverse	  
AUCUUAUUCCGAAAGCGGCtg;	   PKCθ	   forward	   CGUUGGAUGAGGUGGAUAAtt,	   reverse	  
UUAUCCACCUCAUCCAACGga;	   RasGRP1	   forward	   CUACGACAAUUACCGGCGAtt,	   reverse	  
UCGCCGGUAAUUGUCGUAGtt.	   Nur77	   forward	   GGUCCCUGCACAGCUUGCUUGUCGA,	   reverse	  
UCGACAAGCAAGCUGUGCAGGGACC.	   Nor1	   forward	   AGAUCUUGAUUAUUCCAGATT,	   reverse	  
UCUGGAAUAAUCAAGAUCUCT.	   The	   efficiency	   of	   all	   the	   siRNAs	   was	   validated	   by	   WB	   or	   qPCR	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analysis.	   Stealth	   RNAi	   Negative	   Control	   Duplexes	   (#	   12935-­‐300,	   Life	   Technologies)	   was	   used	   as	  
negative	  control.	  	  
	  
Jurkat	  cells	  live	  imaging,	  Raji	  loading	  and	  conjugate	  experiments	  
For	   the	   experiment	   performed	  with	   the	   DGKα	   inhibitor	   R59949,	   Jurkat	   shSAP	   or	   shCNTR	  were	  
transfected	  with	  DMRIE-­‐C	  (Invitrogen)	  according	  to	  the	  manufacturers’	   instructions,	  and	  after	  48	  
hours	  R59949	  10	  µM	  was	  added	  30	  min	  before	  cells	  conjugation.	  
For	   the	   experiments	   performed	   with	   siRNA,	   0.5	   x	   106	   Jurkat	   shSAP	   or	   shCNTR	   cells	   were	  
microporated	   (Neon®	   Transfection	   System,	   Life	   Technologies)	   according	   to	   the	   manufactures’	  
instructions	   (1400V,	   30	   sec,	   1	   pulse).	   Cells	   were	   then	   transferred	   into	   2	  ml	   fresh,	   pre-­‐warmed	  
complete	  RPMI	  and	  incubated	  for	  96	  hours	  prior	  to	  performing	  the	  conjugation	  experiments.	  
For	  the	  Raji	  B	  cells	  loading	  and	  the	  conjugation	  experiments,	  Raji	  B	  cells	  were	  washed	  once	  in	  PBS	  
and	  resuspended	  in	  RMPI	  0%	  FCS	  +	  5	  µM	  of	  CellTracker	  Red	  CMPTX	  (Invitrogen)	  for	  30	  min	  at	  37	  
°C.	   Cells	   were	   then	   washed	   twice	   with	   RMPI	   10%	   FCS,	   and	   resuspended	   in	   RPMI	   10%	   FCS	   +	  
Staphylococcal	   enterotoxin	   E	   (SEE,	   Toxin	   technology	  #ET404)	   1	  µg/ml	   for	   1	  hour	   at	   37	   °C.	   Then	  
cells	  were	  washed	  twice	  with	  RMPI	  10%	  FCS	  and	  resuspended	  in	  conjugation	  medium	  (RPMI/0.2	  %	  
BSA	  (endotoxin	  low,	  f.a.f.)/50	  mM	  HEPES	  pH	  7.5).	  	  
Jurkat	   cells	   (1	   x	   105)	   were	   resuspended	   in	   conjugation	  medium	   and	  mixed	   with	   Raji	   cells	   SEE-­‐
loaded	  1:1,	  centrifugated	  at	  100	  x	  g	  for	  1	  min	  to	  force	  conjugate	  formation,	  and	  then	  incubated	  for	  
10	  min	  at	  37°C.	  Cells	  conjugates	  were	  then	  resuspended	  in	  warm	  conjugation	  medium,	  seeded	  on	  
polylisine-­‐coated	  glasses	  and	   let	  adhere	  for	  5	  min	  at	  37	  °C.	  Live	  cells	  were	   imaged	  with	  an	  Zeiss	  
LSM	  510	  (Carl	  Zeiss)	   inverted	  laser	  scanning	  microscope	  (LSM)	  using	  a	  C-­‐	  Apochromat	  X63	  water	  
immersion	  objective	  (Zeiss).	  
	  
Immunofluorescence	  experiments	  with	  primary	  human	  PBLs	  
Freshly	  isolated	  human	  PBLs	  were	  isolated	  and	  cultured	  as	  described	  before	  and	  transfected	  with	  
Amaxa	  NucleofectorTM	  	  Kit	   for	  Human	  T	  Cells	   (Cat.	  VVPA-­‐1002)	  with	  control,	  SAP-­‐specific	  and/or	  
DGKα-­‐specific	  siRNA.	  After	  72	  hours	  T	  cells	  were	  incubated	  with	  Raji	  B	  cells	  loaded	  with	  mixed	  SEE	  
(1	  µg/ml)	  and	  SEB	  (0.5	  µg/ml)	  for	  15	  minutes,	  fixed	  and	  stained	  for	  either	  PKCθ	  or	  RasGRP1.	  For	  
the	   experiments	   performed	  with	   the	   DGKα	  inhibitor	   R59949,	   CNTRL	   or	   SAP-­‐silenced	   PBLs	  were	  
pre-­‐treated	  with	  R59949	  (10	  µM,	  30	  minutes,	  37°C)	  or	  DMSO	  before	  allowing	  conjugation.	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Quantification	  and	  data	  processing	  
To	  quantify	  the	  mean	  fluorescence	  intensity	  (MFI)	  of	  Lifeact-­‐GFP	  or	  PKCθ-­‐CRD	  at	  the	  contact	  site	  
between	   T	   cell	   and	   Raji	   B	   cell,	   we	   have	   programmed	   an	   automatic	   cell	   image	   segmentation	  
algorithm	   that	   yields	  masks	   for	   Raji	   B	   cell	   (always	   labeled	   in	   red,	   blue	   in	   the	  mask)	   and	   T	   cell	  
transfected	   with	   GFP-­‐plasmids	   of	   interest	   (green,	   shown	   in	   green	   in	   the	   mask).	   The	   algorithm	  
arbitrary	  takes	  in	  account	  a	  2	  µm	  width	  area	  in	  the	  juxtaposed	  zone	  between	  the	  two	  masks	  (red	  
area).	  The	  data	  processing	  is	  a	  step-­‐by-­‐step	  procedure	  performed	  as	  follow:	  
1. Creating	  a	  Microsoft	  Office	  Excel	   file,	  which	  contains	   the	  sorted	  data.	  This	   file	   tracks	   the	  
measurements	  automatically.	  
2. Loading	  the	  image	  in	  the	  LSM	  format	  (which	  contains	  all	  the	  meta-­‐information	  about	  the	  
image)	  
3. Adjusting	   contrast	   and	   brightness,	  while	   filtering	   the	   image	   to	   reduce	   “salt	   and	   pepper”	  
noise	  
4. Exclusion	   of	   other	   cells	   rather	   then	   the	   two	   in	   exam	  by	   drawing	   a	   tight	   ROI	   around	   the	  
conjugate	  	  
5. Segmentation	  which	  allows	  to	  automatically	  recognize	  the	  regions	  of	  interest	  (ROIs)	  	  
6. Selection	  of	  the	  perimeter:	  it	  allows	  fixing	  the	  size	  of	  the	  contact	  area.	  
	  
Figure	  8.	  Step-­‐by-­‐step	  procedure	  of	  the	  automated	  segmentation	  process.	  
The	  automatic	  segmentation	  algorithm	  was	  created	  by	  using	  MatLab	  software.	   Input:	   loading	  the	  original	  
image	   in	   the	   LSM	   Zeiss	   format.	  Output:	  MFI	   of	   ROI1	   (contact	   area,	   in	   red)	   and	   ROI2	   (remaining	   part,	   in	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green)	   and	   the	   ratio	   MFI-­‐ROI1/MFI-­‐ROI2,	   which	   was	   used	   for	   the	   statistic.	   	   The	   steps	   are	   described	   in	  
details	   in	   the	   text	   above.	   The	  algorithm	  was	  modified	   from	  a	  previous	  one	  originally	   created	   to	  quantify	  
native	  Ras	  activation	  in	  single	  living	  cells	  from	  Christoph	  Biskup	  [126]	  
	  
The	  MTOC	  repositioning	  in	  the	  conjugate	  experiments	  was	  analyzed	  by	  calculating	  a	  polarization	  
index	  equal	  to	  the	  distance	  from	  the	  MTOC	  to	  the	  immunological	  synapse	  divided	  by	  the	  distance	  
from	   the	   immunological	   synapse	   to	   the	   distal	   pole	   of	   the	   T	   cell	   [52].	   Distances	   in	  micrometers	  
were	  measured	  by	  using	  the	  LSM	  software,	  Zeiss.	  	  
PKCθ	  and	  RasGRP1	  localization	  at	  the	  IS	  were	  scored	  by	  counting	  cells	  which	  display	  accumulation	  




To	  test	  the	  restimulation	  induced	  cell	  death	  (RICD),	  activated	  T	  cells	  (105	  cells/well)	  were	  plated	  in	  
triplicate	   in	   96-­‐well	   round-­‐bottom	   plate	   and	   treated	  with	   anti-­‐CD3	  mAb	  OKT3	   (1-­‐100	   ng/ml)	   in	  
RPMI-­‐GlutaMAX	  supplemented	  with	  100	  IU/ml	  rhIL-­‐2	  for	  24	  hours.	   In	  some	  assays	  R59949	  (5-­‐10	  
μM)	  or	  DAG	  (50	  μM)	  or	  U0126	  (5	  μM)/FR180204	  (10	  μM)/Rottlerin	  (6	  μM)	  inhibitors	  were	  added	  
30	  minutes	  before	   the	   restimulation.	  24	  hours	  after	   treatment,	   cells	  were	   stained	  with	  1	  μg/ml	  
propidium	  iodide	  and	  collected	  for	  a	  constant	  time	  of	  30	  seconds	  per	  sample	  on	  a	  FACScan	  flow	  
cytometer	   (FACS	  Calibur,	   BD).	   Cell	   death	  was	   analyzed	  with	  CellQuest	   software	   (BD)	   or	   Flowing	  
software	   (Turku	  Bioimaging)	   as	  percentage	  of	   cell	   loss	  =	   (1	  –	   [number	  of	   viable	   cells	   (treated)	   /	  
number	  of	  viable	  cells	  (untreated)])	  ×	  100	  as	  described	  before	  [90].	  
Alternatively,	  for	  Annexin	  V+	  assays,	  cells	  were	  plated	  in	  triplicate	  (1.5	  x	  106	  cells/well)	  in	  12-­‐well	  
plate	  and	  treated	  with	  anti-­‐CD3	  clone	  OKT3	  (10	  ng/ml)	  in	  RPMI-­‐GlutaMAX	  supplemented	  with	  100	  
IU/ml	  rhIL-­‐2	   for	  24	  hours.	  24	  hours	  after	  treatment,	  cells	  were	  stained	  with	  the	  Kit	  Alexa	  Fluor®	  
488	  Annexin	  V+/Dead	  Cell	  Apoptosis	  Kit	  (Invitrogen)	  according	  to	  manufacturer’s	  instructions	  and	  
analysed	  on	  a	  FACScan	  flow	  cytometer	  (FACS	  Calibur,	  BD).	  	  
	  
Western	  blotting	  
The	  activated	  lymphocytes	  were	  stimulated	  at	  density	  of	  15	  x	  106	  cell/ml	  in	  RPMI-­‐GlutaMAX	  10%	  
H.I.	  FCS	  with	  10	  μg/ml	  anti-­‐CD3	  clone	  OKT3	  for	  5,	  30	  minutes	  or	  4	  hours.	   In	  some	  western	  blots	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R59949	  (5	  μM)	  was	  added	  30	  minutes	  before	  the	  restimulation.	  The	  restimulation	  was	  stopped	  by	  
washing	  the	  cells	  with	  cold	   (4°C)	  PBS	  and	  the	  cells	  were	   lysate	  at	  15	  X	  106	  cell/ml	   in	   lysis	  buffer	  
(25mM	  Hepes,	  pH	  8,	  150mM	  NaCl,	  0.5/1%	  Nonidet	  P-­‐40,	  5	  mM	  EDTA,	  2	  mM	  EGTA,	  1	  mM	  ZnCl2,	  
50	   mM	   NaF,	   10%	   glycerol	   supplemented	   with	   fresh	   1	   mM	   Na3VO4,	   and	   protease	   inhibitors),	  
clarified	   after	   centrifugation	   of	   15	  minutes	   at	   12000	   rpm	   at	   4°C,	   heat-­‐denatured	  with	   Laemmli	  
buffer	  (100°C	  for	  5	  minutes)	  and	  separated	  by	  SDS-­‐PAGE	  (Biorad).	  Proteins	  were	  then	  transferred	  
on	  PVDF	  membrane	  (Hybond	  P,	  Amersham)	  by	  using	  semi-­‐dry	  system	  (Biorad).	  Membranes	  were	  
then	  blocked	  with	  5%	  BSA	  in	  TBS	  and	  incubated	  at	  4°C	  overnight	  with	  primary	  antibodies	  diluted	  in	  
TBS-­‐tween	  (150	  mM	  NaCl,	  20	  mM	  Tris,	  pH	  7.5,	  0.1	  %	  Tween),	  BSA	  2%,	  0.01%	  azide.	  After	  4	  washes	  
with	  TBS-­‐Tween	  0.1%,	  membranes	  were	  incubated	  with	  secondary	  antibodies	  and	  washed	  again.	  
Western	  blots	  were	  visualized	  using	  Western	  Lightening	  Chemiluminescence	  Reagent	  Plus	  (Perkin	  
Elmer)	   and	   the	   images	   were	   acquired	   by	   using	   Versadoc	  Model	   4000	   Imaging	   System	   (Biorad)	  
whose	  software	  was	  used	  for	  densitometry.	  	  
	  
Quantitative	  RT-­‐PCR	  
The	   activated	   lymphocytes	   were	   stimulated	   at	   density	   of	   15	   x	   106	   cell/ml	   in	   complete	   RPMI-­‐
GlutaMAX	  with	  10	  μg/ml	  anti-­‐CD3	  clone	  OKT3	  for	  4	  hours.	  	  Where	  indicated,	  R59949	  (5	  μM)	  was	  
added	  30	  minutes	  before	  the	  restimulation.	  Cells	  were	  washed	  with	  cold	  PBS	  and	  the	  mRNA	  was	  
extracted	  by	  ChargeSwitch	  Total	  RNA	  Cell	   Kit	   (Life	  Technologies).	   The	  RNA	  was	   retrotranscribed	  
with	  High-­‐Capacity	  cDNA	  Reverse	  Transcription	  Kits	  (Applied	  Biosystems)	  and	  cDNA	  quantified	  by	  
real	  time	  PCR	  (C1000	  Thermal	  Cycler	  CFX96	  realtime	  system,	  Biorad)	  using	  GUSB	  as	  normalizer.	  	  
TaqMan	   gene	   expression	   assays	   were	   from	   Life	   Technologies:	   Hs00939627_m1	   (GUSB),	  
Hs00176278_m1	   (DGKα),	   Hs00174114_m1	   (IL-­‐2),	   Hs00158978_m1	   (SH2D1A),	   Hs01076940_m1	  
(BCL2L11),	  Hs00181225_m1	  (FASLG),	  Hs	  00374226_m1	  (NR4A1)	  and	  Hs	  00545007_m1(NR4A3).	  
	  
Mice	  and	  in	  vivo	  experiments	  
Sap	  KO	  mice	  were	  as	  described	   [127].	   	  C57BL/6	   (B6)	  were	  purchased	   from	  Jackson	  Laboratories	  
(Bar	  Harbor,	  ME).	  Experimental	  procedures	  were	  approved	  by	   the	   Institutional	  Animal	  Care	  and	  
Use	   Committee	   at	   The	   Children’s	   Hospital	   of	   Philadelphia.	   To	   establish	   LCMV	   infection,	   mice	  
received	  2x105	  plaque-­‐forming	  units	   (PFU)	  of	  LCMV-­‐Armstrong	  (LCMVarm)	  by	   intraperitoneal	   (i.p)	  
injection	  on	  day	  0	  and	  experiments	  were	  carried	  out	  until	  day	  +8	  post-­‐infection.	  Beginning	  at	  day	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4,	  mice	  were	  given	  twice	  daily	  i.p	  injections	  of	  R59022	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO)	  dissolved	  in	  
DMSO	  (2mg/kg	  body	  weight).	  Mice	  in	  all	  groups	  were	  sex	  and	  age	  matched.	  	  
	  
Mouse	  splenocytes	  in	  vitro	  stimulations,	  flow	  cytometry	  and	  ELISA	  
Splenocytes	  were	  cultured	  at	  a	  concentration	  of	  10	  x	  106	  cells/mL	  with	  or	  without	  gp33	  peptide	  
(0.4	  ng/μL,	  AnaSpec,	  Fremont,	  CA)	  in	  the	  presence	  of	  monensin	  and	  fluorochrome	  conjugate	  anti-­‐
CD107α	   (BD	  Biosciences,	  San	   Jose,	  CA)	   for	  5	  hours.	  Cells	  were	  washed,	   fixed	  and	  permeabilized	  
with	   cytofix/cytoperm	   (BD	   Biosciences,	   San	   Diego,	   CA)	   and	   stained	   for	   intracellular	   cytokines.	  	  
Fluorochrome	  conjugated	  anti-­‐mouse	  CD4,	  CD8,	  TCRβ,	  and	  IFNγ	  monoclonal	  antibodies	  were	  from	  
BD	  Biosciences	  (San	  Jose,	  CA,	  USA).	  	  Anti-­‐mouse	  CD44	  and	  TNFα	  antibodies	  were	  purchased	  from	  
eBioscience	   (San	   Diego,	   CA,	   USA).	   	   APC-­‐conjugated	  MHC-­‐I	   restricted	   LCMV	   gp33	   tetramer	   was	  
provided	  by	   John	  Wherry	   (The	  University	  of	  Pennsylvania).	  Data	  were	  collected	  on	  an	  LSRII	   flow	  
cytometer	   (BD	  Biosciences)	  and	  analyzed	  using	  FlowJo	  software	   (Tree	  Star;	  Ashland,	  OR).	  Serum	  




Livers	   were	   fixed	   overnight	   in	   10%	   formalin	   (w/v)	   (Fischer	   Scientific,	   Fair	   Lawn,	   New	   Jersey),	  
embedded	  in	  paraffin,	  cut	  in	  5	  μm	  sections,	  and	  stained	  with	  hematoxylin	  and	  eosin.	  Images	  were	  
captured	  using	  a	  Nikon	  Eclipse	  90i	  equipped	  with	  a	  Nikon	  DS-­‐Fi1	  camera	  and	  NIS-­‐Elements	  BR	  3.0	  
software	  (Nikon,	  Japan).	  	  For	  each	  sample,	  five	  random	  fields	  were	  captured	  at	  20x	  magnification	  
(Nikon	  Plan	  Apo	  10x;	  NA	  0.45)	  and	  subjected	   to	  computer-­‐based	  quantification	  of	   inflammatory	  
infiltrates	   using	   the	   BZ-­‐II	   Analyzer	   Hybrid	   Cell	   Count	   software	   (Keyence,	   Japan).	   The	   average	  
number	  of	  inflammatory	  foci	  (defined	  as	  clusters	  containing	  >	  8	  lymphocytes)	  was	  determined	  for	  
each	  treatment	  group,	  along	  with	  the	  area	  of	  the	  inflammatory	  infiltrate.	  
Statistics	  
Data	  are	  shown	  as	  the	  mean	  ±	  SEM.	  For	  statistical	  analysis,	  Student’s	  t-­‐test	  was	  used.	  Experiments	  
shown	   are	   representative	   of	   at	   least	   3	   independent	   experiments.	   Statistical	   analyses	   of	   in	   vivo	  
experiments	   and	   of	   data	   presented	   in	   Figs	   1,	   2	   and	   4	  were	   calculated	  with	  GraphPad	   software	  
(GraphPad	  PRISM	  software;	  San	  Diego,	  CA),	  using	  One-­‐way	  ANOVA	  Kruskal-­‐Wallis	  test	  followed	  by	  
a	  Dunn’s	  multiple	  comparison	  test.	  Group	  comparisons	  of	  cell	  percentages	  and	  absolute	  numbers,	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serum	  cytokine	  levels	  and	  organ/body	  weight	  ratios	  were	  performed	  using	  Student’s	  t-­‐test.	  Data	  
are	  representative	  of	  2	  independent	  experiments	  with	  6-­‐10	  mice	  analyzed	  in	  each	  cohort	  and	  all	  
error	   bars	   indicate	   SD.	  A	  p-­‐value	   less	   than	  or	   equal	   to	   0.05	  was	  deemed	   to	  be	   significant	   in	   all	  
experiments.	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Results	  
In	  SAP-­‐silenced	  cells,	  DGKα 	  activity	  impairs	  IS	  formation.	  
We	  previously	  showed	  that	  SAP-­‐deficient	  T	  cells	  fail	  to	  inhibit	  DGKα	  upon	  TCR	  triggering,	  resulting	  
in	   decreased	   DAG-­‐mediated	   signaling	   [116].	   As	   DAG	   signaling	   at	   the	   IS	   is	   relevant	   for	   IS	  
organization	   [124],	  we	   hypothesized	   that	   the	   aberrant	   DGKα	   activity	   in	   SAP	   deficient	   cells	  may	  
perturb	  IS	  organization	  and	  signaling.	  Indeed,	  prior	  studies	  provided	  evidences	  that	  SAP	  is	  required	  
to	  form	  stable	  interactions	  between	  the	  T	  cells	  and	  the	  APCs	  [86,	  128].	  	  
We	   reasoned	   that	   if	   the	  DGKα	   aberrant	  activity	   in	  SAP-­‐deficient	  cells	  was	   responsible	   for	   the	   IS	  
defects,	  then	  the	  silencing	  or	  inhibition	  of	  DGKα	  would	  rescue	  the	  T	  :	  B	  cells	  conjugation	  in	  SAP-­‐
deficient	  cells.	  To	  address	  this	  hypothesis,	  we	  tracked	  actin	  dynamics	  using	  Lifeact-­‐GFP	  in	  control	  
or	   SAP-­‐deficient	   Jurkat	   T	   cells	   (shCNTRL	   and	   shSAP,	   respectively)	   during	   conjugation	   with	  
superantigen	  (SEE)-­‐loaded	  Raji	  B	  cells.	  As	  previously	  reported	  in	  murine	  CTLs	  [128],	  shSAP	  Jurkat	  
cells	  failed	  to	  assemble	  F-­‐actin	  at	  the	  IS	  with	  SEE-­‐loaded	  Raji	  B	  cells	  (Fig.	  1a-­‐d).	  DGKα	  silencing	  or	  
inhibition	  with	  R59949	  rescued	  IS	  formation	  in	  those	  cells,	  suggesting	  that	  excessive	  DGKα	  activity	  
is	   responsible	   for	   the	   defective	   IS	   assembling	   of	   SAP-­‐deficient	   cells	   (Fig.	   1a-­‐d).	   Notably,	   DGKα	  
silencing	  or	  inhibition	  had	  no	  effect	  on	  F-­‐actin	  polarization	  of	  control	  cells	  (Fig.	  1a-­‐d).	  	  
In	   response	   to	   TCR	   stimulation,	   SAP	   recruitment	   is	   specifically	   responsible	   for	   DGKα	   inhibition,	  
while	  the	  activity	  of	  DGKζ	  is	  not	  affected	  [116].	  Nevertheless,	  both	  DGKζ	  and	  DGKα	  were	  found	  to	  
be	  recruited	  at	  the	  IS	  upon	  TCR	  engagement	  [52,	  125].	  Therefore,	  we	  did	  the	  experiments	  by	  co-­‐
transfecting	  DGKζ-­‐specific	  siRNA	  and	  Lifeact-­‐GFP	  in	  shCNTRL	  or	  shSAP	  Jurkat	  cells.	  In	  SAP-­‐deficient	  
cells,	  silencing	  of	  DGKζ	  showed	  a	  trend	  in	  restoring	  actin	  polarization	  at	  the	  IS,	  although	  without	  
reaching	  statistical	  significance	  (Fig.	  1e,f).	  	  
These	  data	  confirm	  that	  excessive	  activity	  of	  the	  α	   isoform	  of	  DGK	   in	  SAP-­‐deficient	   lymphocytes	  
interferes	  with	  the	  actin	  remodeling	  at	  the	  IS,	  likely	  by	  metabolizing	  DAG.	  	  
	   	  




Figure	  1.	   In	  SAP-­‐silenced	  cells,	  DGKα 	  activity	   impairs	   IS	   formation.	  Live-­‐cells	  imaging	  analysis	  of	  shCNTRL	  or	  shSAP	  
Jurkat	  cells	   transfected	  with	  Lifeact-­‐GFP	  to	  follow	  F-­‐actin	  movements	  during	  the	  conjugation	  with	  SEE-­‐loaded	  Raji	  B	  
cells	   (a)	   Jurkat	   shCNTRL	  or	  shSAP	  were	   transiently	  cotransfected	  with	  DGKα-­‐specific	   siRNA	  or	  non	  specific	   siRNA	  as	  
control	  together	  with	  Lifeact-­‐GFP	  (green).	  4	  days	  later,	  cells	  were	  mixed	  1:1	  with	  SEE-­‐loaded	  Raji	  B	  cells	  (Red)	  to	  allow	  
conjugate	  formation.	  Representative	  pictures	  are	  shown,	  scale	  bar	  10	  µm	  (b)	  Synaptic	  localization	  of	  Lifeact-­‐GFP	  was	  
quantified	  ratiometrically	  comparing	  the	  mean	  fluorescence	  intensity	  (MFI)	  of	  GFP	  at	  the	  contact	  zone	  between	  the	  
Jurkat	  cell	  and	  the	  Raji	  B	  cell	  and	  the	  MFI	  at	  the	  perimeter	  of	  the	  Jurkat	  cell	  (see	  material	  and	  methods	  for	  details).	  
Data	  are	  derived	  from	  n	  >	  20	  conjugates	  per	  condition.	  Red	  lines	  and	  error	  bars	  in	  the	  scatter	  plots	  denote	  means	  and	  
SEM,	  respectively.	  ***P	  <	  0.001,	  ns	  P	  >	  0.05.	  Data	  are	  representative	  of	  at	   least	  three	  independent	  experiments.	  (c)	  
Jurkat	  shCNTRL	  or	  shSAP	  were	  pretreated	  with	  DMSO	  or	  R59949	  10	  µM	  for	  30	  min	  before	  allowing	  conjugation	  with	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SEE-­‐loaded	   Raji	   B	   cells.	   R59949	  was	  maintained	   in	   the	  medium	   for	   all	   the	   time	   of	   the	   experiment.	   Representative	  
pictures	  are	  shown,	  scale	  bar	  10	  µm	  (d)	  Graph	  shows	  the	  quantification	  of	  the	  MFI	  at	  the	  IS	  measured	  as	  in	  (b),	  n	  >	  20,	  
***P	  <	  0.001,	  ns	  P	  >	  0.05.	  Data	  are	  representative	  of	  at	  least	  three	  independent	  experiments.	  (e)	  Jurkat	  shCNTRL	  or	  
shSAP	  were	  transiently	  cotransfected	  with	  DGKζ-­‐specific	  siRNA	  or	  non	  specific	  siRNA	  as	  control	  together	  with	  Lifeact-­‐
GFP	   (green).	   3	   days	   later,	   cells	   were	   mixed	   1:1	   with	   SEE-­‐loaded	   Raji	   B	   cells	   (Red)	   to	   allow	   conjugate	   formation.	  
Representative	  pictures	  are	  shown,	  scale	  bar	  10	  µm.	  (f)	  Quantification	  performed	  as	  in	  (b),	  n	  >	  20,	  ***P	  <	  0.001,	  ns	  P	  >	  
0.05.	  Data	  are	  representative	  of	  at	  least	  three	  independent	  experiments.	  
	  
In	  SAP-­‐silenced	  cells,	  DGKα 	  activity	  impairs	  DAG	  accumulation	  at	  the	  IS.	  
We	   next	   sought	   to	   investigate	   whether	   in	   SAP-­‐deficient	   cells	   the	   increased	   DGKα	   activity	   was	  
responsible	  for	  an	  impaired	  DAG	  accumulation	  at	  the	  IS.	  With	  this	  purpose,	  we	  transfected	  control	  
or	   SAP-­‐deficient	   Jurkat	   cells	   with	   a	   DAG	   biosensor	   containing	   the	   tandem	   C1	   domains	   of	   PKCθ	  
fused	  to	  GFP	  (PKCθ-­‐CRD)	  [48],	  together	  with	  control	  or	  DGKα-­‐specific	  siRNA.	  In	  control	  cells,	  PKCθ-­‐
CRD	   was	   recruited	   to	   the	   contact	   zone	   between	   T	   and	   APC	   cell,	   while	   in	   absence	   of	   SAP	   this	  
recruitment	   was	   impaired.	   Notably,	   silencing	   or	   inhibition	   of	   DGKα	   were	   able	   to	   restore	   DAG	  
polarization	   toward	   the	   IS	   in	   SAP-­‐deficient	   cells	   (Fig.	   2a-­‐d).	   As	  DGKζ	   plays	   a	  major	   role	   in	  DAG	  
metabolism	  at	   the	   IS	   [103,	  125],	  we	  did	   similar	  experiments	  by	   silencing	  DGKζ.	   In	   SAP-­‐deficient	  
cells,	   DGKζ-­‐specific	   silencing	   did	   not	   significantly	   rescue	   PKCθ-­‐CRD	   accumulation	   at	   the	   IS,	  
although	  we	  noticed	  a	  positive	  trend	  (Fig.	  2e,f).	  Interestingly,	  in	  control	  cells	  DGKα,	  but	  not	  DGKζ,	  
silencing	  perturbed	  the	  localization	  of	  the	  biosensor,	  which	  accumulated	  also	  at	  the	  periphery	  of	  
the	  cells	  (Fig.	  2a,b),	  thus	  indicating	  a	  role	  of	  DGKα	  in	  localizing	  DAG	  at	  the	  IS.	  Indeed,	  DGKα	  plays	  a	  
specific	  role	  in	  limiting	  the	  area	  in	  which	  DAG	  accumulates	  at	  the	  IS	  [52].	  	  
Those	   data	   confirm	   that	   an	   increased	  DGKα	   activity	  metabolizes	  DAG	   in	   SAP-­‐deficient	   cells	   and	  
consequently	  impairs	  IS	  organization.	  According	  with	  a	  key	  role	  of	  polarized	  DAG	  signaling	  in	  the	  
synapse	  organization,	  we	  observed	   that	  administration	  of	  exogenous	  PMA,	  a	  DAG	  analog	  which	  
potently	  activates	  ERK1/2	  (Fig.	  3c),	  during	  the	  conjugation	  experiments	  strongly	  inhibited	  F-­‐actin	  
polarization	  in	  both	  in	  control	  and	  SAP-­‐deficient	  cells	  (Fig.	  3a,b	  and	  [124]).	  
	  
	   36	  
	  
Figure	  2.	  In	  SAP-­‐silenced	  cells,	  DGKα 	  activity	  impairs	  DAG	  accumulation	  at	  the	  IS.	  	  
Live-­‐cells	   imaging	   analysis	   of	   shCNTRL	   or	   shSAP	   Jurkat	   cells	   transfected	   with	   EGFP-­‐PKCθ-­‐CRD	   to	   follow	   DAG	  
accumulation	  during	  the	  conjugation	  with	  SEE-­‐loaded	  Raji	  B	  cells.	  
shCNTRL	  and	  shSAP	  Jurkat	  T	  cells	  were	  transiently	  co-­‐transfected	  with	  EGFP-­‐tagged	  PKCθ-­‐CRD	  and	  DGKα-­‐specific	  (a),	  
DGKζ-­‐specific	  (e),	  or	  non	  specific	  siRNA.	  After	  4	  days	  were	  stimulated	  with	  SEE-­‐loaded	  Raji	  B	  cells,	  and	  confocal	   live	  
cell	   images	  were	  taken	  during	  T	  cell-­‐APC	  conjugation.	  The	  fluorescence	  intensity	  of	  EGFP-­‐tagged	  PKCθ-­‐CRD	  is	  shown	  
by	  pseudocolor	  as	   indicated	   in	   the	   calibration	  bar,	  with	   the	  position	  of	   the	  APC	   indicated	   in	  white	  dotted	   line	   (top	  
row).	  The	  bottom	  row	  shows	  the	  corresponding	  phase	  contrast	  images.	  Scale	  bar	  10	  μm.	  (b,	  d	  and	  f)	  Quantification	  of	  
the	  EGFP-­‐tagged	  PKCθ-­‐CRD	  accumulation	  at	  the	   IS	  (see	  Materials	  and	  Methods	  for	  details),	  which	  was	  calculated	  as	  
the	  ratio	  of	  the	  mean	  fluorescence	  intensity	  (MFI)	  of	  GFP	  at	  the	  contact	  zone	  between	  the	  Jurkat	  cell	  and	  the	  Raji	  B	  
cell	  and	  the	  MFI	  at	  the	  perimeter	  of	  the	  Jurkat	  cell.	  Data	  are	  derived	  from	  n	  >	  20	  conjugates	  per	  condition.	  Red	  lines	  
and	  error	  bars	  in	  the	  scatter	  plots	  denote	  means	  and	  SEM,	  respectively.	  ***P	  <	  0.001,	  **	  P	  <	  0.01,	  *P	  <	  0.05,	  ns	  P	  >	  
0.05.	  All	  data	  are	  representative	  of	  at	  least	  three	  independent	  experiments.	  (c)	  shCNTRL	  or	  shSAP	  Jurkat	  T	  cells	  were	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transiently	  transfected	  with	  EGFP-­‐tagged	  PKCθ-­‐CRD.	  After	  48	  h,	  cells	  were	  pretreated	  for	  30	  minutes	  with	  R59949	  10	  
µM	   or	   DMSO	   and	   stimulated	   with	   SEE-­‐loaded	   Raji	   B	   cells.	   Confocal	   live	   cell	   images	   were	   taken	   during	   T	   cell-­‐APC	  
conjugation.	  Representative	  images	  are	  shown	  in	  pseudo-­‐colors	  as	  indicated	  in	  the	  calibration	  bar,	  with	  the	  position	  










Figure	  3.	  PMA	  disrupts	  the	  IS	  formation.	  
(a)	  Jurkat	  shCNTRL	  or	  shSAP	  were	  transiently	  transfected	  with	  Lifeact-­‐GFP	  (green).	  48	  hours	  later,	  cells	  were	  treated	  
for	   15	   min	   with	   PMA	   (200	   ng/ml)	   mixed	   1:1	   with	   SEE-­‐loaded	   Raji	   B	   cells	   (Red)	   to	   allow	   conjugate	   formation.	  
Representative	   pictures	   are	   shown.	   Scale	   bar	   10	   μm.	   (b)	   Quantification	   of	   Lifeact-­‐GFP	   polarized	   to	   the	   IS.	   The	  
histogram	  shows	  the	  means	  and	  SEM	  of	  the	  %	  of	  polarized	  cells	  on	  the	  total	  of	  the	  cells	  counted,	  n	  >	  20	  conjugates	  for	  
each	  condition,	  for	  at	  least	  three	  independent	  experiments.	  Statistic	  was	  calculated	  by	  using	  the	  unpaired	  two-­‐tailed	  t	  
test,	  where	  **P	  <	  0.01,	  *P	  <	  0.05.	   (c)	   shCNTRL	  and	  shSAP	   Jurkat	   cells	  were	   treated	  with	  PMA	   (200	  ng/ml,	  15	  min),	  
lysed	  and	  analyzed	  by	  WB	  for	  P-­‐ERK	  1/2,	  ERK	  and	  tubulin	  content.	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In	  SAP-­‐silenced	  cells,	  DGKα 	  activity	  impairs	  MTOC	  reorientation.	  
DAG	  gradients	  and	  actin	  polymerization	  at	  the	  IS	  are	  required	  to	  orient	  the	  MTOC	  toward	  the	  IS	  
[50,	  124].	   Indeed,	  CTLs	   from	  SAP	  KO	  mice	  exhibit	  both	  F-­‐actin	  polarization	  defects	  and	   impaired	  
MTOC	  reorientation	  towards	  B	  cell	  targets	  [128].	  To	  determine	  whether	  DGKα	  inhibition	  may	  also	  
restore	   MTOC	   docking	   at	   the	   IS,	   we	   performed	   conjugation	   experiments	   in	   control	   and	   SAP-­‐
deficient	  cells	  expressing	  GFP-­‐Tubulin	  in	  the	  presence	  of	  the	  DGK	  inhibitor	  R59949.	  We	  found	  that,	  
compared	   to	   shCNTRL	   Jurkat	   cells,	   shSAP	   Jurkat	   cells	   exhibit	   a	   defect	   in	   MTOC	   polarization,	  
measured	   as	   distance	   between	  MTOC	   and	   the	   IS.	   Here,	   DGKα	   inhibition	  was	   able	   to	   drive	   the	  
MTOC	  relocation	  behind	  the	  IS,	  while	  did	  not	  have	  any	  significant	  effect	  on	  MTOC	  positioning	   in	  
control	  cells	  (Fig.	  4a,b).	  	  
These	  data	  collectively	  indicates	  that	  DGKα	  plays	  a	  pivotal	  role	  in	  regulating	  the	  DAG	  gradient	  that	  
is	  required	  for	  both	  actin	  dynamics	  and	  MTOC	  repositioning	  toward	  the	  IS.	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Figure	  4.	  In	  SAP-­‐silenced	  cells,	  DGKα 	  activity	  impairs	  MTOC	  reorientation.	  
(a)	  shCNTRL	  and	  shSAP	  Jurkat	  cells	  were	  transfected	  with	  GFP-­‐Tubulin	  (green).	  Two	  days	  later,	  cells	  were	  pretreated	  
for	   30	  minutes	  with	   R59949	   10	   μM	   or	   DMSO	   and	  mixed	   1:1	  with	   SEE-­‐loaded	   Raji	   B	   cells	   (red)	   to	   allow	   conjugate	  
formation,	  seeded	  on	  polylysine-­‐coated	  glasses	  and	  acquired.	  Representative	  images	  are	  shown,	  scale	  bar	  10	  μm.	  (b)	  
The	   polarization	   index	   was	   measured	   by	   calculating	   the	   distance	   from	   the	   MTOC	   to	   the	   immunological	   synapse	  
divided	  by	  the	  distance	  from	  the	  immunological	  synapse	  to	  the	  distal	  pole	  of	  the	  T	  cell.	  Red	  lines	  and	  error	  bars	  in	  the	  
scatter	  plots	  denote	  means	  and	  SEM,	  respectively.	  ***P	  <	  0.001,	  **P	  <	  0.01.	  n	  >	  20	  conjugates	  for	  each	  experimental	  
condition,	  all	  data	  are	  representative	  of	  at	  least	  two	  independent	  experiments.	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In	  SAP-­‐silenced	  cells,	  DGKα 	  activity	  impairs	  DAG-­‐dependent	  signaling.	  
We	  next	  sought	  to	  investigate	  whether	  inhibition	  or	  silencing	  of	  DGKα	  restores	  the	  defective	  DAG	  
signaling	  of	  SAP-­‐deficient	  cells.	  	  
At	  first,	  we	  used	  primary	  T	  lymphocytes	  to	  track	  the	  recruitment	  to	  the	  IS	  of	  two	  DAG-­‐dependent	  
signal	   transducers:	   PKCθ	   [129]	   and	   RasGRP1	   [130].	   Consistent	   with	   our	   previous	   findings,	  
recruitment	  of	  PKCθ	  and	  RasGRP1	  to	  the	  IS	  was	  strongly	  reduced	  in	  SAP-­‐silenced	  T	  cells	  (Fig.	  5a-­‐h).	  
Silencing	  or	  inhibition	  of	  DGKα	  did	  not	  influence	  the	  recruitment	  of	  PKCθ	  and	  RasGRP1	  in	  control	  T	  
cells,	   but	   fully	   restored	   localization	   at	   the	   IS	   in	   SAP-­‐silenced	   cells	   (Fig.	   5a-­‐h).	   These	   data	   are	  
consistent	  with	  previous	  observation	  in	  Jurkat	  T	  cells	  [116]	  and	  suggest	  that	  in	  the	  absence	  of	  SAP,	  
excessive	  DAG	  metabolism	  limits	  TCR	  signaling	  and	  cytoskeletal	  remodeling	  at	  the	  IS.	  
Since	   is	   known	   that	   inhibition	  of	  DGKα	   activity	   potentiates	  DAG-­‐dependent	   signaling	   [131-­‐134],	  
and	  we	  found	  that	  was	  sufficient	  to	  rescue	  RasGRP1	  recruitment	  at	  the	  IS	  in	  SAP-­‐deficient	  primary	  
T	   cells,	   we	   asked	   whether	   DGKα	   inhibition	   could	   also	   restore	   the	   defective	   ERK	   activation	  
observed	   in	   SAP-­‐deficient	   primary	   T	   cells	   [66,	   68].	   Indeed,	   we	   observed	   that	   silencing	   or	  
pharmacologic	   inhibition	  of	  DGKα	  did	  not	  affect	  basal	  ERK	  activity	   in	   resting	  control	  T	   cells,	  but	  
potentiated	   ERK1/2	   phosphorylation	   following	   TCR	   stimulation	   (Fig.	   6a,b).	   Compared	   to	   control	  
cells,	  SAP-­‐silenced	  cells	  exhibited	  decreased	  ERK	  activation	  upon	  TCR	  stimulation;	  however,	  DGKα	  
knockdown	   or	   inhibition	   restored	   TCR-­‐driven	   ERK	   activation	   bringing	   it	   back	   to	   nearly	   normal	  
levels	  (Fig.	  6a,b).	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Figure	  5.	  In	  SAP-­‐silenced	  cells,	  DGKα 	  activity	  impairs	  PKCθ	  and	  RasGRP1	  recruitment	  to	  the	  IS.	  
Primary	   human	   PBLs	  were	   transfected	  with	   the	   indicated	   siRNA	   and	   after	   72	   hours	   incubated	   1:1	  with	   Raji	   B	   cells	  
loaded	  with	  mixed	  SEE	  and	  SEB	  superantigens	  for	  15	  minutes,	  fixed	  and	  stained	  for	  PKCθ	  (a)	  or	  RasGRP1	  (c),	  both	  in	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green.	  Scale	  bar	  10	  μm.	  Histograms	  show	  the	  percentage	  of	  cells	  displaying	  PKCθ	  (b)	  and	  RasGRP1	  (d)	  at	  the	  IS.	  n	  =	  
100	   conjugates	  were	   counted	   in	   six	   replicates	   from	   two	   independent	   experiments	   as	  mean	   ±	   SEM	   (unpaired	   two-­‐
tailed	  t	  test,	  *P	  <	  0.01).	  	  
Human	  PBLs	  were	   transfected	  with	   control	  or	   SAP-­‐specific	   siRNA.	  After	  72	  hours	  were	  pretreated	  with	  R59949	   (10	  
µM,	  30	  minutes)	  and	  incubated	  with	  Raji	  B	  cells	   loaded	  with	  mixed	  SEE	  and	  SEB	  superantigens	  for	  15	  minutes,	  fixed	  
and	   stained	   for	  PKCθ	   (e)	  or	  RasGRP1	   (g).	  Representative	  pictures	  are	   shown.	   Scale	  bar	  5	  µm.	  Histogram	  shows	   the	  
percentage	   of	   cells	   displaying	   PKCθ	   (f)	   and	   RasGRP1	   (h)	   at	   the	   IS.	   Data	   are	   derived	   from	   three	   independent	  
























































Figure	   6.	   DGKα 	   silencing	   or	   inhibition	   enhances	   ERK1/2	   phosphorylation,	   IL-­‐2	   expression	   and	   CD25	   membrane	  
exposure	  in	  WT	  and	  SAP-­‐deficient	  primary	  T	  cells.	  
(a)	  Primary	  human	  PBLs	  were	  transfected	  with	  the	  indicated	  siRNA.	  After	  4	  days,	  cells	  were	  stimulated	  with	  OKT3	  (10	  
µg/ml)	  for	  30	  min,	  lysed	  and	  analysed	  by	  WB	  for	  P-­‐ERK	  1/2,	  ERK,	  DGKα	  and	  SAP	  content.	  (b)	  Primary	  human	  PBLs	  were	  
transfected	   with	   a	   SAP-­‐specific	   siRNA.	   After	   4	   days,	   cells	   were	   pretreated	   with	   R59949	   (5	   µM,	   30	   min)	   and	   then	  
stimulated	  with	  OKT3	  (10	  µg/ml)	   for	  5	  min,	   lysed	  and	  analysed	  by	  WB	  for	  P-­‐ERK	  1/2,	  ERK,	  tubulin	  and	  SAP	  content.	  
Histograms	   in	   (a)	  and	   (b)	   shows	   the	  mean	  ±	  SEM	  of	   the	  corresponding	  densitometries.	  5	   independent	  experiments	  
were	  performed	  for	  (a)	  and	  6	  for	  (b),	  unpaired	  two-­‐tailed	  t	  test,	  *P	  <	  0.05.	  (c)	  Primary	  human	  PBLs	  were	  transfected	  
with	   the	   indicated	  siRNA.	  4	  days	   later,	   they	  were	  restimulated	  with	  10	  µg/ml	  OKT3	   for	  4	  hours	   (left),	  or	  pretreated	  
with	  R59949	  (5	  µM,	  30	  minutes)	  and	  then	  restimulated	  (right).	  IL-­‐2	  was	  quantified	  by	  quantitative	  RT-­‐PCR	  using	  GUSB	  
as	  reference	  gene.	  Graphs	  show	  the	  mean	  ±	  SEM	  of	  six	  independent	  experiments.	  Unpaired	  t	  test	  ***P	  <	  0.001,	  *P	  <	  
0.05.	  (d)	  Primary	  human	  PBLs	  were	  transfected	  with	  control,	  SAP,	  or	  SAP	  +	  DGKα-­‐specific	  siRNAs.	  After	  4	  days,	  cells	  
were	   treated	   with	   OKT3,	   fixed	   and	   stained	   for	   CD25.	   The	   histograms	   show	   the	   FACS	   analysis	   of	   the	   CD25	  MFI	   in	  
untreated	  (left)	  and	  OKT3-­‐treated	  (right)	  cells.	  On	  the	  right,	  the	  graph	  shows	  the	  mean	  ±	  SEM	  of	  the	  MFI	  relative	  to	  
the	  stimulated	  control	  (unpaired	  two-­‐tailed	  t	  test,	  *P	  <	  0.05).	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DGKα 	  knockdown	  or	  inhibition	  reinforces	  the	  strength	  of	  the	  signal	  upon	  TCR	  ligation	  in	  SAP-­‐
deficient	  T	  lymphocytes.	  
We	  next	  sought	  to	  examine	  to	  what	  extent	  DGKα	   silencing	  or	   inhibition	  restore	  TCR	  signaling	   in	  
SAP-­‐silenced	  T	  cells.	  To	  this	  purpose,	  we	  selected	  a	  panel	  of	  TCR	  responsive	  genes,	  with	  a	  specific	  
attention	  to	  genes	  involved	  in	  apoptosis	  previously	  reported	  to	  be	  less	  expressed	  in	  T	  lymphocytes	  
from	  XLP1	  patients	  [90].	  	  
First,	   as	  T	   cells	  derived	   from	  XLP1	  patients	   show	  defective	   induction	  of	   IL-­‐2	  and	   IL-­‐2	   receptor	  α	  
chain	  (CD25)	  [135],	  we	  evaluated	  the	  TCR-­‐stimulated	  induction	  of	  IL-­‐2	  mRNA	  in	  SAP	  silenced	  PBLs	  
upon	  DGKα	  silencing	  or	  inhibition.	  As	  previously	  described	  [8,	  116],	  we	  found	  that	  DGKα	  silencing	  
or	   inhibition	   strongly	   potentiated	   TCR-­‐induced	   IL-­‐2	   mRNA	   expression	   (Fig.	   6c)	   without	   altering	  
induction	  of	  CD25	   (Fig.	   6d).	   In	   SAP-­‐deficient	   cells,	  we	  observed	  a	   lower	   induction	  of	   IL-­‐2	  mRNA	  
compared	   to	  SAP-­‐sufficient	   cells,	  which	  was	   completely	   rescued	  by	  DGKα	   silencing	  or	   inhibition	  
(Fig.	  6c).	  Similarly,	  SAP-­‐silenced	  cells	  displayed	  a	  reduced	  induction	  of	  CD25,	  which	  was	  completely	  
rescued	  by	  DGKα	  silencing	  (Fig.	  6d).	  
Altogether,	   these	   data	   suggest	   that	   DGKα	   silencing	   or	   inhibition	   in	   both	   control	   and	   SAP	  
knockdown	  cells	  enhances	  IL-­‐2	  production	  and	  CD25	  exposure,	  thus	  potentiating	  the	  TCR-­‐induced	  
IL-­‐2	  autocrine	  loop.	  
	  
Among	   other	   genes	   whose	   activation	   is	   strongly	   induced	   downstream	   the	   TCR-­‐triggering,	   we	  
selected	  BIM	   (BCL2L11),	   FASL	   (FASLG),	  Nur77	   (NR4A1)	  and	  Nor1	   (NR4A3),	  which	  were	  shown	  to	  
have	   also	   pro-­‐apoptotic	   functions	   [34,	   35,	   88,	   89,	   136,	   137].	   Particularly,	   XLP1-­‐derived	   T	  
lymphocytes	   features	   a	   defective	   induction	   of	   BIM	   and	   FASL	   [90].	   Accordingly,	   we	   observed	   a	  
reduced	  TCR-­‐induced	  transcription	  of	  BIM	  (BCL2L11)	  and	  FASL	  (FASLG)	   in	  SAP-­‐silenced	  PBLs	  (Fig.	  
7a-­‐d).	   However,	   the	   expression	   of	   these	   two	   genes	   was	   not	   rescued	   by	   DGKα	   silencing	   or	  
inhibition	   (Fig.	   7a-­‐d).	   Similarly,	   the	   DGKα	   inhibitor	   R59949	   did	   not	   restore	   FASL	   and	   BIM	  
expression	  at	  the	  protein	  level	  in	  XLP1	  derived	  T	  lymphocytes	  (Fig.	  7e).	  When	  we	  measured	  FASL	  
in	  the	  supernatants	  (sFASL)	  of	  TCR-­‐stimulated	  T	  cells,	  we	  detected	  a	  substantial	  reduction	  of	  sFASL	  
released	  from	  T	  cells	  from	  XLP1	  patients,	  which	  was	  not	  rescued	  by	  R59949	  or	  by	  the	  other	  DGKs	  
inhibitor	  R59022	  (Fig.	  7f).	  
On	   the	   other	   hand,	   Nur77	   expression	   has	   been	   used	   as	   a	   report	   of	   the	   TCR	   receptor	   signal	  
strength	  [138]	  and,	  together	  with	  its	  closed	  homolog	  Nor1,	  mediates	  activation-­‐induced	  cell	  death	  
[139].	  The	  transcription	  of	  both	  Nur77	  (NR4A1)	  and	  Nor1	  (NR4A3)	  was	  severely	  impaired	  in	  SAP-­‐
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silenced	  cells	  and	  both	  DGKα	  silencing	  and	  inhibition	  were	  able	  to	  fully	  rescue	  their	  expression	  in	  
SAP-­‐silenced	  cells,	  without	  affecting	  their	  induction	  in	  control	  cells	  (Fig.	  7g-­‐j).	  A	  similar	  trend	  was	  
observed	  at	  the	  protein	   level	   in	  Jurkat	  cells,	  were	  Nur77	  was	   induced	  between	  2	  and	  4	  hours	  of	  
TCR	  stimulation	  in	  a	  SAP-­‐dependent	  manner	  (Fig.	  7k).	  The	  defective	  induction	  in	  Jurkat	  shSAP	  was	  
fully	   rescued	   by	   the	   DGKα	   inhibitor	   R59949	   (Fig.	   7k).	   Finally,	   the	   DGKα	   inhibitors	   R59949	   and	  
R59022	  were	  also	  capable	  of	  partially	  restoring	  Nur77	  and	  Nor1	  induction	  in	  XLP1	  patients-­‐derived	  
T	  cells	  (Fig.	  7l).	  	  
Those	  data	  indicates	  that	  DGKα	  silencing	  or	  inhibition	  selectively	  rescues	  the	  expression	  of	  some	  
TCR-­‐dependent	  target	  genes	  in	  SAP	  deficient	  cells,	  and	  also	  suggest	  that	  in	  SAP-­‐deficient	  cells	  the	  
defective	   induction	   of	   IL-­‐2,	   CD25,	   Nur77	   and	   Nor1	   is	   due	   to	   a	   reduced	   TCR	   signaling	   strength	  
caused	  by	  excessive	  DGKα	  activity.	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Figure	  7.	  DGKα 	  silencing	  or	  inhibition	  enhances	  Nur77	  and	  Nor1	  expression	  in	  WT	  and	  SAP-­‐deficient	  primary	  T	  cells.	  
Primary	   human	  PBLs	  were	   transfected	  with	   the	   indicated	   siRNA.	   4	   days	   later,	   they	  were	   stimulated	  with	   10	  µg/ml	  
OKT3	  for	  4	  hours	  (a,b),	  or	  pretreated	  with	  R59949	  (5	  µM,	  30	  minutes)	  and	  then	  restimulated	  (c,d).	  BIM	  (a,c)	  and	  FASL	  
(b,d)	   were	   quantified	   by	   quantitative	   RT-­‐PCR	   using	   GUSB	   as	   reference	   gene.	   Graphs	   show	   the	  mean	   ±	   SEM	   of	   six	  
independent	  experiments.	  Unpaired	  t	  test	  **P	  <	  0.01,	  *P	  <	  0.05,	  ns	  P	  >	  0.05.	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(e)	   Primary	   human	   PBLs	   from	   healthy	   donor	   or	   XLP1	   patient	   were	   pretreated	   with	   DMSO	   or	   R59949	   (5	   µM,	   30	  
minutes)	  and	  then	  restimulated	  for	  4	  hours.	  BIM	  and	  FASL	  expression	  was	  verified	  by	  WB	  analysis.	  (f)	  Primary	  human	  
PBLs	  from	  healthy	  donor	  or	  XLP1	  patient	  were	  pretreated	  or	  not	  with	  R59022	  or	  R59949	  (5	  µM,	  30	  minutes)	  and	  then	  
unstimulated	   or	   restimulated	   for	   4	   hours.	   sFASL	   release	   was	   quantified	   by	   ELISA.	   (g-­‐j)	   The	   same	   cDNA	   of	   the	  
experiments	  performed	  in	  (a-­‐d)	  was	  used	  to	  measure	  by	  quantitative	  RT-­‐PCR	  NR4A1	  (Nur77)	  and	  NR4A3	  (Nor1),	  using	  
GUSB	  as	  reference	  gene.	  Graph	  shows	  the	  mean	  ±	  SEM	  of	  six	  independent	  experiments.	  Unpaired	  t	  test	  ***P	  <	  0.001,	  
**P	  <	  0.01,	  *P	  <	  0.05.	  (k)	  shCNTR	  or	  shSAP	  Jurkat	  T	  cells	  were	  pretreated	  with	  R59949	  (5	  µM,	  30	  min),	  stimulated	  with	  
anti-­‐CD3	  (UCHT1	  clone)	  for	  0,	  2	  and	  4	  hours,	   lysed	  and	  analysed	  by	  WB	  for	  Nur77,	  tubulin	  and	  SAP	  content.	  (l)	  PBLs	  
from	  healthy	  donor	  or	  XLP1	  patient	  were	  pretreated	  with	  R59022	  or	  R59949	   (5	  µM,	  30	  min)	  and	  stimulated	  or	  not	  
with	  anti-­‐CD3	  (OKT3	  clone).	  4	  hours	  later,	  cells	  were	  lysed	  and	  analysed	  by	  WB	  for	  Nur77,	  Nor1	  and	  β-­‐actin	  content.	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DGKα 	  silencing	  or	  inhibition	  rescues	  RICD	  in	  SAP-­‐deficient	  T	  cells	  from	  healthy	  donors	  or	  T	  
lymphocytes	  from	  XLP1	  patients.	  
XLP1	   patients	   exhibit	   resistance	   to	   restimulation-­‐induced	   cell	   death	   (RICD)	   due	   to	   a	   reduced	  
signaling	   strength	  and	   impaired	   induction	  of	  pro-­‐apoptotic	  proteins	   [90].	  Therefore,	  we	  asked	   if	  
the	  RICD	  defect	  observed	  in	  cells	  from	  XLP1	  patients	  could	  depend	  on	  the	  aberrant	  DGKα	  activity,	  
which	  -­‐	  by	  consuming	  DAG	  -­‐	  lowers	  the	  TCR	  signal	  strength,	  and	  whether	  the	  inhibition	  of	  DGKα	  
could	  reestablish	  RICD	  in	  SAP-­‐deficient	  T	  lymphocytes.	  	  
We	   performed	   RICD	   experiments	   in	   T	   cells	   from	   healthy	   donors	   transfected	   with	   SAP-­‐specific	  
siRNA,	   in	  presence	  or	  not	  of	   the	  two	  commercial	   inhibitors	  of	  DGKs,	  R59949	  and	  R59022.	  While	  
both	   inhibitors	   did	   not	   show	   significant	   effects	   on	   cell	   death	   of	   control	   cells,	   at	   any	   of	   the	  
concentration	  used,	  R59949	  and	  R59022	  treatment	  rescued	  the	  cell	  death	  of	  SAP-­‐silenced	  cells	  to	  
nearly	  normal	  levels	  (Fig.	  8a,b).	  We	  then	  repeated	  the	  experiments	  on	  T	  cells	  from	  XLP	  patients.	  
Again,	   the	   two	  DGKs	   inhibitors	   did	   not	   affect	   RICD	   in	   cells	   from	   healthy	   donors,	  while	   partially	  
rescued	   the	   cell	   death	   in	   4	   different	   XLP1	   patients-­‐derived	   T	   lymphocytes	   (Fig.	   8c-­‐f).	   We	   next	  
performed	   the	   same	  experiments	   transfecting	   cells	  with	   a	   siRNA	   specific	   for	  DGKα.	   In	  both	  our	  
experimental	   systems	   (i.e.	   T	   cells	   from	   healthy	   donors	   silenced	   for	   SAP	   or	   T	   cells	   from	   XLP1	  
patients),	   silencing	  of	  DGKα	   is	   sufficient	   to	  completely	   rescue	   the	  RICD	  defect	   (Fig.	   8g,h).	  Those	  
data	   indicate	   a	   specific	   involvement	   of	   DGKα	   activity	   in	   the	   RICD	   resistance	   of	   these	   cells	   and	  
suggest	  a	  key	  role	  for	  DAG	  signaling	  in	  the	  induction	  of	  cell	  death	  in	  a	  context	  of	  restimulation.	  To	  
further	   support	   this	   hypothesis,	   we	   performed	   the	   RICD	   experiments	   in	   SAP-­‐deficient	   T	   cells	  
treated	  with	   a	   soluble,	   short	   form	  of	  DAG	   (C8-­‐DAG).	   As	   showed	   in	   Fig.	   8i,	   50	  µM	  DAG	  did	   not	  
affect	  RICD	   in	  control	  cells,	  while	  completely	   rescued	  the	  defective	  cell	  death	  of	  SAP-­‐deficient	  T	  
cells.	  
As	  DGKζ	  is	  the	  main	  responsible	  for	  DAG	  metabolism	  in	  T	  cells	  [103,	  125],	  we	  verified	  the	  effect	  of	  
DGKζ	  silencing	  on	  RICD.	  We	  found	  that	  DGKζ-­‐specific	  silencing	  did	  not	  affect	  RICD	  in	  control	  cells	  
but	  partially	  restored	  it	  in	  SAP	  silenced	  cells	  (Fig.	  8j),	  suggesting	  that	  the	  strength	  of	  TCR-­‐induced	  
DAG	  signaling	  controls	  RICD.	  	  
As	  RICD	  is	  an	  apoptotic	  process,	  we	  analyzed	  phosphatidylserine	  exposure	  and	  propidium	  iodide	  
uptake	  during	  the	  assay	  to	  exclude	  a	  toxic/necrotic	  side	  effects	  of	  our	  treatments.	  DGKα	  silencing	  
or	  inhibition	  in	  control	  cells	  did	  not	  affect	  apoptosis,	  while	  in	  SAP-­‐deficient	  T	  cells	  or	  T	  cells	  from	  
XLP	  patients	  both	  silencing	  or	   inhibition	  of	  DGKα	  restored	  the	  size	  of	  the	  AnnV+	  cell	  population.	  
The	  small	  necrotic/late	  apoptotic	  fraction	  is	  not	  perturbed	  (Fig.	  9a,b)	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Collectively,	  our	  data	  show	  that	  the	  RICD	  defect	  observed	  in	  T	  lymphocytes	  from	  XLP1	  patients	  is	  
due	  to	  the	  aberrant	  activity	  of	  DGKα.	  Therefore,	  DGKα	  inhibition	  could	  potentially	  overcome	  the	  
cell	  death	  defects	  of	  T	  cells	  from	  XLP1	  patients.	  Moreover,	  also	  other	  approaches	  to	  increase	  DAG	  
levels	  within	  the	  cells	  -­‐	  i.e.	  silencing	  of	  DGKζ,	  or	  administration	  of	  exogenous	  DAG	  at	  the	  beginning	  
of	  the	  death	  assay	  –	  were	  able	  to	  rescue	  the	  RICD.	  This	  suggests	  that	  DGKα,	  by	  consuming	  DAG,	  
terminates	  the	  signal	  responsible	  for	  the	  apoptosis	   in	  T	  cells	   from	  XLP1	  patients,	  thus	  explaining	  
their	  resistance	  to	  RICD.	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Figure	  8.	  DGKα 	  silencing	  or	   inhibition	  rescues	  RICD	  in	  SAP-­‐deficient	  T	  cells	  from	  healthy	  donors	  or	  T	   lymphocytes	  
from	  XLP1	  patients.	  Lymphocytes	  from	  control	  subjects	  were	  transfected	  with	  a	  SAP-­‐specific	  siRNA	  and	  after	  4	  days	  
pretreated	  with	   the	   indicated	  doses	  of	  R59949	   for	  30	  min	   (a)	   or	  R59022	   (b)	   and	   then	   restimulated	  with	   increasing	  
doses	  of	  CD3	  agonist	  OKT3.	  After	  24	  hours	  the	  %	  of	  cell	  loss	  was	  evaluated	  by	  PI	  staining.	  Data	  are	  the	  mean	  ±	  SEM	  of	  
three	   independent	   experiments	   performed	   in	   triplicate.	   Lymphocytes	   from	   control	   subject	   or	   XLP	   patient	   were	  
pretreated	  with	  the	  indicated	  doses	  of	  R59949	  for	  30	  min	  (c,e,f)	  or	  R59022	  (d,f)	  and	  then	  restimulated	  with	  increasing	  
doses	  of	  CD3	  agonist	  OKT3.	  After	  24	  hours	  the	  %	  of	  cell	  loss	  was	  evaluated	  by	  PI	  staining.	  Data	  are	  the	  mean	  ±	  STDEV	  
of	  one	  experiment	  performed	  in	  triplicate.	  	  
(g)	  Lymphocytes	  from	  control	  subjects	  were	  transfected	  with	  the	  indicated	  siRNA	  and	  after	  4	  days	  restimulated	  with	  
increasing	  doses	  of	  CD3	  agonist	  OKT3.	  After	   24	  hours	   the	  %	  of	   cell	   loss	  was	  evaluated	  by	  PI	   staining.	  Data	   are	   the	  
mean	  ±	  SEM	  of	  three	  independent	  experiments	  performed	  in	  triplicate.	  (h)	  Lymphocytes	  from	  control	  subject	  or	  XLP	  
patient	   were	   transfected	   with	   a	   DGKα-­‐specific	   siRNA	   and	   after	   4	   days	   restimulated	   with	   increasing	   doses	   of	   CD3	  
agonist	   OKT3.	   After	   24	   hours	   the	   %	   of	   cell	   loss	   was	   evaluated	   by	   PI	   staining.	   Data	   are	   the	  mean	   ±	   STDEV	   of	   one	  
experiment	  performed	  in	  triplicate.	  (i)	  Lymphocytes	  from	  control	  subjects	  were	  transfected	  with	  a	  SAP-­‐specific	  siRNA	  
and	  after	  4	  days	  pretreated	  with	  50	  µM	  of	  C8-­‐DAG	  and	  then	  restimulated	  with	  increasing	  doses	  of	  CD3	  agonist	  OKT3.	  
After	  24	  hours	  cells	  were	  washed	  and	  the	  %	  of	  cell	  loss	  was	  evaluated	  by	  PI	  staining.	  Data	  are	  the	  mean	  ±	  SEM	  of	  three	  
independent	  experiments	  performed	   in	   triplicate.	   	   (j)	   Lymphocytes	   from	  control	   subjects	  were	   transfected	  with	   the	  
indicated	  siRNA	  and	  after	  4	  days	  restimulated	  with	  increasing	  doses	  of	  CD3	  agonist	  OKT3.	  After	  24	  hours	  the	  %	  of	  cell	  











Figure	   9.	   DGKα 	   silencing	   or	   inhibition	   increased	   the	   apoptotic	   fraction	   of	   SAP-­‐deficient	   cells	   or	   cells	   from	   XLP1	  
patients.	  
(a)	  AnnexinV/PI	  analysis	  of	  the	  experiments	  showed	  in	  Fig.	  8a,b	  (right)	  and	  Fig.	  8g	  (left).	  Data	  are	  the	  mean	  ±	  SEM	  of	  
three	   independent	   experiments	   performed	   in	   triplicate.	   Paired	   t	   test,	   *	   P	   <	   0.05	   (b)	   AnnexinV	   staining	   of	   the	  
experiments	  showed	  in	  Fig.8c,e.	  A	  representative	  experiment	  is	  showed.	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DGKα 	  knockdown	  restores	  RICD	  by	  activating	  DAG	  signaling	  through	  PKCθ	  and	  the	  MAPK	  
cascade.	  	  
We	  already	  showed	  that	  DGKα	   inhibition	  in	  SAP-­‐deficient	  cells	  is	  able	  to	  restore	  DAG-­‐dependent	  
PKCθ	  and	  RasGRP1	  recruitment	  at	  the	  IS,	  and	  to	  activate	  ERK1/2.	  Interestingly,	  these	  pathways	  are	  
relevant	  for	  the	   induction	  of	  RICD	  [140,	  141],	  prompting	  us	  to	  verify	  whether	  they	  mediates	  the	  
restoration	  of	  apoptosis	  upon	  DGKα	  knockdown	  in	  SAP-­‐deficient	  T	  cells.	  Indeed,	  by	  silencing	  PKCθ	  
and	  RasGRP1,	  we	  observed	  that	  both	  were	  required	  for	  RICD	  in	  both	  control	  cells	  and	  SAP+DGKα	  
silenced	  cells,	  while	  their	  silencing	  did	  not	  affect	  the	  residual	  apoptosis	  of	  SAP-­‐deficient	  cells	  (Fig.	  
10a,b).	  	  
Similarly,	   Rottlerin,	   an	   inhibitor	  of	   nPKCs	   (including	  PKCθ	   isoform)	   [142],	   at	   6 µM	  concentration	  
had	  minimal	  effects	  on	  RICD	  of	  control	  cells.	  However,	  it	  completely	  abolished	  the	  rescue	  of	  RICD	  
mediated	  by	  DGKα	  silencing	  in	  SAP-­‐deficient	  cells	  (Fig.	  10c).	  Equally,	  the	  MEK	  and	  ERK	  inhibitors	  
(U0126	   [143]	  and	  FR180204	   [144],	   respectively)	  at	  doses	   that	   showed	  a	   slight	  effect	  on	  RICD	  of	  
control	   cells,	   were	   able	   to	   completely	   abolish	   the	   induction	   of	   cell	   death	   mediated	   by	   DGKα	  
silencing	  in	  SAP-­‐deficient	  cells	  (Fig.	  10d).	  Those	  results	  indicate	  that	  silencing	  of	  DGKα	  reestablish	  
RICD	   by	   activating	   PKCθ	   activity	   and	   the	   RasGRP1/MEK/ERK	   signaling	   cascade,	   prompting	   us	   to	  
focus	  on	  the	  RSK2	  S6	  kinase,	  which	   is	  activated	  downstream	  of	  ERK,	  and	  phosphorylates	  Nur77.	  
This	  phosphorylation	  is	  in	  turn	  responsible	  for	  Nur77	  mitochondrial	  translocation	  and,	  ultimately,	  
for	  cell	  apoptosis	  [33,	  34].	  
The	   RSK	   inhibitor	   SL0101-­‐1	   (100 µM)	   drastically	   induced	   resistance	   to	   RICD	   in	   control	   cells,	  
confirming	  that	  RSK	  activity	  is	  required	  for	  RICD,	  likely	  by	  promoting	  Nur77	  phosphorylation	  (Fig.	  
10e).	   Notably,	   SL0101-­‐1	   also	   abolished	   the	   rescue	   of	   RICD	   induced	   by	   DGKα	   silencing	   in	   SAP-­‐
deficient	   cells,	   indicating	   that	  DGKα	   knockdown	   restores	  RICD	   via	   RSK	   activation	   (Fig.	   10e).	  We	  
observed	   similar	   effects	   on	   T	   cells	   derived	   from	   XLP1	   patients.	   Here,	   the	   rescue	   of	   RICD	   upon	  
R59949	  treatment	  was	  totally	  blunted	  by	  the	  RSK	  inhibitor	  SL0101-­‐1	  (Fig.	  10f).	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Figure	   10.	   DGKα 	   knockdown	   restores	   RICD	   by	   activating	   DAG	   signaling	   through	   PKCθ	   and	   the	   MAPK	   cascade.	  
Lymphocytes	  were	  transfected	  with	  SAP	  siRNA	  and	  PKCθ-­‐specific	   (a)	  or	  RasGRP1-­‐specific	  siRNA	  (b)	  and	  after	  4	  days	  
were	  restimulated	  with	  CD3	  agonist	  OKT3	  (10	  ng/ml).	  After	  24	  hours	  the	  %	  of	  cell	   loss	  was	  evaluated	  by	  PI	  staining.	  
Data	  are	  the	  mean	  ±	  SEM	  of	  four	  independent	  experiments	  performed	  in	  triplicate.	  Paired	  T	  test	  **P	  <	  0.01,	  *P	  <	  0.05.	  
(c)	  Lymphocytes	  were	  transfected	  with	  the	  indicated	  siRNA	  and	  after	  4	  days	  were	  pretreated	  with	  the	  PKCs	  inhibitor	  
Rottlerin	  (6	  µM).	  After	  30	  minutes	  cells	  were	  restimulated	  with	  CD3	  agonist	  OKT3	  (100	  ng/ml).	  After	  24	  hours	  the	  %	  of	  
cell	   loss	   was	   evaluated	   by	   PI	   staining.	   Data	   are	   the	   mean	   ±	   SEM	   of	   four	   independent	   experiments	   performed	   in	  
triplicate.	  Paired	  T	  test	  ***P	  <	  0.001,	  **P	  <	  0.01,	  *	  P	  <	  0.05.	  (d)	  Experiments	  performed	  as	  in	  (c),	  except	  that	  cells	  were	  
pretreated	  with	  MEK	  (U0126,	  5	  µM)	  and	  ERK	  (FR180204,	  10	  µM)	  inhibitors.	  (e)	  Experiments	  performed	  as	  in	  c,	  except	  
that	  cells	  were	  pretreated	  with	  the	  RSK2	  inhibitor	  (SL0101-­‐1,	  100	  µM).	  (f)	  Lymphocytes	  from	  control	  subject	  (left)	  or	  
XLP1	   patient	   2	   (right)	   were	   pretreated	   for	   30	   minutes	   with	   R59949,	   5	   µM	   and	   restimulated	   for	   24	   hours	   with	  
increasing	  doses	  of	  OKT3.	  A	  representative	  experiment	  is	  shown.	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RSK-­‐dependent	  Nur77	  phosphorylation	  is	  required	  for	  the	  RICD.	  
Altogether,	  our	  data	  suggest	  that,	  upon	  DGKα	  silencing,	  Nur77	  induction	  and	  phosphorylation	  by	  
RSK2	  may	  be	  the	  key	  events	  required	  for	  restoring	  the	  RICD	  in	  SAP-­‐silenced	  cells.	  	  
Thus,	  we	  evaluated	  the	  amount	  and	  phosphorylation	  of	  the	  Nur77	  protein	  in	  primary	  T	  cells	  upon	  
SAP	  or	  SAP+DGKα	  silencing	  treated	  or	  not	  with	  SL0101-­‐1.	  In	  these	  experiments,	  P-­‐S6	  was	  used	  as	  a	  
read	  out	   for	  RSK	  activity.	   In	   line	  with	   the	  experiments	   shown	   in	  Fig.	  7,	  we	  saw	  a	  defect	   in	  TCR-­‐
induced	  Nur77	  expression	   in	  SAP-­‐silenced	  cells	  which	   is	   rescued	  by	  DGKα	  silencing	   (Fig.	   11a).	   In	  
parallel,	  we	  observed	  that	  SAP-­‐deficient	  cells	  displayed	  a	  severely	  decreased	  phosphorylation	  of	  
Nur77	  on	  the	  RSK-­‐dependent	  phosphorylation	  site	  S351,	  which	  is	  fully	  rescued	  by	  DGKα	  silencing	  
in	  a	  RSK	  dependent	  manner	  (Fig.	  11a).	  	  
Moreover,	   in	   XLP1-­‐derived	   T	   cells,	   the	   simultaneous	   silencing	   of	   Nur77	   and	   Nor1	   reduced	   the	  
effect	  on	  RICD	   induced	  by	  DGKα	   inhibition,	   indicating	  a	   synergistic	   role	   for	   those	   two	   factors	   in	  
boosting	   the	   RICD	   (Fig.	   11b).	   Indeed,	  Nur77	   knockdown	   alone	   had	   no	   effect	   on	   RICD	   (data	   not	  
shown).	   Interestingly,	   Nur77	   and	   Nor1	   silencing	   did	   not	   affect	   apoptosis	   of	   control	   cells	   from	  
healthy	   donors,	   indicating	   that	   in	   those	   cells	   other	   apoptotic	   pathways	   concur	   in	   achieving	   the	  
RICD	  (Fig.	  11b).	  
Altogether,	   those	   results	   indicate	   that	   the	   reestablishment	   of	   DAG	   signaling	   at	   the	   IS	   observed	  
upon	  DGKα	  knockdown	  restores	  apoptosis	  in	  SAP-­‐deficient	  cells	  by	  activating	  PKCθ	  and	  the	  MAPK	  
cascade,	   leading	   to	   RSK-­‐mediated	   phosphorylation	   of	   Nur77	   and	   Nor1,	   whose	   induction	   is	  
specifically	  required	  for	  the	  rescue	  of	  the	  RICD	  mediated	  by	  DGKα	  silencing	  or	  inhibition.	  
 
 
	   	  




Figure	  11.	  RSK-­‐driven	  phosphorylation	  of	  Nur77	  and	  Nor1	  is	  required	  for	  the	  RICD.	  
(a)	  Human	  primary	  T	  lymphocytes	  were	  transfected	  with	  control,	  SAP	  and	  SAP+DGKα	  siRNAs.	  After	  4	  days,	  cells	  were	  
pretreated	  with	  SL0101-­‐1	  (100	  µM,	  30	  minutes)	  and	  stimulated	  with	  OKT3	  (10	  µM,	  4	  hours),	  lysed	  and	  analyzed	  by	  WB	  
for	  P-­‐Nur77	  (S531),	  Nur77,	  P-­‐S6,	  S6,	  DGKα,	  SAP	  and	  tubulin	  content.	  P-­‐S6	  was	  used	  as	  read	  out	  for	  SL0101-­‐1	  activity.	  A	  
representative	  experiment	   is	  shown,	  n	  =	  3	  (b)	  Primary	  T	   lymphocytes	  from	  control	  subject	  or	  XLP1	  patient	  were	  co-­‐
transfected	  with	  Nur77	  and	  Nor1	  specific	  antibodies	  (NN).	  After	  4	  days,	  cells	  were	  pretreated	  with	  DMSO	  or	  R59949	  (5	  
µM,	  30	  minutes)	  and	  stimulated	  with	  5	  or	  50	  ng/ml	  of	  anti-­‐CD3	  OKT3.	  A	  representative	  experiment	  is	  shown,	  n	  =	  3.	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Discussion	  
	  
SAP	   deficiency	   in	   XLP1	   causes	   multiple	   defects	   in	   the	   immune	   response.	   In	   particular,	   XLP1	  
patients	   display	   uncontrolled	   lymphoproliferation	   and	   extensive	   tissue	   damage	   upon	   EBV	  
infection,	   which	   leads	   to	   fulminant	   infection	   mononucleosis	   (FIM).	   The	   lymphocyte	   expansion	  
involves	   primarily	   the	   CD8+	   compartment	   and	  mediates	   the	   tissue	   damage	   and	   illness	   [145].	   A	  
critical	  contribution	  to	  this	  process	  is	  due	  to	  resistance	  to	  restimulation-­‐induced	  cell	  death	  (RICD),	  
which	  depends	  on	  the	  NTB-­‐A/SAP	  signaling	  pathway	  [90,	  96].	  	  
We	  based	  this	  work	  on	  the	  finding	  that	  TCR-­‐triggering	  inhibits	  DGKα	  in	  a	  SAP-­‐dependent	  manner,	  
thus	  allowing	  an	  efficient	  downstream	  DAG	  signaling	  [116,	  146].	  Inhere	  we	  demonstrate	  that	  the	  
resistance	   to	   RICD	   observed	   in	   SAP-­‐deficient	   lymphocytes	   from	   XLP1	   patients	   is	   due,	   at	   least	  
partially,	  to	  the	  uncontrolled	  DGKα	  activity.	  Moreover,	  we	  identified	  a	  strong	  correlation	  between	  
DAG	   levels	   and	   the	   induction	   of	   the	   expression	   of	   the	   pro-­‐apoptotic	   orphan	   nuclear	   receptors	  
Nur77/Nor1.	   In	   an	   in	   vivo	   model	   of	   XLP1,	   we	   also	   provide	   evidence	   that	   DGKα	   inhibition	  
attenuates	   the	   expansion	   of	   CD8+	   lymphocytes	   and	   tissue	   damage.	   This	   suggests	   potential	  
therapeutic	   applications	   for	   DGKα	   inhibitors,	   such	   as	   the	   stabilization	   of	   patients	   before	   the	  
hematopoietic	  stem	  cell	  transplant.	  	  
	  
The	  demonstration	  of	  a	  crucial	  role	  of	  uncontrolled	  DGKα	  activity	  in	  promoting	  resistance	  to	  RICD	  
comes	  from	  the	  striking	  finding	  that	  DGKα	  silencing	  or	   inhibition	   is	  sufficient	  to	  fully	  restore	  cell	  
death	  in	  SAP-­‐silenced	  T	  cells	  but	  also	  in	  T	  lymphocytes	  from	  XLP1	  patients	  (Fig.	  8).	  	  
Interestingly,	  DGKα	  knockdown	  had	  no	  effect	  on	  RICD	   in	   SAP-­‐sufficient	   cells	   (Fig.	   8).	   This	   result	  
confirms	  that,	  in	  normal	  T	  lymphocytes,	  DGKα	  activity	  is	  limited	  by	  SAP	  and	  couples	  with	  previous	  
findings	   indicating	   that,	   despite	   high	   expression	   levels,	   DGKα	   plays	   a	   minor	   role	   in	   DAG	  
metabolism	  in	  TCR-­‐activate	  lymphocytes	  [125,	  134].	  	  
Interestingly,	   the	   observation	   that	   also	   the	   specific	   silencing	   of	   DGKζ	   restored	   RICD	   in	   SAP-­‐
deficient	   cells	   (Fig.	   8j)	   suggests	   that	   the	   crucial	   regulator	   of	   RICD	   is	   DAG	   signaling.	   Indeed,	  
exogenous	  administration	  of	  a	  short	  chain	  C8-­‐DAG	  was	  sufficient	  to	  restore	  RICD	  as	  well	  (Fig.	  8i).	  
Conversely,	  stimulation	  with	  phorbol	  ester	  (PMA),	  a	  DAG	  analog	  which	  bypass	  early	  TCR	  signaling	  
events,	   strongly	   potentiated	   the	   signal,	   thus	   enhancing	   cell	   death	   while	   perturbing	   the	   IS	  
formation	   (Fig.	   3a-­‐c	   and	   data	   not	   shown).	   These	   data	   strongly	   suggest	   that	   a	   localized	   DAG	  
signaling	  is	  required	  for	  RICD.	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The	  DAG	  accumulation	   induced	  by	   the	  TCR-­‐triggering	   is	   highly	   localized	  at	   the	   immune	   synapse	  
and	  controls	  both	  the	  organization	  of	  the	  actin	  cytoskeleton	  and	  the	  downstream	  events,	  leading	  
to	  MTOC	  orientation	  towards	  the	   IS	  and	  activation	  of	  downstream	  effectors	   [37,	  47].	  DGKα	  and	  
DGKζ	   are	   both	   recruited	   at	   the	   immune	   synapse,	   but	   they	   have	   distinct	   and	   non-­‐redundant	  
functions:	  while	  the	  ζ	   isoform	  prevalently	  phosphorylates	  the	  bulk	  of	  DAG,	  the	  α	  isoform	  plays	  a	  
specific	   role	   in	   the	   controlling	   the	   synapse	   organization	   and	   T	   cell	   polarization	   [52,	   125].	  
Interestingly,	   lymphocytes	   from	   SAP	   KO	  mice	   display	   several	   defects	   in	   the	   IS	   signaling,	   which	  
couple	  with	  variable	  alterations	  in	  the	  IS	  assembly	  and	  MTOC	  polarization,	  depending	  on	  the	  cell	  
type.	   Specifically,	   CTLs	   exhibit	   impaired	  actin	   reorganization	  and	  MTOC	   reorientation	   towards	  B	  
cell	  targets,	  iNKT	  shows	  normal	  actin	  polymerization	  but	  are	  defective	  in	  MTOC	  orientation,	  while	  
CD4+	  T	  cells	  display	  normal	  IS	  but	  decreased	  DAG-­‐dependent	  PKCθ	  recruitment	  [67,	  128,	  147].	  To	  
verify	  the	  correlation	  between	  these	  defects	  and	  DGK	  activity,	  we	  developed	  specific	  algorithms	  to	  
quantify	   the	   accumulation	   of	   the	   PKCθ-­‐CRD	   DAG	   biosensor,	   Lifeact-­‐GFP	   and	   Tubulin-­‐GFP	   in	  
conjugates	   between	   SEE-­‐loaded	   Raji	   B	   cells	   and	   Jurkat	   T	   cells,	   to	   follow	   DAG,	   actin	   and	  MTOC	  
movements,	  respectively.	  Our	  results	  indicates	  that	  the	  defects	  of	  the	  IS	  morphology	  and	  function	  
in	  SAP	  deficient	  cells	  are	  due	  to	  the	   increased	  DAG	  metabolism	  by	  DGKα.	   Indeed,	  DGKα-­‐specific	  
silencing	   restores	   not	   only	   the	  DAG	  accumulation	   at	   the	   IS	   but	   also	   the	   IS	  morphology	   and	   the	  
MTOC	   orientation	   in	   SAP-­‐deficient	   cells	   (Fig.	   1,2,4).	   We	   can	   also	   confirm	   that	   in	   control	   SAP-­‐
sufficient	  cells,	  DGKα	  limits	  DAG	  polarization	  at	  the	  IS,	  without	  affecting	  conjugate	  formation	  [52,	  
124].	   In	   contrast,	  DGKζ	   silencing	  was	  not	   sufficient	   to	   significantly	   rescue	  actin	  accumulation	   to	  
the	  IS	  in	  SAP-­‐deficient	  cells	  (Fig.	  1),	  or	  to	  disrupt	  the	  polarity	  in	  control	  cells	  (Fig.	  1,2),	  accordingly	  
to	  the	  prominent	  role	  of	  the	  α	  isoform	  in	  regulating	  the	  polarity	  of	  the	  T	  cells	  [52].	  	  
Notably,	   the	   MTOC	   repositioning	   controls	   the	   secretion	   of	   cytotoxins,	   which	   travel	   along	  
microtubules	  to	  the	  centrosome,	  and	  are	  then	  released	  towards	  the	  target	  cell	  [50].	  It	  is	  likely	  that	  
DGKα	   inhibition	   in	   SAP-­‐deficient	   cells,	   by	   controlling	   MTOC	   reorientation,	   might	   restore	   the	  
cytotoxic	  activity	  of	  CTLs	  (and	  possibly	  of	  NK	  cells).	  It	  would	  be	  interesting	  to	  test	  this	  hypothesis,	  
since	  XLP	  patients	  not	  only	  display	  impaired	  T	  cell	  restimulation-­‐induced	  cell	  death,	  but	  also	  have	  
impaired	  clearance	  of	  EBV+	  B	  cells	  leading	  to	  HLH	  and	  lymphomas.	  
Altogether,	   our	   data	   demonstrates	   that	   DGKα	   controls	   the	   IS	   formation,	   the	   strength	   of	   the	  
signaling,	  and	  the	  RICD	  in	  SAP-­‐deficient	  cells,	  thus	  suggesting	  that	  DAG	  at	  the	  IS	  might	  regulates	  
the	  RICD	  process.	  Indeed,	  SAP-­‐deficient	  cells	  show	  decreased	  recruitment	  of	  the	  DAG-­‐dependent	  
signal	   transducer	   PKCθ	   and	   impaired	   activation	   of	   the	   DAG-­‐dependent	  MAPK	   pathway	   [64,	   67,	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116].	   Therefore,	   we	   immuno-­‐localized	   PKCθ	   and	   RasGRP1	   to	   follow	   DAG	   signaling	   at	   the	   IS	   of	  
primary	   T	   lymphocytes,	   confirming	   a	   decreased	   recruitment	   in	   SAP-­‐deficient	   cells	  which	   is	   fully	  
rescued	   by	   DGKα	   silencing	   or	   inhibition	   (Fig.	   5a-­‐h).	   Accordingly,	   the	   TCR-­‐induced	   activation	   of	  
ERK1/2	  kinases	   is	   reduced	   in	  SAP	  absence	  but	   fully	   rescued	  by	  DGKα	  silencing	  or	   inhibition	   (Fig.	  
6a,b).	  
Both	  PKCθ	  and	  RasGRP1	  were	  previously	  implicated	  in	  apoptosis	  induced	  by	  the	  activation	  of	  the	  
TCR	  [140,	  141].	  Therefore,	  we	  tested	  whether	  DGKα	  silencing	  might	  induce	  rescue	  of	  RICD	  in	  SAP	  
deficient	  cells	  by	  reestablish	  PKCθ	  and	  RasGRP1	  pathways.	  Indeed,	  we	  found	  that	  both	  PKCθ	  and	  
RasGRP1-­‐specific	  siRNA	  decreased	  the	  RICD	  in	  control	  cells	  without	  affecting	  the	  residual	  RICD	  of	  
SAP-­‐deficient	   cells,	   while	   blunted	   the	   rescue	   of	   RICD	   promoted	   by	   DGKα	   silencing	   (Fig.	   10a,b).	  
Similar	  results	  were	  obtained	  when	  we	  used	  inhibitors	  of	  the	  DAG-­‐dependent	  effectors	  PKCs	  and	  
MEK/ERK,	  confirming	  the	  relevance	  of	  those	  pathways	  downstream	  to	  DGKα	  silencing	  (Fig.	  10c,d).	  
Those	   results	   indicate	   that	   the	   residual	   RICD	   in	   SAP-­‐deficient	   cells	   is	   not	   mediated	   by	   DAG	  
signaling,	  while	   the	  rescue	  of	  cell	  death	  mediated	  by	  DGKα	  silencing	   in	   those	  cells	   is	  completely	  
dependent	  on	  DAG	  signaling	  at	  the	  IS	  (Fig.10).	  	  
To	   investigate	  to	  what	  extent	  the	  potentiation	  of	  DAG	  signaling	  restores	  the	  TCR	  signaling	   levels	  
required	  to	  initiating	  the	  RICD,	  we	  evaluated	  a	  set	  of	  TCR-­‐responsive	  genes	  involved	  in	  the	  control	  
of	  the	  cell	  death.	  
We	  found	  that	  DGKα	  silencing	  or	  inhibition	  in	  control	  cells	  do	  not	  altered	  TCR-­‐induced	  exposure	  of	  
IL-­‐2	  receptor	  (CD25),	  nor	  the	  expression	  of	  pro-­‐apoptotic	  genes	  such	  as	  FASL,	  BIM,	  Nur77	  or	  Nor1,	  
while	   potently	   enhanced	   IL-­‐2	   expression	   	   (Fig.6	   and	   Fig.7),	   in	   line	  with	   published	  data	   [8,	   123].	  
Conversely,	   SAP-­‐deficient	   cells	   present	   a	   reduced	   TCR	   signaling	   strength	   with	   decreased	  
expression	  of	  IL-­‐2,	  CD25	  and	  pro	  apoptotic	  proteins	  (Fig.	  6	  and	  7),	  as	  previously	  demonstrated	  in	  
[68,	  90,	  116,	  135].	  
Surprisingly,	  among	  them,	  DGKα	  knockdown	  selectively	  rescued	  IL-­‐2	  expression,	  CD25	  membrane	  
exposure,	  Nur77	  and	  Nor1	  expression	  in	  SAP-­‐deficient	  cells	  (Fig.6,	  Fig.7g-­‐j),	  while	  the	  expression	  
of	   FASL	   and	   BIM,	   as	   well	   as	   sFASL	   secretion,	   remain	   low	   and	   not	   responsive	   to	   TCR	   triggering	  
(Fig.7a-­‐f).	   This	   selectivity	   may	   reflect	   the	   inability	   of	   DGKα	   inhibition	   to	   compensate	   for	   the	  
reduced	   LCK	   recruitment	   and	   activation	   to	   the	   NTB-­‐A	   receptor	   in	   SAP	   absence	   [96],	   which	   is	  
responsible	  for	  the	  decreased	  FASL	  and	  BIM	  expression	  in	  SAP-­‐deficient	  cells	  [96].	  	  
Our	  results	  also	  suggest	  that	  DGKα	  silencing	  rescues	  cell	  death	  in	  SAP	  deficient	  cells	  by	  promoting	  
FASL	  and	  BIM	  independent	  pathways.	  Therefore,	  we	  turned	  our	  attention	  on	  Nur77	  and	  Nor1,	  as	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those	  two	  orphan	  nuclear	  receptors	  are	  known	  mediators	  of	  apoptosis	  in	  T	  cells	  [34-­‐36,	  139,	  148].	  
Moreover,	  their	  pro-­‐apoptotic	  activity	  is	  promoted	  by	  RSK-­‐mediated	  phosphorylation	  downstream	  
to	   the	  MAPK	   pathway	   [33,	   34].	   Upon	   phosphorylation,	   Nur77	   binds	   Bcl-­‐2,	   which	   acquires	   pro-­‐
apoptotic	   functions	   [35].	   This	   signaling	   pathway	   is	   taking	   place	   upon	   DGKα	   silencing	   in	   SAP-­‐
deficient	  cells	  as	  in	  those	  cells	  we	  noted	  a	  strong	  increase	  of	  Nur77	  protein	  and	  phosphorylation	  
as	  compared	  to	  both	  control	  and	  SAP-­‐deficient	  cells	   	   (Fig.	   7k,l	  and	   Fig.	   11a).	  Strikingly,	   the	  RSK-­‐
specific	   inhibitor	   SL0101-­‐1	   completely	   abolishes	   apoptosis	   in	   double	   SAP/DGKα-­‐deficient	   cells,	  
thus	   demonstrating	   the	   key	   role	   of	   the	   kinase	   in	   mediating	   the	   DGKα	   KD	   effects	   on	   the	   RICD	  
process	  (Fig.	  10e,f).	  Furthermore,	  Nur77/Nor1	  double	  knockdown	  had	  a	  minimal	  effect	  on	  RICD	  of	  
control	  cells,	  while	  reduces	  the	  R59949-­‐mediated	  boost	  of	  cell	  death	  in	  XLP1	  patient	  derived	  cells	  
(Fig.	   11b).	  These	  results	  demonstrate	  that	  by	   inhibiting	  DGKα	  we	  potentiate	  the	  MAPK	  pathway	  
leading	   to	   Nur77/Nor1	   induction	   and	   phosphorylation,	   which	   contributes	   to	   the	   RICD	   onset.	  
However,	  other	  DAG-­‐dependent	  signaling	  pathways	  possibly	  contribute	  to	  cell	  death	  in	  those	  cells,	  
as	   the	   effects	   obtained	   by	   silencing	   Nur77/Nor1	   are	   relatively	   small	   when	   compared	   to	   RSK	  
inhibition	  (Fig.	  10e,f	  and	  Fig.	  11b).	  	  
By	  collaborating	  with	  K.	  E.	  Nichols,	  we	  tested	  the	  efficacy	  of	  the	  R59022	  DGK	  inhibitor	  in	  a	  mouse	  
model	   of	   XLP1.	   In	   this	  model,	   SAP	   KO	  mice	   are	   infected	   by	   Lymphocytic	   Choriomeningitis	   virus	  
Armstrong	   (LCMV),	  which	   induces	   hepatosplenomegaly	   and	   potent	   CD8+	   T	   cell	   activation	   [127,	  
145,	   149].	   Following	   LCMV	   infection,	   SAP	   KO	   mice	   developed	   significant	   hepatosplenomegaly	  
when	  compared	  to	  uninfected	  mice	  (Fig.	  12a,b).	  This	  organomegaly	  was	  associated	  with	  a	  marked	  
expansion	   in	   the	   absolute	   number	   of	   total	   (CD8+),	   activated	   (CD8+CD44+)	   and	   LCMV-­‐specific	  
(CD8+CD44+gp33+)	  T	  lymphocytes	  in	  both	  spleen	  and	  liver	  (Fig.	  12e,g).	  We	  then	  tested	  the	  efficacy	  
of	  DGKα	   inhibition	   in	  the	  reduction	  of	   the	  CD8+	  expansion	  by	  adopting	  a	  “curative”	  protocol,	   in	  
which	   SAP	   KO	   mice	   were	   infected	   with	   LCMV	   and	   after	   4	   days	   treated	   with	   twice-­‐daily	  
intraperitoneal	   injections	   of	   R59022	   (2mg/kg	   body	   weight).	   We	   selected	   this	   inhibitor	   and	   the	  
current	  dosage	  as	  it	  has	  been	  previously	  reported	  to	  inhibit	  DGKα	  activity	  in	  vivo	  without	  inducing	  
significant	   toxicity	   [150].	   Compared	   to	   LCMV-­‐infected	   untreated	   SAP	   KO	   mice,	   R59022-­‐treated	  
mice	   had	   smaller	   spleens	   (Fig.	   12a).	   Moreover,	   both	   spleens	   and	   livers	   contained	   significantly	  
fewer	  lymphocytes	  (Fig.	  12a,b).	  The	  decrease	  was	  due	  to	  a	  reduction	  of	  the	  number	  of	  activated	  
and	  LCMV-­‐specific	  CD8+	  lymphocytes	  (Fig.	  12e,g).	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Figure	  12.	  The	  DGK	  inhibitor	  R59022	  reduces	  the	  numbers	  of	  activated	  LCMV-­‐specific	  CD8+T	  cells	  in	  LCMV-­‐infected	  
SAP	  KO	  mice.	  Representative	  images,	  ratio	  over	  body	  weight,	  and	  total	  splenocytes	  count	  of	  spleen	  from	  SAP	  KO	  (a)	  
and	  WT	  (b)	  mice	  injected	  with	  PBS	  (P)	  or	  LCMV,	  without	  (L)	  or	  with	  R59022	  treatment	  (L+DI).	  Ratio	  over	  body	  weight	  
and	   total	   intra-­‐hepatic	   lymphocyte	   count	  of	   liver	   from	  SAP	  KO	   (c)	   and	  WT	   (d)	  mice	   injected	  with	  PBS	   (P)	  or	   LCMV,	  
without	  (L)	  or	  with	  R59022	  treatment	  (L+DI).	  (e-­‐f)	  Absolute	  number	  of	  CD8+,	  CD8+CD44+	  and	  CD8+CD44+gp33+	  cells	  
in	  the	  spleens	  of	  PBS	  (P),	  LCMV	  (L)	  and	  LCMV+	  R59022	  (L+DI)	  treated	  SAP	  KO	  (e)	  or	  WT	  mice	  (f).	  (g-­‐h)	  Absolute	  number	  
of	  CD8+,	  CD8+CD44+	  and	  CD8+CD44+gp33+	  cells	   in	  the	   liver	  of	  PBS	  (P),	  LCMV	  (L)	  and	  LCMV+	  R59022	  (L+DI)	  treated	  
SAP	  KO	  (g)	  or	  WT	  mice	  (h).	  	  	  	  
Data	  are	  from	  1	  of	  2	  experiments	  in	  which	  a	  total	  of	  6-­‐10	  mice	  in	  each	  cohort	  was	  examined.	  Error	  bars	  represent	  SD.	  
Statistical	  significance	  was	  determined	  by	  unpaired	  two-­‐tail	  t-­‐test.	  *	  P	  <	  0.05,	  **	  P	  <	  0.001,	  ns:	  not	  significant.	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To	  assess	  whether	  DGKα	   inhibition	   influenced	  CD8+	  cytokine	  production	  and	  effector	   functions,	  
we	  performed	   in	  vitro	  stimulation	  experiments	  using	  splenic	  T	  cells	   isolated	  from	  control,	  LCMV-­‐
infected,	  and	  LCMV	  infected	  but	  R59022	  treated	  SAP	  KO	  mice.	  In	  these	  assays,	  splenocytes	  were	  
cultured	  directly	  ex	  vivo	  with	  the	  MHC	  class	  I	  restricted	  LCMV	  peptide	  gp33.	  Five	  hours	  later,	  cells	  
were	   harvested	   and	   analyzed	   for	   intracellular	   TNFα	   and	   IFNγ	   and	   for	   expression	   of	   CD107,	   a	  
marker	  of	  degranulation	   commonly	  used	  as	  a	   surrogate	   for	   cytolytic	  potential.	   Interestingly,	  we	  
observed	  a	  significant	  reduction	  in	  the	  absolute	  number	  of	  TNFα+,	  IFNγ+	  and	  CD107+	  CD8+	  T	  cells	  
(Fig.	   13a).	   In	  agreement	  with	   the	   reduction	  of	   the	  absolute	  number	  of	   IFNγ-­‐producing	   cells,	  we	  
found	   significant	   lower	   serum	   IFNγ	   levels	   in	   the	   R59022	   treated	  mice	   (Fig.	   13b)	   and	   a	   reduced	  
number	  and	  size	  of	  lymphocytic	  infiltrates	  within	  the	  livers	  (Fig.	  13e,f).	  Taken	  together,	  these	  data	  
indicate	   that	   the	   pharmacologic	   inhibition	   of	   DGKα	   in	   vivo	   reduces	   virus-­‐induced	   CD8+	   T	   cell	  
expansion,	   spleen	   enlargement,	   liver	   infiltration	   and	   the	   cytokine	   storm	   that	   characterize	   this	  
pathology.	  The	   first	  phase	  of	   LCMV-­‐induced	   illness	   is	   similar	   in	  WT	  mice,	  but	  R59022	   treatment	  
had	  minimal	   to	  no	  effect	  on	  CD8+	  expansion	  (Fig.	   12b,d,f,h),	  cytokine	  production	  (Fig.	   13c,d)	  or	  
liver	   infiltration	   (Fig.	   13g,h)	   indicating	   that	  R59022	   is	   not	   impairing	   immune	   response	   to	   LCMV.	  
These	   results	   are	   consistent	   with	   a	   recent	   work	   of	   Shin	   and	   colleagues	   that	   elegantly	  
demonstrated	  that	  CD8+	  T	  cells	  from	  DGKα	  KO	  mice	   infected	  with	  LCMV	  do	  not	  show	  enhanced	  
expansion	  compared	  to	  T	  cells	  from	  WT	  mice.	  [151].	  We	  consider	  that	  those	  data	  are	  in	  line	  with	  
our	  observation	   that	  DGKα	   inhibition	  or	   silencing	  did	  not	  affect	  apoptosis	  of	  SAP-­‐sufficient	  cells	  
(Fig.	  8),	  and	  reflect	  the	  physiological	  inhibition	  exerted	  by	  SAP	  on	  DGKα.	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Figure	  13.	  The	  DGK	  inhibitor	  R59022	  reduces	  the	  number	  of	  virus-­‐specific	  activated	  CD8+	  cytokine	  producing	  cells	  in	  
the	  spleens	  of	  LCMV-­‐infected	  SAP	  KO	  mice.	  	  
2	  ×	  106	  splenocytes	  were	  left	  unstimulated	  or	  stimulated	  with	  0.4	  ng/mL	  gp33	  peptide,	  in	  the	  presence	  of	  1000	  μg/mL	  
monensin	   for	   5	   hours	   and	   analyzed	   for	   intracellular	   cytokines	   production	   and	   degranulation.	   Absolute	   number	   of	  
	   65	  
CD8+IFNγ+,	  IFNγ+TNFα+	  and	  IFNγ+CD107α+	  cells	  from	  SAP	  KO	  (a)	  and	  WT	  mice	  (b).	  Error	  bars	  represent	  SD.	  Statistical	  
significance	  was	  determined	  by	  unpaired	  two-­‐tail	  t-­‐test.	  *	  P	  <	  0.05,	  **	  P	  <	  0.001,	  ns:	  not	  significant.	  (c-­‐d)	  Serum	  IFNγ	  
levels	   from	  SAP	  KO	   (c)	  and	  WT	   	   (d)	  mice	  were	  assayed	  on	  day	  8	  post-­‐infection	  by	  ELISA.	  Data	  are	  compiled	   from	  2	  
experiments,	  n=	  6-­‐10.	  Error	  bars	  represent	  SEM.	  Statistical	  significance	  was	  determined	  by	  unpaired	  two-­‐tail	  t-­‐test.	  **	  
P	  <	  0.001,	  ns:	  not	  significant.	  (e-­‐f)	  Histology	  of	  livers	  from	  representative	  SAP	  KO	  (e)	  and	  WT	  (f)	  mice	  under	  low	  (top	  
row,	   2X)	   and	   high	   (middle	   row,	   20X)	   power	   magnification.	   Arrows	   point	   to	   inflammatory	   foci	   (top)	   and	   a	  
representative	  inflammatory	  focus	  (middle	  row).	  (g-­‐h)	  Histological	  sections	  were	  analyzed	  for	  the	  number	  and	  area	  of	  
the	  inflammatory	  foci	  in	  each	  group	  of	  SAP	  KO	  (g)	  or	  WT	  (h)	  mice.	  Micrographs	  in	  the	  bottom	  row	  are	  the	  respective	  
analyzed	   images	  shown	   in	   the	  middle	   row.	  Statistical	   significance	  was	  determined	  by	  unpaired	  two-­‐tail	   t-­‐test.	  *	  P	  <	  
0.05,	  **	  P	  <	  0.001,	  ns:	  not	  significant.	  
	  
	  
Altogether,	  these	  findings	  suggest	  that	  the	  reduction	  of	  CD8+	  expansion	  in	  R59022-­‐treated	  SAP	  KO	  
mice	  might	  be	  due	  to	  the	  reestablishment	  of	  the	  T	  cell	  apoptosis,	  since	  also	  splenocytes	  from	  SAP	  
KO	  mice	  display	  a	  RICD	  defect	  which	  is	  rescued	  in	  vitro	  by	  DGKα	  inhibition	  (data	  not	  shown).	  
This	   work	   is	   the	   result	   of	   an	   international	   collaboration	   aimed	   to	   verify	   the	   relevance	   of	   SAP-­‐
mediated	   DGKα	   inhibition	   in	   the	   regulation	   of	   TCR	   signaling	   strength.	   In	   this	   study	  we	   provide	  
evidence	  that	  in	  SAP-­‐deficient	  T	  cells	  the	  IS	  morphology	  is	  altered	  and	  the	  TCR	  signaling	  strength	  is	  
reduced	  by	  excessive	  DGKα	  activity,	  leading	  to	  a	  defective	  restimulation-­‐induced	  cell	  death.	  	  
Collectively,	  with	   our	   in	   vitro	   results	  we	   characterized	   a	   crucial	   signaling	   pathway	   that	   leads	   to	  
RICD,	  providing	  new	   insights	   in	  understanding	   this	  complex	  process,	  which	   is	   initiated	  with	  DAG	  
accumulation	   and,	   through	   PKCθ	   and	   RasGRP1,	   terminates	   with	   the	   RSK	   activation	   and	   Nur77	  
phosphorylation.	  	  
Notably,	  with	   the	   in	   vivo	   data	  we	   identified	   the	   inhibition	   of	  DGKα	   as	   a	   promising	   approach	   to	  
reduce	  the	   life-­‐threatening	  hyperproliferation	  of	  the	  T	   lymphocytes	  that	  occurs	  during	  the	  acute	  
phase	  of	  EBV	  infection	  in	  XLP1	  patients.	  Also,	  the	  same	  strategy	  might	  be	  used	  for	  the	  treatment	  
of	   other	   diseases,	   which,	   as	   XLP1,	   exhibit	   an	   increased	   signal	   strength	   threshold	   required	   for	  
undergo	  apoptosis,	  such	  as	  ITK	  deficiency	  [152,	  153].	  	  
	   	  
	   66	  
Appendix	  	  
	  
During	  my	  PhD	  fellowship,	  I	  have	  been	  involved	  in	  other	  two	  projects,	  which	  have	  been	  published	  
in	  two	  international	  journals.	  
Particularly,	  the	  first	  project	  (Rainero	  et	  al.,	  2014)	  was	  meant	  to	  elucidate	  the	  mechanism	  of	  the	  
SDF-­‐1α-­‐induced	  matrix	  invasion	  of	  the	  invasive	  carcinoma	  breast	  line	  MDA-­‐MB-­‐231.	  We	  based	  this	  
work	   on	   previous	   publication	   in	   which	   we	   demonstrated	   that,	   in	   epithelial	   cells,	   DGKα	   activity	  
promotes	  cytoskeletal	  remodeling	  and	  matrix	  invasion	  by	  recruiting	  atypical	  PKCs	  at	  ruffling	  sites	  
[154]	  and	  by	  promoting	  RCP-­‐mediated	  recycling	  of	  α5β1	  integrin	  to	  the	  tip	  of	  pseudopods	  [155].	  
Here,	  we	  found	  that	  DGKα	  is	  activated	  and	  translocates	  to	  the	  cell	  protrusion	  in	  response	  to	  SDF-­‐
1α	   stimulation,	   thus	   promoting	   Rac	   and	   PKCs-­‐mediated	   elongation	   of	   protrusion,	   MMP-­‐9	  
metalloproteinase	  secretion,	  matrix	   invasion	  and	  cell	  elongation.	  Phosphatidic	  acid	  generated	  by	  
DGKα	  at	  the	  cell	  protrusion	  was	  able	  to	  recruit	  atypical	  PKCs,	  which	  in	  turn	  was	  responsible	  for	  the	  
recruitment	   of	   β1	   integrin	   and	   MMP-­‐9	   to	   the	   cell	   tip.	   Finally,	   we	   demonstrated	   that	   the	  
DGKα/atypical	  PKCs/β1	  integrin	  axis	  is	  required	  for	  MDA-­‐MB-­‐231	  cells	  matrix	  invasion.	  
I	  enthusiastically	  contributed	  to	  this	  work	  by	  generating	  the	  inducible	  MDA-­‐MB-­‐231	  shDGKα	  cell	  
line	   and	   the	   MDA-­‐MB-­‐231	   OST-­‐tagged	   DGKα	   cell	   line.	   Also,	   I’ve	   designed	   and	   carried	   out	   the	  
experiments	  performed	  with	  both	  the	  inducible	  cell	  lines,	  which	  were	  used	  for	  the	  localization	  of	  
DGKα,	   for	   the	   invasion,	   migration	   and	   wound	   healing	   experiments,	   and	   for	   the	   evaluation	   of	  
DGKα,	  atypical	  PKCs,	  Rac	  and	  β1	  integrin	  contribution	  to	  the	  protrusion	  elongation	  of	  the	  cells.	  	  
	  
The	   second	   project	   came	   from	   collaboration	  with	   the	   Immunology	   group	   led	   by	   Prof.	   Umberto	  
Dianzani	   (Dianzani	  et	  al.,	  2014).	  The	  work	  was	  based	  on	  the	  observations	  that	  a	  soluble	   form	  of	  
ICOS	  (ICOS-­‐Fc)	   inhibits	  the	  adhesion	  of	  different	  tumor	  cells	   lines	  to	  HUVECs	  expressing	  B7h,	  the	  
ICOS	   ligand,	   suggesting	   that	   may	   act	   as	   an	   anti-­‐tumoral	   agent	   by	   preventing	   metastatic	  
dissemination.	   Here,	   we	   performed	   migration	   assays	   to	   evaluate	   the	   efficacy	   of	   ICOS-­‐Fc	   in	  
inhibiting	   cell	   migration	   on	   a	   number	   of	   different	   cell	   lines.	   ICOS-­‐Fc	   specifically	   inhibited	   the	  
migration	  of	  HUVECs,	  human	  dermal	  lymphatic	  ECs,	  and	  the	  HT29,	  HCT116,	  PC-­‐3,	  HepG2,	  JR8,	  and	  
M14	   tumor	  cell	   lines	  expressing	  high	   levels	  of	  B7h,	  whereas	   it	  was	   ineffective	   in	   the	  RPMI7932,	  
PCF-­‐2,	   LM,	   and	   BHT-­‐101	   cell	   lines	   expressing	   low	   levels	   of	   B7h.	  Moreover,	   ICOS-­‐Fc	  was	   able	   to	  
prevent	  the	  epithelial-­‐mesenchimal	  transition	  induced	  by	  HGF	  treatment	  of	  Hep-­‐G2	  cells,	  but	  not	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in	   low	   B7h	   BHT-­‐101	   cells.	   Those	   effects	   of	   ICOS-­‐Fc	   on	   both	   HUVECs	   and	   tumor	   cell	   lines	   were	  
shown	  to	  be	  dependent	  on	  the	  dowmodulation	  of	  FAK	  phosphorylation	  and	  β-­‐PIX	  expression.	  	  
Finally,	   treatment	  with	   ICOS-­‐Fc	   inhibited	   the	  development	  of	   lung	  metastases	  upon	   injection	  of	  
NOD-­‐SCID-­‐IL2Rγnull	   mice	   with	   CF-­‐PAC1	   cells,	   as	   well	   as	   C57BL/6	   mice	   with	   B16-­‐F10	   cells.	  
Therefore,	   the	   B7h-­‐ICOS	   interaction	   may	   modulate	   the	   spread	   of	   cancer	   metastases,	   which	  
suggests	   the	   novel	   use	   of	   ICOS-­‐Fc	   as	   an	   immunomodulatory	   drug.	   However,	   in	   the	   B16-­‐F10–
metastasized	   lungs,	   ICOS-­‐Fc	   also	   increased	   IL-­‐17A/RORc	   and	   decreased	   IL-­‐10/Foxp3	   expression,	  
which	  indicates	  that	  it	  also	  exerts	  positive	  effects	  on	  the	  antitumor	  immune	  response.	  
My	   contribution	   to	   this	   project	   was	   to	   perform	   the	   morphological	   and	   scatter	   experiments	   in	  
response	  to	  hepatocytes	  growth	  factor	  stimulation	  on	  different	  cancer	  cells	  types,	  with	  the	  aim	  to	  






























	   	  
The Diacylglycerol Kinase a/Atypical PKC/b1 Integrin
Pathway in SDF-1a Mammary Carcinoma Invasiveness
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Abstract
Diacylglycerol kinase a (DGKa), by phosphorylating diacylglycerol into phosphatidic acid, provides a key signal driving cell
migration and matrix invasion. We previously demonstrated that in epithelial cells activation of DGKa activity promotes
cytoskeletal remodeling and matrix invasion by recruiting atypical PKC at ruffling sites and by promoting RCP-mediated
recycling of a5b1 integrin to the tip of pseudopods. In here we investigate the signaling pathway by which DGKa mediates
SDF-1a-induced matrix invasion of MDA-MB-231 invasive breast carcinoma cells. Indeed we showed that, following SDF-1a
stimulation, DGKa is activated and localized at cell protrusion, thus promoting their elongation and mediating SDF-1a
induced MMP-9 metalloproteinase secretion and matrix invasion. Phosphatidic acid generated by DGKa promotes
localization at cell protrusions of atypical PKCs which play an essential role downstream of DGKa by promoting Rac-
mediated protrusion elongation and localized recruitment of b1 integrin and MMP-9. We finally demonstrate that activation
of DGKa, atypical PKCs signaling and b1 integrin are all essential for MDA-MB-231 invasiveness. These data indicates the
existence of a SDF-1a induced DGKa - atypical PKC - b1 integrin signaling pathway, which is essential for matrix invasion of
carcinoma cells.
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Introduction
Most cancer-associated mortality is caused by metastatic
dissemination of primary tumors and the outgrowth of secondary
tumors at distant sites. Among the microenvironment signals
sustaining the invasive phenotype of cancer cells, stromal cell-
derived factor-1a (SDF-1a, also named CXCL12), plays a major
role in promoting cancer metastasis in several cancers, including
breast cancer [1]. SDF-1a is a chemokine secreted by tumor-
associated fibroblasts and bone marrow stromal cells, which
through activation of its CXCR4 receptor, promotes migration
and invasion of malignant cells and their homing to target organs
[2,3]. Indeed CXCR4 is a poor prognosis predictor in several
cancer types [4].
In breast cancer, the chemotactic and invasive activity of SDF-
1a/CXCR4 is mediated by both Ga13-mediated activation of
RhoA and Gai-mediated activation of Rac1 via DOCK180/
ELMO, which regulate cytoskeletal remodeling [5,6]. In myeloid
cells, Rac1 mediates SDF-1a-induced increase of integrin affinity,
while RhoA mediates formation of membrane protrusions and
CXCR4 trafficking to the cell surface in Rab11+ endosomes [7,8].
Moreover, in gastric cancer cells SDF-1a invasive and proliferative
activity is also stimulated by Gai- and PI3Kb-mediated activation
of mTOR complex 1, which contributes to Rac1 activation as well
[9]. Finally, atypical protein kinases C (PKCf and i, hereafter
aPKCs), which do not bind diacylglycerol (DG), play a key role in
mediating chemotaxis of bone marrow and muscle stem cells, and
of lymphocytes [10,11]. However neither the mechanisms by
which SDF-1a stimulates aPKCs nor their role in SDF-1a invasive
signaling in breast cancer cells have been elucidated.
DGKs are a multigenic family of ten enzymes phosphorylating
DG to generate phosphatidic acid (PA), thus reciprocally
regulating in a highly compartmentalized manner the concentra-
tion of both lipid second messengers and their signaling activities
[12]. Indeed, activation of DGKs results in the termination of DG-
mediated signals, while triggering PA-mediated ones. Increasing
evidence points to DGKa as a critical node in oncogenic signaling
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and as a putative novel therapeutic target in cancer: inhibition or
silencing of DGKa has been shown to reduce tumor growth and
mortality in glioblastoma and hepatic carcinoma xenograft models
[13,14]. Moreover, we recently showed that DGKa activity
sustains the pro-invasive activity of metastatic p53 mutations, by
promoting the recycling of a5b1 integrin to the tip of invasive
protrusions in tridimensional matrix [15]. DGKa is activated and
recruited to the membrane by growth factors, estrogen and
tyrosine kinase oncogenes through Src-mediated phosphorylation.
Upon growth factor stimulation, activation of DGKa mediates cell
migration, invasion and anchorage-independent growth [16–21].
Indeed, activation of DGKa is a central element of a novel lipid
signaling pathway involving PA-mediated recruitment at the
plasma membrane and activation of aPKCs in a complex with
RhoGDI and Rac1, thus providing a positional signal regulating
Rac1 activation and association to the membrane [22,23].
Altogether these data suggest that DGKa and aPKCs may act
as signaling nodes in the molecular crosstalk between soluble
chemotactic factors and the extracellular matrix, thus prompting
us to investigate the involvement of DGKa in cell migration and
invasion induced by SDF-1a in breast cancer cells. In here we
show that upon SDF-1a stimulation of breast cancer cells, DGKa
activity mediates aPKCs localization at protrusion sites and the
subsequent recruitment of b1 integrin and MMP-9 secretion.
Conversely over-expression of DGKa is sufficient to induce
aPKCs-dependent cell elongation. Finally, we observed that the
DGKa – aPKCs – b1 integrin pathway is an essential mediator of
chemokine-promoted cell migration and matrix invasion.
Materials and Methods
Cells Culture and Reagents
MDA-MB-231 cells were from ATCC, 293FT were from Life
Technologies. Cells were cultured in DMEM (Life Technologies)
with 10% FCS (LONZA) and antibiotics/antimycotics (Sigma-
Aldrich) in humidified atmosphere 5% CO2 at 37uC.
R59949 (Sigma-Aldrich) was dissolved in DMSO; equal
amounts of DMSO were used in the control samples. All reagents
are from Sigma-Aldrich apart: matrigel growth factor reduced (BD
Bioscences), human recombinant SDF-1a and HGF (Peprotech),
Myr-PKCf/i peptide inhibitor (BIOMOL) and NSC23766
(Tokris bioscience).
Antibodies: myc (clone 9E10 Santa Cruz), MMP-9 (2C3 Santa
Cruz for western blotting and immunofluorescence or IC9111F
RDsystems); PKCf/i (P0713 Sigma); b1 integrin (cat. 610467 BD
Transduction Laboratories for western blotting and immunoflu-
orescence or BV7 Abcam for cytofluorimetry); StrepMab-tag II (2-
1507-001 IBA); actin (C-2 Santa Cruz); tubulin (DM1A Sigma-
Aldrich); DGKa (Shaap et al., 1993), human RCP (rabbit in-house
Ab raised against RCP residues 379–649); Cdc42 (2462 Cell
signaling). Secondary antibodies HRP-mouse and HRP-rabbit
were from Perkin Elmer. Secondary antibodies anti-rabbit Ig
Alexa Flour-488 and anti-mouse Ig Alexa Flour-488 were from
Life Technologies as well as Alexa Flour 546-phalloidin, TO-
PRO-3 is from Life Technologies.
Invasion Assay
Invasion assay were performed in BD BioCoat Matrigel
Chambers. 50,000 cells/well were plated in the upper chamber
whereas SDF-1a (100 ng/ml) or 10% FCS were added to the
lower chamber in serum free medium. After 22 hours of
incubation in a humidified atmosphere 5% CO2 at 37uC, non
invading cells were removed from the upper surface of the
membrane and invading cells were fixed and stained with Diff-
Quik (Medion Diagnostic) before counting.
Wound Healing Assay
Cells were grown to confluence in 12 wells plates and the
monolayer wounded with a pipet tip. Cell debris were removed
and monolayer maintained in serum free medium for 24 hours
with or without HGF (50 ng/ml). The cells were stained with Diff-
Quik (Medion Diagnostic) and for each experimental point 8 fields
photographed (Axiovert inverted microscope with a 4x objective
and a digital camera). Cells migrating inside 2.3 mm of wound
were counted.
DGKa Activation Assay
Cells homogenates were prepared by collecting the cells with a
rubber scraper in buffer B (25 mM Hepes (pH 8), 10% glycerol,
150 mM NaCl, 5 mM EDTA, 2 mM EGTA, 1 mM ZnCl2,
50 mM ammonium molibdate, 10 mM NaF, 1 mM sodium
orthovanadate and Protease Inhibitor Cocktail), homogenizing
them with a 23 G syringe and by spinning at 500 g for 15 min.
Protein concentration was determined by the bicinchoninic acid
method (Pierce) and equalized for each point with buffer.
DGKa activity in cell homogenates (25 ml) was assayed by
measuring initial velocities (5 min at 30uC) in presence of
saturating substrates concentration (1 mg/ml diolein, 5 mM
ATP, 3 mCi/ml c32P-ATP (Perkin Elmer), 10 mM MgCl2,
1 mM ZnCl2, 1 mM EGTA in 25 mM Hepes pH 8, final
reaction volume 50 ml). Reaction was terminated with 0.1 M HCl
and lipids were extracted with cloroform methanol (1:1). PA was
separated by TLC in chloroform:methanol:water:25% ammonium
hydroxide (60:47:11:4). 32P-PA was identified by co-migration
with PA standards stained by incubation in iodine chamber.
Radioactive signals were detected and quantified by Molecular
Imager (Bio-Rad).
Immunofluorescence
Cells (30,000/well) were plated on matrigel coated coverlips in
24 wells cell culture plate and serum deprived for 16–24 hours
before stimulation. After stimulation cells were washed with PBS,
fixed in PBS containing 3% paraformaldehyde and 4% sucrose
and permeabilized in cold Hepes-Triton buffer (20 mM Hepes,
300 mM sucrose, 50 mM NaCl, 3 mM MgCl2, 0.5% Triton X-
100, pH 7.4). PBS containing 2% BSA was used as blocking
reagent for 15 minutes and as diluting agent for primary and
secondary antibodies (incubated for at least 1 hour). Intermediate
washing was performed with PBS containing 0.2% BSA.
Antibodies were added directly onto each glass coverslip in a
humidified chamber. Finally, each glass coverslip was washed
briefly in water and mounted onto a glass microscope slide using
Mowiol (20% Mowiol 4–88, 2.5% 1, 4-diazabicyclo [2.2.2] octane
in PBS, pH 7.4).
Confocal images were acquired with Leica confocal microscope
TCS SP2 using a 63x objective, NA = 1.32, equipped with LCS
Leica confocal software. Basal planes are shown. Each experi-
mental point was performed in duplicate. Depending on
preparation quality in each replicate roughly 30 images were
taken, containing between 70 and 100 cells.
Morphometry
For cell length analysis cells were plated in 24 wells plates and
phase contrast images of live cell were acquired with an Axiovert
inverted microscope equipped with a 40x objective and a digital
camera (Carl-Zeiss) and total cell length was measured with
DGKa/aPKCs/b1 Pathway in Matrix Invasion
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Image-Pro Plus software (MediaCybernetics). Alternatively in
Fig. 6D and Fig. S5B we used a 10x Plan Fluor objective, NA
0.3, and an inverted microscope (TE200; Nikon) with a digital
camera (CoolSNAP HQ; Photometrics) and Metamorph software
(Molecular Devices). For each experimental condition 5 random
fields were photographed containing more than 100 cells.
Cytofluorimetry
Cells were detached with ice could PBS 4 mM EDTA, fixed
with PBS containing 3% paraformaldehyde and stained as
indicated for 30 min. After washing with PBS containing 0.2%
BSA cells were analyzed with a FACScalibur instrument an
CellQuest software (BD) or Flowing software (Turku Bioimaging).
siRNA for Transient Silencing
Transient silencing was obtained by transfection of siRNA
(Sigma Genosys or Life Technologies). Briefly were plated on
matrigel coated coverlips to 30–50% confluence the day before
transfection and transfected using lipofectamine 2000 (Life
Technologies) according to manufacturer’s instructions. The day
after transfection cells were serum deprived for further 18 hours
before immunofluorescences or western blotting.
Figure 1. DGKa is necessary for SDF-1a-induced cell invasion. MDA-MB-231 cells were infected with lentiviral vectors expressing an inducible
shRNA against DGKa (shRNA-DGKa1) or an inducible control shRNA (shRNA-CTRL). Parental and infected cells were treated with 1 mg/ml doxycycline
for 72 hours to promote shRNA transcription. A) 50,000 cells were plated on matrigel invasion chamber and incubated for 24 hours in presence or in
absence of SDF-1a (100 ng/ml). Histogram reports mean 6 SE of fold over control values from 3 independent experiments with *t-test p,0.05, **t-
test p,0.01. B) The efficiency of DGKa down–regulation by shRNA was verified by quantitative RT-PCR. **t-test p,0.01. A) Cells were lysed and the
efficiency of DGKa down–regulation by shRNA was verified by western blot, tubulin was used as a loading control.
doi:10.1371/journal.pone.0097144.g001
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Validated siRNA DGKa [17] sense 59 GGAUGGCGA-
GAUGGCUAAAtt 39 antisense 59UUUAGCCAUCUCGC-
CAUCCgg 39.
siRNA PKCf sense 59CGUUCGACAUCAUCACCGAtt39an-
tisense 59UCGGUGAUGAUGUCGAACGgg39.
siRNA PKCi sense 59CGUUCGACAUCAUCACCGAtt39
antisense 59UCGGUGAUGAUGUCGAACGgg39.
siRNA b1 integrin sense 59GGAGGAAUGUUACACGGCU39
antisense 59 AGCCGUGUAACAUUCCUCCag 39.
Figure 2. SDF-1a stimulates DGKa activity and localization at protrusions site. A) MDA-MB-231 cells, stably expressing myc-DGKa, were
plated on matrigel-coated coverslips for 20 hours in FCS containing medium and cultured for further 20 hours in serum free medium. Cells were then
stimulated with 50 ng/ml of SDF-1a for the indicated times, fixed and stained for actin (red) and myc-DGKa (green). Representative images at 4 hours
after stimulation. Arrowheads indicate DGKa at protrusions. Histogram (B) reports the percentage of cells displaying myc-DGKa at protrusion as mean
6 SE of 5 independent experiments, *t-test p,0.05, **t-test p,0.005. Scale bar 24 mm. C) MDA-MB-231 cells were infected with a lentiviral vector
expressing inducible OST-tagged DGKa or an empty vector. To induce DGKa expression, cells were treated overnight with doxycycline (1 mg/ml) in
serum free medium. Cell were homogenized with buffer B in absence of detergent and analysed for DGK activity (upper panel). Values are mean 6 SE
of 4 independent experiments with *t-test p,0.05. OST-DGKa and actin protein expression was verified by anti-OST and anti-actin western blot
(lower panel).
doi:10.1371/journal.pone.0097144.g002
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Figure 3. DGKa mediates SDF-1a-induced cell invasion by regulating aPKCs recruitment to cell pseudopods. A) MDA-MB-231 cells
were plated on matrigel-coated coverslips for 20 hours in FCS containing medium, transfected with CTRL or DGKa –specific siRNA and cultured for
further 20 hours in serum free medium. Cells were then stimulated for 6 hours with 50 ng/ml SDF-1a, fixed, and stained for actin (red) and aPKCs
(green). Arrowhead indicates aPKCs at protrusions. Scale bar 24 mm. B) Histogram reports the percentage of cells displaying aPKCs at protrusions as
mean 6 SE of 3 independent experiments with **t-test p,0.005, ***t-test p,0.0005. C) MDA-MB-231 cells were transfected with CTRL or DGKa –
DGKa/aPKCs/b1 Pathway in Matrix Invasion
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siRNA RCP: ON-TARGETplus RAB11FIP1 siRNA L-
015968-00-0005 (Dharmacon). Silencer negative control siRNA
AM4611 (Life Technologies) was used as negative control.
Generation of Tet-inducible Strep-tagged DGKa
Construct and Cell Infection
Human DGKa was amplified from pMT2- DGKa [24] by
PCR using the primers DGKa_ScII_fw (59-CCGCGGGCAG-
CATGGCCAAGGAGAGGGGC-39) and DGKa_H3_rv (59-
AAGCTTTTAGCTCAAGAAGCCAAA-39) and cloned into
pEXPR-IBA-105 (IBA GmbH) via SacII and HindIII to generate
pEXPR-Strep-DGKa. In a further step Strep-DGKa was
amplified by PCR using primers IBA_fw_N1 (59-GCGGCCGCA-
GACCCACCATGGCTAGC-39) and 105DGKa_MluI_rv (59-
ACGCGTTTAGCTCAAGAAGCCAAA-39) and cloned via NotI
and MluI to pLVX-Tight-Puro (Clontech). All constructs were
verified by DNA sequencing.
The resulting pLVX-Tight-PURO-OST-DGKa presents OST-
DGKa after a tetracycline controlled promoter and was used with
the Lenti-X Tet-On Advanced Inducible Expression System
(Clontec) according to manufacturer’s instruction. Lentiviral
particles were obtained in 293FT packaging cells co-transfected
with helper vectors. After double infection and selection we
obtained a polyclonal population of MDA-MB-231 cells express-
ing OST-DGKa in a tetracycline inducible manner. A control cell
line was also generated with an empty vector.
Generation of MDA-MB-231 Stably Expressing Myc-DGKa
Myc-DGKa was amplified from PMT2-myc-DGKa [16] by





cloned in the pDONOR211 vector using the Gateway system
(Life Technologies) according to manufacturer’s instructions. The
Gateway Technology (Life Technologies) was also used to
subclone myc-DGKa into pLenti4/V5-DEST lentiviral vector.
Lentiviral particles were obtained in 293FT packaging cells co-
transfected with helper vectors. After infection and selection we
obtained a polyclonal population of MDA-MB-231 cells constitu-
tively expressing myc-DGKa.
Inducible Silencing of DGKa in MDA-MB-231
We used the commercial pTRIPZ Inducible Lentiviral Human
DGKA shRNA Clone ID: V3THS_340705 (shRNA-DGKa1) or
pTRIPZ Inducible Lentiviral Non-silencing shRNA Control
RHS4743 (shRNA-CTRL). Those vectors express shRNA and
turboRFP under a doxycycline regulated promoter (Thermo
Scientific Open Biosystems). Lentiviral particles were obtained in
293FT packaging cells co-transfected with helper vectors. After
infection and selection we obtained a polyclonal population of
MDA-MB-231 cells which upon induction with doxycycline
(1 mg/ml, 72 hours) are 100% RFP positive.
Stable Silencing DGKa in MDA-MB-231
The shRNA for DGKa (forward: 59 GATCCCCGGTCAGT-
GATGTCCTAAAGTTCAAGAGACTTTAGGACATCACT-
GACCTTTTTGGAAA reverse: 59 AGCTTTTC-
CAAAAAGGTCAGTGATGTCCTAAAGTCTCTTGAACTT-
TAGGACATCACTGACCGGG) was cloned with H1-Promoter
within the lentiviral vector pCCL.sin.PPT.hPGK.GFPWpre [25].
The resulting vector co-express shRNA-DGKa and GFP (shRNA-
DGKa2). Empty vector was used as a control. Lentiviral particles
were obtained in 293FT packaging cells co-transfected with helper
vectors (Life Technologies). At 1 week after infection nearly 100%
of cells were GFP+.
Generation of ShRNA- b1 Integrin MDA-MB-231
ShRNA-b1integrin in pLKO were a kind gift of P. Defilippi
[26]. Lentiviral particles were generated with Sigma Mission
Lentivaral packaging mix according to manufacturer’s instruction
in 293FT cells and selected with puromycin. Empty pLKO was
used as a control.
Western Blotting
To verified protein down-regulation cells were lysed 48 hours
after transfection. Cell were washed with ice cold PBS, scraped on
ice in lysis buffer (25 mM Hepes, pH 8, 150 mMNaCl, 0.5/1%
Nonidet P-40, 5 mM EDTA, 2 mM EGTA, 1 mM ZnCl2,
50 mM NaF, 10% glycerol supplemented with fresh 1 mM
Na3VO4, and protease inhibitors) and clarified after centrifugation
of 15 minutes at 12000 rpm at 4uC. Samples were then
resuspended in Laemmli buffer, heat denatured, and separated
by SDS/PAGE. Proteins were then transferred on PVDF
membrane by using semi-dry system. Membrane was then blocked
with 5% BSA in PBS and incubated at 4uC overnight with
primary antibodies diluted in TBS tween 0.1%, BSA 2%, 0.01%
azide. After 4 washes with TBS-Tween 0.1%, membranes were
incubated with secondary antibodies and washed again. Western
blot were visualized using Western Lightning Chemiluminescence
Reagent Plus (Perkin Elmer).
Quantitative RT-PCR
RNA was extracted by TRI-Reagent Solution (Life Technol-
ogies) retrotrascribed with High-Capacity cDNA Reverse Tran-
scription Kits (Life Technologies) and cDNA quantified by real
time PCR using GUSB as normalizer. TaqMan gene expression
assays we from Life Technologies: b1 integrin (Hs 00559595),
GUSB (Hs 00939627), DGKa (Hs 00176278) and MMP-9 (Hs
00234579).
MMP-9 Secretion
MDA-MB-231 cells (250,000 cells/well) were plated in 6-well
cell culture plate and transfected with the indicated siRNA. After
24 hours in serum free media cells were treated with SDF-1a
(100 ng/ml in 500 ml serum-free medium). After 24 hours the
MMP-9 concentration in the supernatants was determined by
ELISA assay (Life Technologies).
specific siRNA and lysed. The efficiency of DGKa down–regulation by siRNA was verified at 48 hours after transfection by western blot, tubulin was
used as loading control. D) MDA-MB-231 cells were plated on matrigel-coated coverslips for 20 hours in FCS containing medium and cultured for
further 20 hours in serum free medium. Cells were then stimulated for 6 hours with 50 ng/ml SDF-1a, in presence or in absence of 1 mM R59949, fixed
and stained for actin (red) and aPKCs (green). Arrowheads indicate aPKCs at protrusions. Scale bar 24 mm. E) Histogram reports the percentage of cells
displaying aPKCs at protrusions as mean 6 SE of 3 independent experiments with ***t-test p,0.0005. F) MDA-MB-231 cells (106/well) were plated on
matrigel invasion chamber and stimulates for 24 hours with SDF-1a (50 ng/ml) in presence or absence of PKCf pseudosubstrate (PS-PKCf, 10 mM).
Histogram reports mean 6 SE of folds over control values from 3 independent experiments with *t-test p,0.05.
doi:10.1371/journal.pone.0097144.g003
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Figure 4. DGKa and aPKCs mediate SDF-1a-induced recruitment of b1 integrin to pseudopods. A) MDA-MB-231 cells were plated on
matrigel-coated coverslips for 20 hours in FCS containing medium, transfected with CTRL or DGKa–specific siRNA and cultured for further 20 hours in
serum free medium. Cells were then stimulated for 6 hours with 50 ng/ml SDF-1a, fixed and stained for actin (red) and b1 integrin (green). Arrows
indicate b1 integrin at protrusions. Scale bar 24 mm. B) Histogram reports the percentage of cells displaying b1 integrin at protrusions as mean 6 SE
values of 3 independent experiments with **t-test p,0.005. C) MDA-MB-231 cells were plated on matrigel-coated coverslips for 20 hours in FCS
containing medium and cultured for further 20 hours in serum free medium. Cells were then stimulated for 6 hours with 50 ng/ml SDF-1a, in
presence or in absence of 1 mM R59949, fixed and stained for actin (red) and b1 integrin (green). Arrow indicates b1 integrin at protrusions. Scale bar
24 mm. D) Histogram reports the percentage of cells displaying b1 integrin at protrusions as mean 6 SE of 3 independent experiments with *t-test
p,0.05, **t-test p,0.005. E) MDA-MB-231 cells were plated on matrigel-coated coverslips for 20 hours in FCS containing medium, transfected with
CTRL or PKCf/i –specific siRNA and cultured for further 20 hours in serum free medium. Cells were then stimulated for 6 hours with 50 ng/ml SDF-1a,
fixed and stained for actin (red) and b1 integrin (green). Arrowheads indicate b1 integrin at protrusions. Scale bar 24 mm. F) Histogram reports the
percentage of cells displaying b1 integrin at protrusions as mean 6 SE of 3 independent experiments with **t-test p,0.005. G) MDA-MB-231 cells
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Statistical Analysis
Data are shown as the mean 6 SEM. For statistical analysis,
Student’s t-test or ANOVA were used. Experiments shown are
representative at least 3 independent experiments.
Results
DGKa Is Necessary for SDF-1a-induced Cell Invasion
We previously showed that DGKa is necessary for matrix
invasion promoted by Epidermal Growth Factor (EGF) [15] or
Hepatocyte Growth Factor (HGF) in MDA-MB-231 breast
carcinoma cells [27]. In order to investigate the role of DGKa
in chemokine invasive signaling in breast cancer, we knocked
down DGKa in MDA-MB-231 using a lentiviral construct
expressing a DGKa-specific shRNA under an inducible promoter
(shRNA-DGKa1). This construct strongly downregulated DGKa
expression when compared with parental cells or a non-targeting
control sequence (shRNA-CTRL, Fig. 1 B and C). The invasive
ability of parental, DGKa-knocked down and control cells were
evaluated in a Matrigel invasion assay. SDF-1a (100 ng/ml)
doubles the number of parental as well as shRNA-CTRL MDA-
MB-231 invading across the matrigel insert (Fig. 1 A). Conversely,
shRNA-DGKa1 cells were unresponsive to SDF-1a stimulation.
We confirmed this finding with an independent shRNA (shRNA-
DGKa2) giving a comparable inhibition of SDF-1a stimulated
matrix invasion (Fig. S1), making off-target effects unlikely.
Those findings indicates that DGKa mediates the pro-invasive
signaling promoted not only by tyrosine kinase receptors [22] but
also by chemokine receptors involved in tumor cells metastatiza-
tion, such as those of SDF-1a.
SDF-1a Stimulates DGKa Activity and Localization at
Protrusions Sites
The previous findings that HGF, EGF and VEGF activate
DGKa and promote its recruitment to the plasma membrane in
epithelial and endothelial cells [15,17,22] suggest that SDF-1a
may promote localized DGKa activation at ruffling sites. Despite
its biological significance, the low level of DGKa expression in
MDA-MB-231 cells hampers activation and localization studies of
the endogenous protein with currently available antibodies.
Thus, for localization studies, MDA-MB-231 cells were stably
infected with a lentiviral vector expressing myc-DGKa and plated
on matrigel-coated coverslip to mimic the epithelial microenvi-
ronment. In unstimulated serum-deprived cells, myc–DGKa was
mainly cytoplasmic, with some cells displaying very little accumu-
lation at cell protrusions (Fig. 2A). Prolonged SDF-1a stimulation
(50 ng/ml; 4 to 6 hours) resulted in the localization of DGKa at
the tip of large protrusions (Fig. 2A and B). No detectable changes
were observed at earlier time points (15 minutes, Fig. 2B).
For enzymatic activation assays, we infected MDA-MB-231
with a lentiviral vector expressing OneStrep-Tagged DGKa
(OST-DGKa) under the control of a doxycycline-inducible
promoter. Upon 48 hours doxycycline treatment (1 mg/ml),
OST-DGKa was strongly overexpressed as compared to endog-
enous protein (Fig. S2A). Under these conditions the enzymatic
activity of OST-DGKa was responsible for almost the entire DGK
activity measured in cell homogenates. Both SDF-1a and HGF (a
well known DGKa activator) induced a further moderate increase
of OST-DGKa activity within 15 minutes of stimulation (Fig. 2C).
Altogether these data indicate that SDF-1a regulates DGKa
activity and localization and suggest that DGKa plays a role in the
formation and/or extension of cell protrusions induced by SDF-
1a.
DGKa Mediates SDF-1a-induced Cell Invasion by
Regulating aPKCs Recruitment to Cell Protrusions
DGKa, by producing PA, mediates aPKCs activation and
recruitment to the cell surface induced by growth factors [23,28].
Thus, we set to investigate whether DGKa mediates SDF-1a-
induced cell invasion by regulating aPKCs. To investigate the role
of DGKa in regulating aPKCs localization, MDA-MB-231 cells
were transiently transfected with control (siRNA-CTRL) or
DGKa-specific siRNA (siRNA-DGKa). Upon 48 hours from
transfection with siRNA-DGKa, the expression of DGKa was
nearly undetectable as compared to its expression in cells
transfected with control siRNA (Fig. 3C). Then, MDA-MB-231
cells were plated on matrigel-coated coverslips, serum starved and
stimulated with 50 ng/ml SDF-1a for 6 hours. In control siRNA
transfected cells, SDF-1a treatment significantly increased the
percentage of cells displaying aPKCs at protrusions, while DGKa
silencing strongly impaired aPKCs recruitment to the membrane
(Fig. 3A and B). In order to verify the requirement for DGKa
enzymatic activity, we carried out aPKCs localization assays in
presence or in absence of 1 mM R59949, a rather specific DGKa
inhibitor [16,29]. R59949 treatment completely abrogated aPKCs
localization at protrusions induced by SDF-1a, while it did not
affect aPKCs localization in unstimulated cells (Fig. 3D and E).
In order to investigate the role of aPKCs in SDF-1a-induced
invasion through extracellular matrix, MDA-MB-231 cells were
treated with 10 mM cell permeable PKCf pseudosubstrate (PS-
PKCf). In a matrigel invasion assay aPKCs inhibition significantly
reduced SDF-1a-induced invasion, while basal invasion was
unaffected in unstimulated cells (Fig. 3F).
Altogether, these data demonstrate that in SDF-1a-stimulated
breast carcinoma cells, localized activity of DGKa at pseudopodial
tips provides a crucial localization lipid signal for aPKCs
recruitment, thus mediating SDF-1a-induced invasive signaling.
DGKa and aPKCs Mediate SDF-1a-induced Recruitment
of b1 Integrin to Protrusions Sites
Recycling and clustering of b1 integrin at the tip of invasive
pseudopods is a key event sustaining the invasive properties of
malignant cells [30]. Conversely, growth factors stimulate invasion
both by inducing integrin clustering at actin-rich adhesive sites and
lamellipodia and by stimulating integrin recycling [26,31]. Thus,
we set to investigate whether the DGKa and aPKCs at protrusions
promote local accumulation of b1 integrin. In serum starved
MDA-MB-231 cells plated on matrigel-coated coverslips b1
integrin is mostly localized in intracellular vesicles in the
perinuclear/Golgi area. Upon SDF-1a stimulation, b1 integrin
also localized in clusters at the tip of cell protrusions (Fig. 4A, C
and E). However, either siRNA-mediated silencing of DGKa or
R59949-mediated inhibition of its enzymatic activity impaired
SDF-1a-induced localization of b1 integrin at cell extensions
were transfected with CTRL and PKCf/i –specific siRNA and lysed. The efficiency of PKCf/i down–regulation by siRNA was verified by western bloting,
tubulin was used as a loading control. H) MDA-MB-231 cells were infected with lentiviral vectors expressing a shRNA against b1-integrin (shRNA-b1)
or a control sequence (shRNA-CTRL). 50,000 cells were plated on matrigel invasion chamber and incubated for 24 hours in presence or in absence of
SDF-1a (100 ng/ml). Histogram reports mean 6 SE of fold over control values from 3 independent experiments with *t-test p,0.05, **t-test p,0.01.
I) The efficiency of b1-integrin down–regulation by shRNA was verified by quantitative RT-PCR.
doi:10.1371/journal.pone.0097144.g004
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Figure 5. DGKa and aPKCs mediates MMP-9 secretion and localization at protrusions. A) MDA-MB-231 cells were transfected with CTRL or
DGKa –specific siRNA and shifted to serum free media. After 24 hours cells were treated with 100 ng/ml SDF-1a in serum free medium for further 20
hours. MMP9 content in the supernatants was measured by ELISA assay, histogram reports secreted MMP-9 as mean 6 SE of 3 independent
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(Fig. 4A, B, C and D). Interestingly SDF-1a stimulation and
DGKa inhibition did not affect the expression of b1 integrin at the
cell surface, as measured by FACS analysis (Fig. S4A). Since
DGKa promotes Rac1 activation and membrane ruffles by
regulating aPKCs [15] and as DGKa mediates SDF-1a-induced
aPKCs recruitment to the membrane protrusions, we assessed
whether aPKCs controls b1 integrin localization. Indeed, siRNA-
mediated silencing of aPKCs (Fig. 4G) impaired SDF1-a-induced
localization of b1 integrin at cell protrusions (Fig. 4E and F).
Altogether these data suggest that SDF-1a, by activating the
DGKa/aPKCs pathway, stimulates the clustering of b1 integrin at
cell protrusions, rather than stimulating its bulk translocation at
the plasma membrane.
Since the expression of constitutively-membrane bound myr-
DGKa stimulates cell invasion by triggering RCP-mediated
recycling of integrin a5b1 [15], we set to investigate the role of
b1 integrin in SDF-1a-promoted cell invasion. To this purpose we
used shRNA mediated knockdown of b1 integrin which resulted in
an 80% reduction of its expression in MDA-MB-231 cells (Fig. 4I).
We found that, b1 integrin knock down severely impaired the
ability of MDA-MB-231 cells to invade through matrigel in
response to SDF-1a stimulation (Fig. 4H).
Altogether these data indicate that DGKa, by regulating
aPKCs, controls chemokine-induced b1 integrin localization at
protrusion sites in breast carcinoma cells, thus confirming the
pivotal role of b1 integrin in SDF-1a-promoted matrix invasion.
DGKa and aPKCs Mediate SDF-1a-induced MMP-
9 Secretion and Localization at Protrusions
Secretion of matrix metalloproteinases (MMPs) is involved in
the extracellular matrix degradation required for invasion of
cancer cells [32,33]. SDF-1a stimulates the secretion of MMP-9 in
several cancer cells, including MDA-MB-231 cells [34,35]. In
migrating cells, MMP-9 is addressed to the cellular extensions
involved in cell migration and accumulates at their tips [36]. Thus,
we investigated whether SDF1-a regulates intracellular localiza-
tion and secretion of MMP-9 through the DGKa/aPKCs axis.
MDA-MB-231 cells presented a low, constitutive secretion of
MMP-9 (40–80 pg/ml in the supernatant), which was not affected
by SDF-1a but was severely reduced by siRNA-mediated silencing
of DGKa (Fig. 5A). However, the mRNA levels of MMP-9 were
not affected by either SDF-1a stimulation or DGKa inhibition,
suggesting that this pathway does not regulate MMP-9 at the
transcriptional level in these cells (Fig. S4C). Conversely, SDF-1a
stimulated MMP-9 accumulation at protrusions of serum-starved
MDA-MB-231 plated on matrigel-coated coverslips (Fig. 5B to E).
We cannot rule out that MMP-9 staining may be associated to the
plasma membrane, indeed FACS analysis of these cells detected
low amounts of membrane-bound MMP-9 with a small increase in
MMP-9 surface positive cells following SDF-1a stimulation (Fig.
S4B). Silencing of DGKa impaired MMP-9 translocation induced
by SDF-1a, while it did not affect its localization in unstimulated
cells (Fig. 5B and C). Similarly, DGKa pharmacological inhibition
with R59949, completely impaired MMP-9 recruitment induced
by SDF-1a (Fig. 5D and E).
Altogether these data suggest that DGKa is essential for MMP-
9 accumulation at protrusions and subsequent release in the
extracellular space. Given the role of DGKa in regulating aPKCs,
we investigated whether aPKCs mediates SDF-1a-induced regu-
lation of MMP-9 localization. Indeed, siRNA-mediated silencing
of aPKCs blunted SDF-1a induced MMP-9 localization at
pseudopodial tips (Fig. 5F and G).
Altogether these data demonstrate that activation of the
DGKa/aPKCs pathway drives both MMP-9 and b1 integrin
localization at the pseudopodial tips, thus regulating the extension
of invasive protrusions and sustaining the invasive behavior of
MDA-MB-231 cells.
DGKa Overexpression Promotes aPKC/Rac Dependent
Cell Elongation
We observed that prolonged SDF1a treatment (6 hours, 50 ng/
ml) of matrigel plated MDA-MB-231 promotes the transition to an
elongated shape with the extension of long protrusions. Interest-
ingly both siRNA downregulation of DGKa and R59949-
mediated inhibition impairs this change in shape (Fig. S3A to C)
indicating the crucial requirement of DGKa activity.
Since the over-expression of membrane-bound myr-DGKa
stimulates cell migration in untransformed cells [18] and
pseudopod extension and invasion in A2780 ovarian cancer cells
[15], we investigated whether wild type DGKa over-expression
was sufficient to further stimulate invasion in MDA-MB-231 cells.
The previously described inducible OST-DGKa construct in
MDA-MB-231 cells allowed us to verify this issue as doxycycline
treatment induced a 30-fold increase in DGKa expression (Fig. 6A
and Fig. S2A), with an increase of about 300-fold of the enzymatic
activity (Fig. 2C). However, over-expression of OST-DGKa was
not sufficient to enhance migration of MDA-MB-231 in wound-
healing assay or to increase invasion through matrigel (Fig. S2B
and C). Nevertheless, over-expression of OST-DGKa led to
elongation of serum-starved MDA-MB-231 cells, while doxycy-
cline did not affect the cell length of empty vector-infected MDA-
MB-231 cells (Fig. 6B and D). Both in elongated and in shorter
cells, OST-DGKa is localized at the tip of cell protrusions (Fig. 6C)
suggesting that despite the absence of cytokines and growth factors
the strong up-regulation of DGKa activity is sufficient to recruit
the signaling machinery for membrane extension and to establish a
feed forward loop recruiting further DGKa.
Consistently, with the reported role of the aPKCs in mediating
DGKa-dependent Rac activation and membrane protrusions
[23], we observed that siRNA-mediated silencing of aPKCs
(Fig. 6G) blunted cell elongation induced by OST-DGKa over-
expression (Fig. 6E). Also the Rac inhibitor NSC23766 completely
experiments normalized for control, with *t-test p,0.05. B) MDA-MB-231 cells were plated on matrigel-coated coverslips for 20 hours in FCS
containing medium, transfected with CTRL or DGKa –specific siRNA and cultured for further 20 hours in serum free medium. Cells were stimulated for
6 hours with 50 ng/ml SDF-1a, fixed and stained for actin (red) and MMP-9 (green). Arrowhead indicates MMP-9 at protrusions. Scale bar 24 mm. C)
Histogram reports the percentage of cells displaying MMP-9 at protrusions as mean 6 SE of 3 independent experiments with ***t-test p,0.0005. D)
MDA-MB-231 cells were plated on matrigel-coated coverslips for 20 hours in FCS containing medium and cultured for further 20 hours serum free
medium. Cells were stimulated for 6 hours with 50 ng/ml SDF-1a, in presence or in absence of 1 mM R59949, fixed and stained for actin (red) and
MMP-9 (green). Arrowhead indicates MMP-9 at protrusions. Scale bar 24 mm. E) Histogram reports the percentage of cells displaying MMP-9 at
protrusions as mean 6 SE of 3 independent experiments with **t-test p,0.005, ***t-test p,0.01. F) MDA-MB-231 cells were plated on matrigel-
coated coverslips for 20 hours in FCS containing medium, transfected with CTRL or PKCf/i –specific siRNA and cultured for further 20 hours in serum
free medium. Cells were then stimulated for 6 hours with 50 ng/ml SDF-1a, fixed and stained for actin (red) and MMP-9 (green). Arrowhead indicates
MMP-9 at protrusions. Scale bar 24 mm. G) Histogram reports the percentage of cells displaying MMP-9 at protrusions as mean 6 SE of 3 independent
experiments with *t-test p,0.05, **t-test p,0.005.
doi:10.1371/journal.pone.0097144.g005
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Figure 6. DGKa overexpression promotes a PKC-dependent cell elongation. MDA-MB-231 cells were infected with lentiviral vector
expressing inducible OST-tagged DGKa or an empty vector. To induce DGKa expression, cells were treated overnight with doxycycline (1 mg/ml) in
serum free medium. A) After cell lysis OST-DGKa induction was verified by western blotting with an antibody recognizing the OST-tag, while the
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blunted OST-DGKa induced elongation indicating the involve-
ment of Rac family GTPases (Fig. 6F). Those findings confirm the
relevance of aPKCs and Rac as DGKa downstream effectors
promoting cytoskeletal remodeling and extension of membrane
protrusions.
The expression of myr-DGKa drives pseudopodial extension by
stimulating RCP-mediated recycling of b1 integrin in A2780
carcinoma cells [15]. However, siRNA-mediated silencing of
either b1 integrin or RCP (Fig. S5C and D) did not affect
protrusion elongation induced by wild type DGKa in serum
starved MDA-MB-231 cells (Fig. S5A and B), suggesting that in
this experimental model b1 integrin and its RCP-mediated
recycling are not required for protrusion elongation.
These data indicate that up-regulation of DGKa activity by
SDF-1a is sufficient to promote the extension of membrane
protrusions through the aPKCs – RhoGDI – Rac pathway
[22,23], but that additional signaling pathways and/or its
localization at specific myrstyoilation-directed membrane com-
partment are required to trigger cells invasion.
Discussion
We and others established the relevance of DGKa activation
and membrane recruitment in growth factors signaling [37]. In
normal epithelia, endothelia and lymphocytes DGKa activity is
required to convey proliferative [17,38,39] and migratory [16–
18,22,23] signaling. Several studies pointed out DGKa involve-
ment in cancer showing that its activity is necessary in vivo for
glioblastoma and hepatocellular carcinoma progression [13], and
in vitro for proliferation and survival of endometrial carcinoma
[21], anaplastic large cell lymphoma [19], and melanoma [40].
Moreover, DGKa activity mediates matrix invasion sustained by
p53 pro-metastatic mutations in cancer cells [15]. However, the
molecular pathways by which DGKa controls carcinoma forma-
tion and metastatization are poorly known.
Inhere we investigated the role of DGKa in invasive signaling of
SDF-1a, one of the key signals driving metastasis [41], whose
receptor, CXCR4, is strongly associated to tumor growth and
spontaneous metastasis formation [1]. We used MDA-MB-231
cells, a highly invasive human breast cancer cell line, whose
invasiveness and tumorigenicity are dependent on the expression
of SDF-1a receptor, CXCR4 [42–44]. In these cells we had
previously shown that DGKa is required for EGF- [15] and HGF-
induced [27] migration in a tridimensional environment.
Interestingly, we show here that DGKa is also regulated by
SDF-1a, which stimulates its enzymatic activity and promotes its
recruitment at ruffling sites (Fig. 2). Moreover, we show that
activation of DGKa provides a key lipid signal required for SDF-
1a pro-invasive activity in MDA-MB-231 cells (Fig. 1).
We previously showed that the PA generated by HGF-induced
activation of DGKa recruits to the plasma membrane and
activates aPKCs in a complex with RhoGDI and Rac1, thus
mediating the release of Rac1 from RhoGDI, and its localization
and activation at ruffle sites [23]. The aPKCs subfamily comprises
the f and i isoforms, which are activated by PA [28] but insensitive
to DG.
Several pieces of evidence show that aPKCs and in particular
PKCi, play a key role in cancer cell invasion and tumor
progression [45]. Interestingly, PKCi is essential for K-Ras-driven
invasion in colon cancer by regulating Rac1 [46], while aPKCs
mediates EGF-induced cell migration of MDA-MB-231 breast
cancer cells [47]. Altogether these data further suggest that the
DGKa/aPKCs signaling axis contributes to pro-invasive signaling.
Accordingly, the finding that SDF-1a induces aPKCs localiza-
tion at protrusion sites through activation of DGKa, indicates that
the DGKa/aPKCs signaling axis mediates chemokine-driven
mammary carcinoma invasiveness (Fig. 3). DGKa-dependent
recruitment of aPKCs at protrusion is an essential signaling event,
since the silencing of either DGKa or aPKCs impairs downstream
events such as accumulation of b1 integrin and MMP-9 at the
plasma membrane (Fig. 4 and 5). The functional relevance of
aPKCs as a DGKa effector is further proved by the observation
that its silencing impairs DGKa-induced cell elongation (Fig. 6E)
and that its inhibition blocks SDF-1a-induced matrix invasion
(Fig. 3F).
The findings that aPKCs, RCP and b1 integrin are all required
for the invasiveness of MDA-MB-231 (Fig. 3F, 4H and ref. [15]),
and that upon SDF-1a stimulation b1 integrin is concentrated at
protrusion tips in a DGKa and aPKCs-dependent manner, are
consistent with our previous data showing that DGKa-generated
PA, through binding to RCP, docks a5b1 recycling vesicles to the
tips of invasive pseudopods. Altogether these findings suggest that
activation of aPKCs may also contribute to integrin recycling
induced by chemokines and growth factors, although there is no
experimental evidence for it.
Several pieces of evidence in different cell types indicate that
activation of aPKCs regulates MMPs production and secretion
[48]. For instance, PKCf activation mediates MMP-9 secretion
induced by SDF-1a in hematopoietic progenitors [11]. MMPs are
key players in the tumor microenvironment and play a major role
in invasion of extracellular matrix [49]. While some MMPs are
transmembrane proteins, most of them are soluble and bind to the
extracellular cell surface by interaction with several membrane
proteins, including b1 integrin and CD44v [50–54].
Our finding that both DGKa and aPKCs are required for SDF-
1a-induced release of MMP9 in the cell medium and for its
accumulation at protrusions, provides further strength to our thesis
that DGKa/aPKCs axis is a major component of chemokine pro-
invasive signaling. Interestingly, in SDF-1a-stimulated cells,
MMP-9 localization at cell surface superimposes with that of b1
integrin, suggesting that their function at protrusion tips is
coordinately regulated by activation of DGKa/aPKCs signaling.
extent of overexpression was verified with anti DGKa antibodies. Tubulin was used as loading control. B) Phase contrast images of control and OST-
DGKa cells cultured in presence or absence of doxycycline. Arrows indicate cells with long protrusions. Scale bar 50 mm. C) Confocal images of
doxycycline induced cells showing OST-DGKa localization, cells were stained for actin (red) and OST (green). Scale bar 24 mm. D) Time course of cell
elongation at 2, 10 and 18 hours with or without doxycycline treatment. Time lapse videos were recorded and total cell length measured. Box and
whiskers plots (black lines show median, whiskers: 5–95 percentile) of data from 3 independent experiments are shown, ***p,0.0001, 1 way ANOVA.
E) MDA-MB-231 cells expressing OST-DGKa were transiently transfected with control or PKCf/i-specific siRNA. After 48 hours DGKa expression was
induced by overnight treatment with doxycycline (1 mg/ml) in serum free medium. Images were acquired with a phase contrast microscope,
representative images are shown. Scale bar 50 mm. Total cell length was measured for at least 100 cells and reported as box and whiskers plot. F)
MDA-MB-231 cells expressing OST-DGKa were induced by overnight treatment with doxycycline (1 mg/ml) in serum free medium with or without
NSC23766 (100 mM). Images were acquired with a phase contrast microscope, representative images are shown. Scale bar 50 mm. Total cell length
was measured for at least 100 cells and reported as box and whiskers plot. MDA-MB-231 cells were transfected with CTRL and PKCf/i –specific siRNA
and lysed. The efficiency of PKCf/i down–regulation by siRNA was verified by western blotting, tubulin was used as a loading control.
doi:10.1371/journal.pone.0097144.g006
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Finally, the observation that DGKa over expression drives by
itself elongation of cell protrusions by regulating aPKCs is
consistent with active PKCf promoting wide cytoskeletal remod-
eling and protrusions in untrasformed cells [23]. The molecular
mechanisms by which aPKCs induces cell elongation downstream
to DGKa is still partially known. In line with our previous
demonstration that activation of the DGKa/aPKCs signaling
module stimulates the RhoGDI driven localization of both Rac1
and Cdc42 at membrane ruffles, we observed that the Rac
inhibitor NSC23766 blunts DGKa induced cell elongation
(Fig. 6G) and that SDF-1a-induced localization of Cdc42 at
protrusions of MDA-MB-231 cells is significantly reduced by
DGKa inhibition (Fig. S3D and E). Conversely, protrusion
extension occurs even in the absence of b1 integrin and RCP,
suggesting that DGKa-dependent activation of aPKCs regulates
cytoskeletal remodeling independently from b1 integrin recycling
and function, which are required, however, to enable cell
migration through a 3D matrix (Fig. 4H). While it is clear that
DGKa/aPKCs activity on cell elongation is independent on b1
integrin recycling, these data cannot rule out that accumulation of
b1 integrin and MMP-9 at protrusion tips depends on DGKa/
aPKCs-induced regulation of Rac1 or Cdc42 and cytoskeletal
contractility [31].
Altogether we showed that activation of the DGKa/aPKCs/b1
integrin pathway plays a key role in chemokine-driven matrix
invasion in breast cancer cells. Those observations suggest that
DGKa inhibition or silencing could be effective not only in
reducing primary tumor growth in vivo [13,14] but could
potentially also reduce the metastatic potential of carcinoma cells.
Supporting Information
Figure S1 DGKa is necessary for SDF-1a-induced cell
invasion. MDA-MB-231 cells were infected with lentiviral
vectors expressing a shRNA against DGKa (shRNA-DGKa2) or
an empty vector. A) Cells were lysed and the efficiency of DGKa
down–regulation by shRNA was verified by western blot, tubulin
was used as a loading control. B) 50,000 cells were plated on
matrigel invasion chamber and incubated for 24 hours in presence
or in absence of SDF-1a (100 ng/ml). Histogram reports mean 6
SE of fold over control values from 3 independent experiments
with *t-test p,0.05, ***t-test p,0.0005.
(TIF)
Figure S2 DGKa overexpression does not affect migra-
tion and invasion of MDA-MB-231 cells. MDA-MB-231
cells were infected with lentiviral vector expressing inducible OST-
tagged DGKa or an empty vector. To induce DGKa expression,
cells were treated overnight with doxycycline (1 mg/ml) in serum
free medium. A) After cell lysis, the extent of DGKa overexpres-
sion was verified with anti DGKa antibodies, long and short
exposures are shown. Actin was used as loading control. B) Cells
were grown to confluence in 12 well plates and subjected to a
wound healing assay for 24 hours in serum free medium. HGF
(50 ng/ml) was used as a positive control. The cells were stained
and those migrating inside 2.3 mm of wound counted. Histogram
reports mean 6 SE of fold over control values from 3 independent
experiments with *t-test p,0.05. C) 50,000 cells were plated on
matrigel invasion chamber and incubated for 24 hours in serum
free medium. Medium with 10% FCS was used as positive control.
Histogram reports mean 6 SE of fold over control values from 3
independent experiments with *t-test p,0.05.
(TIF)
Figure S3 DGKa is required for SDF-1a-induced pseu-
dopod elongation. A) MDA-MB-231 cells were plated on
matrigel-coated coverslips for 20 hours in FCS containing
medium, transfected with CTRL or DGKa -specific siRNA and
cultured for further 20 hours in serum free medium. Cells were
then stimulated for 6 hours with 50 ng/ml SDF-1a, fixed and
photographed at phase contrast. B) Histogram reports protrusions
length in mm as mean 6 SE values of 4 independent experiments
with *t-test p,0.005. C) MDA-MB-231 cells were plated on
matrigel-coated coverslips for 20 hours in FCS containing medium
and cultured for further 20 hours in serum free medium. Cells
were then stimulated for 6 hours with 50 ng/ml SDF-1a, in
presence or in absence of 1 mM R59949, fixed and photographed
at phase contrast. Histogram reports protrusions length in mm as
mean 6 SE of 3 independent experiments with *t-test p,0.005.
D) MDA-MB-231 cells were plated on matrigel-coated coverslips
for 20 hours in FCS containing medium and cultured for further
20 hours serum free medium. Cells were stimulated for 6 hours
with 50 ng/ml SDF-1a, in presence or in absence of 1 mM
R59949, fixed and stained for actin (red) and Cdc42 (green).
Arrowhead indicates Cdc42 at protrusions. Scale bar 24 mm. E)
Histogram reports the percentage of cells displaying Cdc42 at
protrusions as mean 6 SE of 3 independent experiments with *t-
test p,0.05.
(TIF)
Figure S4 SDF-1a is not affecting surface exposition of
b1-integrin and MMP-9. A) Surface expression of b1 integrin
was analyzed before (turquoise) and after (red) SDF-1a stimula-
tion. Flow cytometry histogram overlay comparing the level of b1
integrin expression before and after SDF-1a expression. Isotype-
matched controls mAb staining are given as dashed lines. MFI,
median fluorescence intensity. B) Surface expression of MMP-9
was analyzed before (turquoise) and after (red) SDF-1a stimula-
tion. Flow cytometry histogram overlay comparing the level of
MMP-9 expression before and after SDF-1a expression. Isotype-
matched controls mAb staining are given as dashed lines. MFI,
median fluorescence intensity. C) MDA-MB-231 cells were plated
on 6 wells dish for 20 hours in FCS containing medium and
cultured for further 20 hours serum free medium. Cells were
stimulated for 24 hours with 100 ng/ml SDF-1a, in presence or in
absence of 1 mM R59949. MMP-9 mRNA was quantified by
quantitative RT-PCR. Histogram reports the mean 6 SE of 3
independent experiments.
(TIF)
Figure S5 DGKa promoted cell elongation is indepen-
dent from b1 integrin and RCP. MDA-MB-231 cells were
infected with lentiviral vector expressing inducible OST-tagged
DGKa or an empty vector. A) Cells were transiently transfected
with control or b1 integrin-specific siRNA. After 48 hours DGKa
expression was induced by overnight treatment with doxycycline
(1 mg/ml) in serum free medium. Images were acquired with a
phase contrast microscope, representative images are shown. Scale
bar 50 mm. Total cell length was measured for at least 100 cells
and reported as box and whiskers plot. B) Cells were transiently
transfected with control or RCP-specific siRNA. After 48 hours
DGKa expression was induced by overnight treatment with
doxycycline (1 mg/ml) in serum free medium. Images were
acquired with a phase contrast microscope, representative images
are shown. Scale bar 50 mm. Total cell length was measured for at
least 100 cells and reported as box and whiskers plot. C) MDA-
MB-231 cells were transfected with CTRL and b1 integrin-specific
siRNA and lysed. The efficiency of b1 integrin down–regulation
by siRNA was verified by western blotting, tubulin was used as a
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loading control. D) MDA-MB-231 cells were transfected with
CTRL and RCP-specific siRNA and lysed. The efficiency of RCP
down–regulation by siRNA and of OST-DGKa induction was
verified by western blotting, actin was used as a loading control.
(TIF)
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54. Redondo-Muñoz J, Ugarte-Berzal E, Terol MJ, Van den Steen PE, Hernández
del Cerro M, et al. (2010) Matrix metalloproteinase-9 promotes chronic
lymphocytic leukemia b cell survival through its hemopexin domain. Cancer
Cell 17: 160–172.
DGKa/aPKCs/b1 Pathway in Matrix Invasion
PLOS ONE | www.plosone.org 15 June 2014 | Volume 9 | Issue 6 | e97144
The Journal of Immunology
B7h Triggering Inhibits the Migration of Tumor Cell Lines
Chiara Dianzani,* Rosalba Minelli,* Casimiro Luca Gigliotti,† Sergio Occhipinti,‡
Mirella Giovarelli,‡ Laura Conti,‡ Elena Boggio,† Yogesh Shivakumar,† Gianluca Baldanzi,x
Valeria Malacarne,x Elisabetta Orilieri,† Giuseppe Cappellano,† Roberto Fantozzi,*
Daniele Sblattero,† Junji Yagi,{ Josè Maria Rojo,‖ Annalisa Chiocchetti,† and
Umberto Dianzani†
Vascular endothelial cells (ECs) and several cancer cells express B7h, which is the ligand of the ICOS T cell costimulatory molecule.
We have previously shown that B7h triggering via a soluble form of ICOS (ICOS-Fc) inhibits the adhesion of polymorphonuclear
and tumor cell lines to HUVECs; thus, we suggested that ICOS-Fc may act as an anti-inflammatory and antitumor agent. Because
cancer cell migration and angiogenesis are crucial for metastasis dissemination, the aim of this work was to evaluate the effect of
ICOS-Fc on the migration of cancer cells and ECs. ICOS-Fc specifically inhibited the migration of HUVECs, human dermal lym-
phatic ECs, and the HT29, HCT116, PC-3, HepG2, JR8, and M14 tumor cell lines expressing high levels of B7h, whereas it was
ineffective in the RPMI7932, PCF-2, LM, and BHT-101 cell lines expressing low levels of B7h. Furthermore, ICOS-Fc downmodu-
lated hepatocyte growth factor facilitated the epithelial-to-mesenchymal transition in HepG2 cells. Moreover, ICOS-Fc downmo-
dulated the phosphorylation of focal adhesion kinase and the expression of b-Pix in both HUVECs and tumor cell lines. Finally,
treatment with ICOS-Fc inhibited the development of lung metastases upon injection of NOD-SCID-IL2Rgnull mice with CF-
PAC1 cells, as well as C57BL/6 mice with B16-F10 cells. Therefore, the B7h2ICOS interaction may modulate the spread of cancer
metastases, which suggests the novel use of ICOS-Fc as an immunomodulatory drug. However, in the B16-F10–metastasized lungs,
ICOS-Fc also increased IL-17A/RORc and decreased IL-10/Foxp3 expression, which indicates that it also exerts positive effects on
the antitumor immune response. The Journal of Immunology, 2014, 192: 4921–4931.
B
7 homologoud protein (B7h, also known as B7H2,
B7-RP1, ICOSL, GL50, and CD275) belongs to the B7
family of surface receptors and it binds ICOS (CD278),
which belongs to the CD28 family (1–9). ICOS is selectively ex-
pressed by activated T cells, whereas B7h is expressed by a wide
variety of cell types, including B cells, macrophages, dendritic cells
(DCs), and a subset of T cells. However, B7h is also expressed by
cells of a nonhemopoietic origin such as vascular endothelial cells
(ECs), epithelial cells, and fibroblasts, as well as in many primary
tumors and tumor cell lines (10–12).
The main known function of B7h is the triggering of ICOS, which
functions as a costimulatory molecule for T cells by enhancing their
cytokine secretion (3, 13, 14), and in particular, the secretion of
IL-10, IL-17, IFN-g (in humans), IL-4 (in mice), and IL-21 (in both
species). The expression of B7h in nonlymphoid tissues, such as the
brain, heart, kidney, liver, and intestine, suggests that it regulates the
activation of Ag-experienced effector/memory T cells, which are
recruited to or reside within these peripheral tissues (15). However,
B7h expression also plays a role in secondary lymphoid tissue, par-
ticularly in the interaction between T and B cells; ICOS is expressed
at high levels by Th follicular cells, and ICOS deficiency has been
associated with the defective formation of lymphoid follicles in mice
and common variable immunodeficiency in humans (16).
Recent reports have shown that the B7h–ICOS interaction may
trigger bidirectional signals that can also modulate the response of
the cells expressing B7h. This B7h-mediated “reverse signaling” can
induce the partial maturation of immature mouse DCs with aug-
mentation of IL-6 secretion (17). In humans, we have found that B7h
triggering via ICOS-Fc, a recombinant soluble form of ICOS, sub-
stantially alters DC behavior by modulating the secreted cytokine
pattern, which promotes the capacity to cross-present endocytosed
Ags in class I MHC molecules and inhibits the adhesiveness to EC
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and the migratory response to chemoattractants (18). Moreover, we
showed that B7h stimulation inhibits the capacity of HUVECs to
adhere to several tumor cell lines and granulocytes (11). This in-
hibitory effect was similarly detected when B7h was triggered on
either HUVECs or the tumor cell lines and was accompanied by the
decreased phosphorylation of ERK and p38 in HUVECs only. This
indicated that the B7h–ICOS interaction modulates the recruitment
of granulocytes in inflammatory sites and the spread of cancer
metastases from the site of the primary tumor through the blood-
stream (11).
The aim of the research reported in this article was to extend
these observations by assessing the effect of B7h triggering on
other key issues of tumor growth. Tumor growth depends on the
proliferation and death rate of the tumor cells, metastasis dissemi-
nation depends on their capacity to migrate, and both tumor growth
and dissemination are favored by neoangiogenesis within the tumor
mass; thus, we assessed the effect of B7h triggering on the pro-
liferation, apoptosis, and migration of tumor cells and vascular
ECs. The results showed that B7h triggering strikingly inhibited
the migration activity of both tumor and ECs in vitro, which was
associated with the dephosphorylation of focal adhesion kinase
(FAK) and decreased b-Pix expression. However, B7h triggering
had no effect on their proliferation, apoptosis, or the ECs’ capacity
to form capillary-like structures. Moreover, B7h triggering ham-
pered tumor cell metastasis in vivo.
Materials and Methods
Cells
HUVECs were isolated from human umbilical veins via trypsin treatment
(1%) and cultured in M199 medium (Sigma-Aldrich, St. Louis, MO) with
the addition of 20% FCS (Invitrogen, Burlington, ON, Canada) and 100 U/ml
penicillin, 100 mg/ml streptomycin, 5 UI/ml heparin (Sigma-Aldrich),
12 mg/ml bovine brain extract, and 200 mM glutamine (Hyclone Labo-
ratories, South Logan, UT). HUVECs were grown to confluence in flasks
and used at the second to fifth passage. The purity of the ECs preparation
was evaluated using morphologic criteria and positive immunofluores-
cence for factor VIII. Contamination with blood leukocytes was assessed
via immunofluorescence with an anti-CD45 Ab. The use of HUVECs was
approved by the Ethics Committee of the ‘‘Presidio Ospedaliero Martini’’
of Turin and conducted in accordance with the Declaration of Helsinki.
Written informed consent was obtained from all donors. Human dermal
lymphatic ECs (HDLECs) were purchased from Promo Cell and cultured
with Endothelial Cell Growth Medium MV2 (Promo Cell GmbH, Hei-
delberg, Germany). The following human tumor cell lines were used:
HT29, HCT116 (colon adenocarcinoma), PC-3 (prostate carcinoma), CF-
PAC1 (human pancreas carcinoma), HepG2 (hepatic carcinoma), and B16-
F10 (murine melanoma) from the American Type Culture Collection
(ATCC; Manassas, VA); M14, JR8, RPMI7932, PCF-2, and LM (mela-
noma) from Dr. Pistoia (Gaslini Institute, Genoa, Italy); and BHT-101
(thyroid carcinoma) from Deutche Sammlung von Mikroorganismen and
Zellculturen (Braunschweig, Germany). The human tumor cell lines were
grown in culture dishes as a monolayer in RPMI 1640 medium (Invitrogen)
and DMEM (Invitrogen) for HepG2, CF-PAC1, BHT-101, and B16-F10
plus 10% FCS, 100 U/ml penicillin, and 100 mg/ml streptomycin at 37˚C
in a 5% CO2 humidified atmosphere.
The cells were treated or not treated with ICOS-Fc and F119SICOS-Fc, in
which the extracellular portion of human ICOS and its mutated form car-
rying a phenylalanine-to-serine substitution at position 119 (F119SICOS-Fc)
were cloned as fusion proteins to the human IgG1 Fc region (11).
The cell-surface phenotypes were assessed via direct immunofluorescence
and flow cytometry using the appropriate PE-conjugated anti-B7h mAb (R&D
Systems, Minneapolis, MN) and the appropriate FITC-, PE-, and allophyco-
cyanin-conjugated mAb to ICAM-1 (Biolegend, San Diego, CA), ICAM-2
(DiaClone Research, Manchester, U.K.), MadCAM (Abcam, Cambridge,
MA), CD31, CD62L, CD62E, CD62P (Immunotools, Friesoythe, Germany),
CD44v6–7 (Bender Med-Systems, Vienna, Austria), Sialyl Lewis X (Santa
Cruz Biotechnology, Dallas, TX), and VCAM-1 (eBiosciences, San Diego,
CA). The expression of Sialyl Lewis A was assessed via indirect immuno-
fluorescence using an appropriate mAb (Santa Cruz Biotechnology) and FITC-
conjugated goat anti-mouse Ig (Caltag Laboratories, Burlingame, CA). The
mean fluorescence intensity ratio (MFI-R) was calculated considering all of
the alive cells according to the following formula: MFI of the B7h-stained
sample histogram (arbitrary units)/MFI of the control histogram (arbitrary
units). The B16-F10 cells were split into two cell lines expressing high or low
levels of B7h (B7hhigh and B7hlow) via magnetic selection with PE-conjugated
anti-B7h mAb and anti-PE microbeads (Miltenyi Biotec, Bergisch Gladbach,
Germany).
Cell growth assays
In the MTT assay, the cells were normalized at 800 or 2500 cells/100 ml
in 96-well plates for HT29 or HUVECs, respectively. After an overnight
incubation, the medium was replaced with 100 ml culture medium with
0.5–4 mg/ml ICOS-Fc. In some experiments, the cells were refilled every
24 h with 4 mg/ml ICOS-Fc. After 24, 48, and 72 h of incubation, the
viable cells were detected via MTT (Sigma-Aldrich) at 570 nm, as de-
scribed by the manufacturer’s protocol. The absorbance of the controls
(i.e., the cells that received no drug) was normalized to 100%, and that
of the ICOS-Fc–treated cells was expressed as the percentage of the controls.
Eight replicate wells were used to determine each data point, and three
different experiments were performed.
In the colony-forming assay, cells (800/well) were seeded into six-well
plates and treated with the compounds. The mediumwas changed after 72 h,
and the cells were cultured for another 10 d. Subsequently, the cells were
fixed and stained with a solution of 80% crystal violet (Sigma-Aldrich) and
20% methanol (Sigma-Aldrich). The colonies were then photographed and
counted with Gel Doc equipment (Bio-Rad Laboratories, Hercules, CA).
In the cell death assay, the cells were incubated with and without either
etoposide (2 mg/ml; Sigma-Aldrich) or FCS for 18 h, and cell death was
then evaluated by counting the live cells with the trypan blue exclusion test
and detecting the dead cells upon cytofluorimetric analysis of the cells
stained with FITC-conjugated Annexin V (BD Biosciences, San Jose, CA)
and propidium iodide (Sigma-Aldrich).
Cell migration assays
In the Boyden chamber (BD Biosciences) migration assay, cells (8000) were
plated onto the apical side of 50 mg/ml Matrigel-coated filters (8.2-mm di-
ameter and 0.5-mm pore size; Neuro Probe; BIOMAP snc, Milan, Italy) in
serum-free medium with or without 2 mg/ml ICOS-Fc or F119SICOS-Fc.
Medium containing either 20% FCS or 10 ng/ml vascular endothelial
growth factor-A (VEGF-A; Sigma-Aldrich) or 50 ng/ml hepatocyte growth
factor (HGF; PeproTech, Rocky Hill, CT) was placed in the basolateral
chamber as a chemoattractant for the tumor, endothelial, or HepG2 cells,
respectively. The chamber was incubated at 37˚C under 5% CO2. After 8 h,
the cells on the apical side were wiped off with Q-tips. The cells on the
bottom of the filter were stained with crystal violet and counted (five fields for
each triplicate filter) with an inverted microscope (magnification 3100). The
results are expressed as the number of migrated cells per high-power field.
In the wound-healing experiments, the cells were plated onto six-well
plates (at a concentration of 106 cells/well) and grown to confluence. The
cells were then left for 12 h with FCS-free medium (to prevent cell prolif-
eration). The cell monolayers were carefully wounded by scratching with a
sterile plastic pipette tip along the diameter of the well. The cells were
washed twice with FCS-free medium and then incubated with culture me-
dium in the absence or presence of 2 mg/ml ICOS-Fc. Five fields of each of
the three wounds analyzed per condition were photographed immediately
after the scratch had been made (0 h) and 24 h later to monitor cell move-
ment into the wounded area.
In the cell scatter assay, the cells were plated on 24-well plates (2 3 104/
well HepG2, 3 3 104/well BHT-101) in 10% FCS and stimulated with the
indicated treatments. Phase-contrast images of random fields were acquired
(after 48 h for HepG2 and 24 h for BHT-101) with an Axiovert 40 CFL
microscope (Zeiss, Oberkochen, Germany) and analyzed with Image-Pro-
Plus software. For each experimental point, the length of at least 100 cells
and the percentage of disaggregated single cells were evaluated in 3 separate
images. For confocal microscopy, the cells were washed with PBS and fixed
in PBS containing 3% paraformaldehyde and 4% sucrose. The cells were
permeabilized in cold HEPES-Triton buffer (20 mM HEPES, 300 mM su-
crose, 50 mM NaCl, 3 mMMgCl2, 0.5% Triton X-100, pH 7.4). Intermediate
washing was performed with PBS containing 0.2% BSA. PBS containing 2%
BSA (Sigma-Aldrich) was used as a blocking reagent. Alexa Fluor 546
Phalloidin (Invitrogen) and TO-PRO3 (Invitrogen) were diluted in 2%
PBS-BSA and added directly onto each glass coverslip in a humidified
chamber for 30 min. Finally, each glass coverslip was washed briefly in water
and mounted onto a glass microscope slide using Mowiol resin (Sigma-
Aldrich, 20% Mowiol 4-88, 2.5% 1,4-diazabicyclo[2.2.2]octane in PBS, pH
7.4). Confocal images were acquired with a Leica confocal microscope TCS
SP2 equipped with LCS Leica confocal software (633 objective for HepG2
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or 403 objective for BHT-101; Leica Microsystems, Wetzlar, Germany).
Basal planes are shown.
Angiogenesis assays
In the tube-formation assay, HUVEC cells were seeded onto 24-well plates
(5 3 104/well) previously coated with 150 ml growth factor–reduced
Matrigel (BD Biosciences) in the presence of ICOS-Fc (2–4 mg/ml) or
control medium. The morphology of the capillary-like structures formed
by the HUVECs was analyzed after 15 h of culture using an inverted
microscope and was photographed with a digital camera. Tube formation
was analyzed with an imaging system (Image-Pro).
In the spheroid sprouting assay, ECs were coated onto Cytodex mi-
crocarriers and embedded in a fibrin gel. Factor X, which was extracted
from confluent fibroblasts medium, was added to the medium to promote
ECs sprouting from the surface of the beads. After 4–5 d, numerous vessels
could be observed with a phase-contrast microscope. The newly formed
vessels were then treated or not treated with ICOS-Fc (4 mg/ml), and
vessel morphology was analyzed 5 d later.
Western blot analysis
The cells were lysed in a buffer composed of 50 mM Tris-HCl pH 7.4,
150 mM NaCl, 5 mM EDTA, 1% nonyl phenoxypolyethoxylethanol 40,
and phosphatase and protease inhibitor cocktails (P2850, P8340; Sigma-
Aldrich). The tissues were lysed in a buffer composed of 160 mM NaCl,
20 mM Tris-HCl pH 7.4, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 1%
sodium deoxycholate, and 0.1% SDS. The lysates were then cleared of
insoluble fractions through high-speed centrifugation, and the protein
concentrations were determined with a commercially available kit (Bio-Rad
Laboratories). Then 40 mg proteins were loaded on 10% SDS PAGE gels,
and after electrophoresis, transferred onto Hybond-C extra nitrocellulose
membranes (Ge Healthcare, Piscataway, NJ). These were blocked for 1 h
at room temperature with 5% nonfat milk dissolved in TBST. The
membranes were then probed overnight with Abs to b-Pix (SH3 domain;
Millipore, Billerica, MA), phospho-FAK (Y397; Cell Signaling Technol-
ogy, Danvers, MA), FAK (BD Biosciences), b-actin (A1978; Sigma-
Aldrich), and after 3 washes, incubated for 1 h with HRP-conjugated
secondary Abs (GE Healthcare, Piscataway, NJ). The bands were detected
via chemiluminescence, and densitometric analysis was performed using
Multi-Analyst software (version 1.1; Bio-Rad Laboratories).
In vivo experiments
Female 4- to 5-wk-old NOD-SCID-IL2Rgnull (NSG; The Jackson Labo-
ratory, Bar Harbor, ME) mice were bred under pathogen-free conditions in
the animal facility of the Molecular Biotechnology Center, University of
Turin, and were treated in accordance with the University Ethical Com-
mittee and European guidelines. The mice were injected in the tail vein
with stably expressing firefly luciferase (Luc) CF-PAC1 (human pancreas
carcinoma) cells (0.5 3 106/mouse) and monitored for pulmonary me-
tastases after 3 d via in vivo optical imaging. In each experiment, the mice
were treated every day via the i.p. injection of either human ICOS-Fc plus
mouse ICOS-Fc, human ICOS-Fc alone, mouse ICOS-Fc alone, human
F119SICOS-Fc alone (100 mg each), or the same volume of PBS as a con-
trol. Three days after tumor cell injection, the mice were injected i.p. with
150 mg/Kg luciferin (Perkin Elmer, Waltham, MA) in sterile PBS. They
were then placed in the IVIS 200 (Perkin Elmer) induction chamber and
subjected to inhalational isoflurane anesthesia (Abbott, Abbott Park, IL) at
2.5% with 1 l/min flow of oxygen. After 10 min, the mice were placed on
the heated imaging platform of the IVIS 200 imaging station with inha-
lational isoflurane anesthesia during the imaging procedure. White light
and Luc activity images were acquired with a 25-s exposure. The images
FIGURE 1. B7h expression in endothelial and tumor cell lines. B7h expression was assessed in the HUVEC, HDLEC, JR8, M14, PC-3, HT29, HCT116,
RPMI7932, PCF-2, LM, and BHT-101 cell lines via flow cytometry using an anti-B7h mAb. The numbers in each panel indicate the MFI-R. The cutoff
between the B7hhigh and B7hlow cells was set at MFI-R = 2.
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were analyzed with the Living Image software (PerkinElmer). The lumi-
nescent signal was quantified as the average radiance (p/s/cm2/sr) mea-
sured in the regions of interest drawn in the lungs.
Female 5- to 7-wk-old C57BL/6 mice (Harlan Laboratories, Indian-
apolis, IN) were injected in the tail vein with B7hhigh B16-F10 cells (106
cells/mouse) and then treated daily with an i.p. injection of either the
mouse ICOS-Fc, the human F119SICOS-Fc (100 mg each), or the same
volume of PBS as a control. Two weeks after cell injection, the mice were
euthanized, and the number of metastases detectable in the lung surfaces
was evaluated by two blinded observers. In some experiments, the mice
were euthanized 3 d after cell injection, and the metastases were counted in
fixed sections of the lungs stained with H&E (Sigma-Aldrich).
The infiltrating cells were obtained by grinding the fresh lungs, obtained
at day 3, through a 100-mm cell strainer mesh (BD Biosciences); the total
RNA was then isolated using TRIzol reagent (Invitrogen). RNA (500 ng)
was retrotranscribed using the ThermoScript RT PCR System (Invitrogen).
IL-17A, IL-10, IL-21, RORc, Foxp3, and Bcl6 expression were evaluated
with a gene expression assay (Assay-on Demand; Applied Biosystems,
Foster City, CA). The b-glucuronidase gene was used to normalize the
cDNA amounts. Real-time PCR was performed using the CFX96 System
(Bio-Rad Laboratories) in duplicate for each sample in a 10 ml final vol-
ume containing 1 ml diluted cDNA, 5 ml TaqMan Universal PCR Master
Mix (Applied Biosystems), and 0.5 ml Assay-on Demand mix. The results
were analyzed with a D-D threshold cycle method.
In other experiments, the C57BL/6 micewere injected s.c. with 106B7hhigh
B16-F10 cells. When the tumor diameter reached 4 mm, the mice received
an intratumoral injection of the mouse ICOS-Fc, humanF119SICOS-Fc
(100 mg each), or the same volume of PBS as a control. After 30 min, the
tumors were excised and immediately frozen in liquid nitrogen for Western
blot analyses.
Data analysis
The data are shown as the mean 6 SEM. The statistical analyses were
performed with GraphPad Prism 3.0 software using one-way ANOVA and
Dunnett’s test (GraphPad Software, San Diego, CA).
Results
B7h triggering has no effect on cell proliferation and apoptosis
To assess the effect of B7h triggering (via ICOS-Fc) on the prolifer-
ation, apoptosis, andmigration of the tumor cells and vascular ECs,we
used two primary EC lines (HUVECs and HDLECs) and nine con-
tinuous tumor cell lines (HT29 and HCT116 [colon carcinoma], PC-3
[prostate carcinoma],M14, JR8, RPMI7932, PCF-2, LM [melanoma],
and BHT-101 cells [thyroid carcinoma]). The surface immunofluo-
rescence and flow cytometry showed that B7h was expressed in
all cell lines and at high levels (B7hhigh) in HUVECs, HDLECs,
JR8, M14, PC-3, HT29, and HCT116, but low levels (B7hlow) in
BHT-101, RPMI7932, PCF-2, and LM (Fig. 1).
Initially, the effect of ICOS-Fc on cell proliferation and death
was assessed in HUVECs, HT29, and PC-3, which expressed high
levels of B7h. In the proliferation assay, the cells were cultured in
the presence of various concentrations of ICOS-Fc (0.5–4 mg/ml)
for 24–96 h, and cell proliferation was then assessed via the MTT
and the clonogenic assays. The results showed that ICOS-Fc did
not modulate cell proliferation in any cell line at any dose or time
FIGURE 2. The effect of ICOS-Fc on the motility of the endothelial and tumor cell lines as assessed via a Boyden chamber assay. Cells: (A) HUVEC and
HDLEC; (B) HT29, HCT116, PC-3, M14, and JR8; (C) RPMI7932, PCF-2, LM, and BHT-101 were plated onto the apical side of Matrigel-coated filters in
50 ml medium in the presence or absence of either 2 mg/ml ICOS-Fc or F119SICOS-Fc; either VEGF-A (10 ng/ml) or 20% FCS was loaded in the basolateral
chamber as chemotactic stimulus. The cells that migrated to the bottom of the filters were stained using crystal violet and counted (five fields for each
triplicate filter) using an inverted microscope. The data are expressed as the mean 6 SEM (n = 5) of the number of migrated cells per high-power field
(*p , 0.05, **p , 0.01 versus the control).
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(data not shown), even when the ICOS-Fc was refilled every 24 h.
In the cell death assay, the cells were cultured for 18 h in the
presence or absence of ICOS-Fc (2 mg/ml) either in the absence of
FCS (to induce cell death by neglect) or in the presence of eto-
poside. Then cell survival was assessed after 18 h by counting the
surviving cells with the trypan blue exclusion test, and the dead
cells were evaluated by staining with propidium iodide and FITC-
conjugated Annexin V followed by cytofluorimetric analysis. The
results showed that ICOS-Fc did not induce cell death and did not
modulate either cell death by neglect or that induced by etoposide
in any cell line (data not shown).
B7h triggering inhibits cell migration and the epithelial-to-
mesenchymal transition
To evaluate the effect of ICOS-Fc on cell migration, we seeded
the endothelial and the tumor cell lines in the upper chamber of
a Boyden chamber in serum-free medium in the presence or ab-
sence of ICOS-Fc (2 mg/ml) and allowed them to migrate for 8 h
toward the lower chamber containing medium supplemented or
not supplemented with either VEGF-A (10 ng/ml) or 20% FCS,
which were used as chemoattractants for the endothelial and the
tumor cells, respectively. As a control, the same experiments were
performed in the presence of F119SICOS-Fc, a mutated form of
ICOS-Fc carrying a phenylalanine-to-serine amino acid substitu-
tion at position 119 that is unable to bind B7h. The results showed
that ICOS-Fc significantly inhibited cell migration by ∼50–70%
in all of the B7hhigh cell lines (i.e., HUVECs, HDLECs, HT29,
HCT116, PC-3, M14, and JR8) in both the presence and the ab-
sence of the chemoattractants (Fig. 2A, 2B). This effect was
specific because it was not exerted by F119SICOS-Fc. In contrast,
neither ICOS-Fc nor F119SICOS-Fc exerted any effect on the
B7hlow cell lines (i.e., RPMI7932, PCF-2, LM, and BHT-101),
which indicated that the inhibitory effect was B7h mediated
(Fig. 2C).
To confirm the effect of ICOS-Fc on directional cell migration,
we performed the scratch assay, an in vitro “wound healing” assay,
on PC-3, HT29, and HUVECs, because cell migration is highly
efficient for PC-3, poor for HT29, and intermediate for HUVECs
in this assay. A linear scratch was performed on a confluent
monolayer of each cell line, and they were then cultured in FCS-
free medium to minimize cell proliferation in the presence or
absence of ICOS-Fc (2 mg/ml). A microscopic analysis evaluating
cell capacity to migrate and fill the empty areas at different times
showed that in the absence of ICOS-Fc, substantial cell migration
was detectable in the wound area for PC-3 and HUVECs, and that
it was substantially inhibited by ICOS-Fc (Fig. 3). This inhibition
was also detectable for HT29 cells, which displayed a low mi-
gratory activity that was detectable as a fringing of the scratch
edges after the 24-h incubation; this pattern was substantially
inhibited by ICOS-Fc.
To assess the effect of ICOS-Fc on the epithelial-to-mesenchymal
transition (EMT), we performed a scatter assay to treat the HepG2
cells (hepatic carcinoma) with HGF. In cultures, these cells grow
as colonies that maintain an epithelial morphology; however,
they break down cell junctions and acquire an elongated mesen-
chymal phenotype upon HGF/scatter factor treatment (19). A cyto-
fluorimetric analysis showed that these cells express high levels of
B7h (Fig. 4A). The cells were treated for 72 h in 10% FCS with or
without HGF (50 ng/ml) and in the presence or absence of either
ICOS-Fc (2 mg/ml) or F119ICOS-Fc (2 mg/ml). They were then
directly analyzed via phase-contrast microscopy (Fig. 4B, left
panel) or stained with Alexa Fluor 546 Phalloidin and imaged via
confocal microscopy (Fig. 4B, right panel). The results showed that
ICOS-Fc substantially inhibited the cell scatter induced by HGF by
FIGURE 3. Effect of ICOS-Fc on the mo-
tility of the PC-3, HT29, and HUVECs as
assessed using a “wound-healing” assay. The
cells were grown to confluence on six-well
plates. A scratch was made through the cell
layer using a pipette tip; the cells were washed
and then cultured in the presence or absence
of 2 mg/ml ICOS-Fc for 24 h. Microphoto-
graphs of the wounded area were taken imme-
diately after the scratch was made (0 h) and
24 h later to monitor cell migration into the
wounded area (original magnification310).
Panels show a representative experiment from
three experiments.
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impairing the acquisition of the elongated mesenchymal mor-
phology (median length of ICOS-Fc–untreated versus –treated cells:
60 mm versus 31 mm; Fig. 4C) and promoting the maintenance
of colonies with cell-to-cell junctions and smooth borders with
decreased numbers of disaggregated single cells (Fig. 4D). We
also assessed the effect of ICOS-Fc on the migration of HepG2
cells induced by HGF (50 ng/ml) in the Boyden chamber assay.
In accordance with the previous results, ICOS-Fc, but not
F119SICOS-Fc, inhibited the stimulated migration of HepG2 by
∼50% (Fig. 4E). To assess whether these effects were depen-
dent on B7h expression, we evaluated the effect of ICOS-Fc and
F119SICOS-Fc on the HGF-induced cell scattering of BHT-101,
which was previously shown to express low levels of B7h (Fig. 1)
and to display no ICOS-Fc–induced migration inhibition (Fig. 2).
Because these cells showed modest elongation upon HGF treatment,
their scattering was quantified only by counting the percentage of
disaggregated single cells. The results showed that neither ICOS-Fc
nor F119SICOS-Fc inhibited BHT-101 cell scattering (Supplemental
Fig. 1).
B7h triggering has no effect on angiogenesis
To assess the effect of B7h triggering on angiogenesis, we eval-
uated the effect of ICOS-Fc via the endothelial tube-formation
assay and the spheroid sprouting assay. In the tube-formation
assay, HUVECs were seeded onto 24-well plates (5 3 104/well)
previously coated with 150 ml growth factor–reduced Matrigel in
the presence of ICOS-Fc (2–4 mg/ml) or control medium. The
morphology of capillary-like structures formed by HUVECs was
analyzed 15 h after culturing. The results showed that ICOS-Fc
did not significantly affect tube formation in HUVECs (data not
shown).
In the spheroid sprouting assay, ECs were coated onto Cytodex
microcarriers and embedded in a fibrin gel in the presence of
factor X to promote EC sprouting from the surface of the beads.
After 4–5 d, the newly formed vessels were treated or not treated
with ICOS-Fc (4 mg/ml); vessel morphology was analyzed 5 d
later. The results showed that ICOS-Fc did not significantly affect
vessel caliper or length (data not shown).
B7h triggering inhibits b-Pix expression and FAK
phosphorylation
To assess whether treatment with ICOS-Fc modulated the ex-
pression of adhesion molecules, we analyzed the surface expres-
sion of ICAM-1, ICAM-2, MadCAM, CD62P, CD31, CD44v6–7,
CD62E, Sialyl Lewis A, CD62L, VCAM-1, and Sialyl Lewis X
via immunofluorescence and flow cytometry in JR8, M14, and
HT-29 cells treated or untreated with ICOS-Fc for 30 min, 1, 4,
and 24 h. The results showed that ICOS-Fc did not modulate the
expression of any of these molecules (data not shown), which is in
accordance with previous data obtained for HUVECs and DCs
(11, 18).
In previous studies, we have shown that B7h triggering inhibits
the phosphorylation of p38 and ERK induced by either E-selectin
triggering or osteopontin in HUVECs (this occurred without af-
fecting their basal phosphorylation), whereas no effect was de-
tected in the tumor cell lines (11). Moreover, we showed that in
FIGURE 4. ICOS-Fc impairs HGF-induced cell scatter in HepG2 cells. (A) Cytofluorimetric analysis of the B7h expression in the HepG2 cells (per-
formed as in Fig. 1). The HepG2 cells were treated for 48 h in 10% FCS with or without HGF (50 ng/ml), ICOS-Fc (2 mg/ml), or F119SICOS-Fc (2 mg/ml).
(B) The cells were photographed via phase contrast (left panel) or stained with Alexa Fluor 546 Phalloidin and imaged via confocal microscopy (right
panel). Scale bar, 40 mm. (C) Whisker plot showing the cell length (excluding the outliers of a representative experiment). (D) Percentage of the dis-
aggregated single cells (mean 6 SEM of 4 experiments); at least 100 cells were counted for each point. (E) Effect of ICOS-Fc on the migration of HepG2
cells treated with HGF in the Boyden chamber assay (performed as in Fig. 2). *p , 0.05, **p , 0.01, ***p , 0.001.
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DCs, B7h inhibits the expression of the Rac-1 activator b-Pix,
which is involved in cell motility (18). Therefore, we evaluated the
effect of ICOS-Fc on the b-Pix expression in two B7hhigh cell
lines (PC-3, HUVECs) and two B7hlow cell lines (RPMI7932,
BHT-101), and extended the analysis to the phosphorylation of
FAK, involved in cell migration. The cells were either not treated
or were treated with ICOS-Fc or F119SICOS-Fc; b-Pix expression
and FAK phosphorylation were then assessed via Western blot
after 30 min. The results showed that ICOS-Fc substantially de-
creased b-Pix expression and FAK phosphorylation in the B7hhigh
cell lines (Fig. 5A, 5B), whereas no effect was detected in the
B7hlow cell lines (Fig. 5C, 5D). The treatment with F119SICOS-Fc
showed no effect for any cell line.
B7h triggering inhibits tumor cell metastasis in vivo
The effect of B7h triggering on the metastasis capability in vivo was
assessed by injecting NSG mice with CF-PAC1 Luc cells (human
pancreas carcinoma). A previous in vitro analysis showed that this
cell line expresses high levels of B7h (Fig. 6A) and that its treatment
with ICOS-Fc, but not with F119SICOS-Fc, inhibits migration in the
Boyden chamber assay (Fig. 6B), as well as b-Pix expression and
FAK phosphorylation (Fig. 6C); these findings are in accordance
with the data obtained for the other B7hhigh cell lines.
NSG mice were i.v. injected with 0.5 3 106 CF-PAC1 Luc cells
and then i.p. treated with both the human and the mouse ICOS-Fc
(n = 7) or PBS (n = 7) every day to trigger both the B7h expressed
by the human tumor cell line and that expressed by the mouse
vascular ECs; this treatment would mimic the putative effect of
the human ICOS-Fc injected in humans. Three days after cell
injection, the mice were i.p. injected with luciferin and analyzed
via in vivo optical imaging to evaluate the tumor cell growth in the
lung. Qualitative (Fig. 6D) and quantitative (Fig. 6E) analyses
showed that a significantly higher luminescent signal was present
in control mice than in those treated with ICOS-Fc. To determine
whether this effect was due to the human or mouse ICOS-Fc, we
repeated these experiments by treating the mice with either the
human ICOS-Fc alone (n = 3), the mouse ICOS-Fc alone (n = 3),
the human F119SICOS-Fc alone (n = 3), or PBS (n = 3). The
qualitative (Fig. 6F) and quantitative (Fig. 6G) analyses showed
that a significantly higher luminescent signal was present in the
control mice and those treated with F119SICOS-Fc than in mice
treated with either the human or mouse ICOS-Fc alone. In con-
trast, no significant differences were detected between the control
mice and those treated with F119SICOS-Fc.
To confirm these data, we assessed the ICOS-Fc effect on the
metastasis of B16-F10 cells (mouse melanoma) in C57BL/6 mice.
In a preliminary experiment, we separated the B7hhigh and B7hlow
B16-F10 cells using magnetic beads and found that these cell lines
maintained their phenotype for several weeks in culture. Moreover,
treatment with ICOS-Fc, but not with F119SICOS-Fc, inhibited mi-
gration in Boyden chamber assay, as well as b-Pix expression and
FAK phosphorylation in the B7hhigh cell line, whereas no effects
were detected in the B7hlow cell line (Supplementary Fig. 2).
The C57BL/6 mice were i.v. injected with 106 B7hhigh B16-F10
cells and then i.p. treated with either the mouse ICOS-Fc (n = 3),
human F119SICOS-Fc (n = 3), or PBS (n = 3) every day. The lung
metastases were analyzed either after 3 d (for the tissue sections
stained with H&E) or after 2 wk by counting the tumor nodules
FIGURE 5. Effect of ICOS-Fc on FAK phosphorylation and b-Pix expression in the B7hhigh (PC-3, HUVEC) and B7low (RPMI7932, BHT-101) cell
lines. The cell lines were treated with 4 mg/ml ICOS-Fc or F119SICOS-Fc for 30 min; p-FAK (A and C) and b-Pix (B and D) expression were then evaluated
via Western blot in the cell lysates. The same blots were also probed with anti-FAK or anti–b-actin Ab as a control. The bar graphs show the densitometric
analysis of the gels expressed in arbitrary units; data are expressed as the mean 6 SEM of the percentage of inhibition versus the control from three
independent experiments (**p , 0.01 versus the control).
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detectable on the lung surface. Both approaches showed that the
mice treated with the mouse ICOS-Fc displayed significantly
fewer metastases than those treated with either PBS or the human
F119SICOS-Fc (Fig. 7A, 7B). To determine whether the treatments
modulated the immune response, we obtained infiltrating cells
from the lungs, and we evaluated the mRNA levels of IL-17A and
RORc (marking Th17 cells), IL-10 and Foxp3 (marking regulatory
T cells [Tregs]), and IL-21 and Bcl6 (marking T follicular helper
cells) via real-time PCR (because ICOS has a key role in Th17,
Treg, and T follicular helper cell function) (3, 13–15). The results
showed that treatment with the mouse ICOS-Fc significantly in-
creased the expression of IL-17A and RORc, and decreased that of
IL-10 and Foxp3 compared with the levels detected in control
mice and those treated with the human F119SICOS-Fc (Fig. 7C). In
contrast, no differences were detected in the expression of Bcl6,
whereas IL-21 was always undetectable (data not shown). More-
over, ICOS-Fc did not modulate the expression of these molecules
in the control mice not injected with the B16-F10 cells; in these
mice, Foxp3 and Bcl6 were expressed at low levels, whereas IL-
17A, RORc, IL-10, and IL-21 were undetectable (data not shown).
To assess whether treatment with ICOS-Fc decreased b-Pix
expression and FAK phosphorylation in vivo, the C57BL/6 mice
were injected s.c. with 106 B7hhigh B16-F10 cells. When the tumor
diameter reached 4 mm, the mice received one intratumor injec-
tion of either the mouse ICOS-Fc, human F119SICOS-Fc, or the
same volume of PBS. After 30 min, the tumors were excised, and
b-Pix expression and FAK phosphorylation were assessed in the
tissue lysates via Western blot. The results showed that treatment
with ICOS-Fc, but not with F119SICOS-Fc, substantially decreased
the expression of b-Pix compared with that detected in the control
mice (Fig. 7D). The FAK expression was similar in all conditions,
and the phospho-FAK expression was always undetectable (data
not shown).
Discussion
Cancer progression involves a complex interplay between the tu-
mor and the microenvironment that results in sustained proliferative
signaling, resistance to cell death, as well as the promotion of an-
giogenesis, invasion, and metastasis (20–23). This work has shown
that ICOS binding to B7h influences several of these events by acting
on both ECs and tumor cells. These effects were specific; they were
not displayed by a mutated form of ICOS-Fc that was incapable of
binding B7h.
Themost striking effect was that on tumor cells: ICOS-Fc inhibited
EMT and migration in vitro, as well as metastasis in vivo. EMT is
a transdifferentiation program required for tissue morphogenesis
during the embryonic development; its induction is exploited by
cancer cells to acquire invasive and metastatic properties. Recent
FIGURE 6. Effects of B7h triggering on CF-PAC1 tumor cell metastasis in vivo. (A) Cytofluorimetric analysis of B7h expression in the CF-PAC1 Luc
cells (performed as in Fig. 1). (B) Effect of ICOS-Fc on the migration of the CF-PAC1 Luc cells in the Boyden chamber assay (performed as in Fig. 2). (C)
Effect of ICOS-Fc on the expression of p-FAK and b-Pix (performed as in Fig. 5). (D and E) Mice were injected i.v. with 0.53 106 CF-PAC1 Luc cells and
treated with the human ICOS-Fc plus mouse ICOS-Fc (n = 7) or PBS (control group, n = 7). (F and G) The mice injected with CF-PAC1 Luc were treated
with either the human ICOS-Fc (n = 3), mouse ICOS-Fc (n = 3), human F119SICOS-Fc (n = 3), or PBS (control group, n = 3). After 3 d, the mice were i.p.
injected with luciferin, and pulmonary metastases were macroscopically detectable and documented via in vivo optical imaging. The luminescent signal
was quantified as the average radiance (p/s/cm2/sr), which was measured in regions of interest drawn in the lungs. Data are expressed as the mean 6 SEM
and were obtained in two independent experiments (*p , 0.05, **p , 0.01).
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reports indicate that EMT is also involved in the emergence of cancer
stem cells and contributes to drug resistance (24). A classical inducer
of EMT is HGF (also known as scatter factor), which promotes an
“invasive growth” of epithelial cells that is characterized by the
disruption of intercellular contacts and the induction of cell motility,
survival, and proliferation (19, 25). Our experiments on HepG2 cells
show that ICOS-Fc effectively impairs their HGF-induced scattering
by preserving the epithelial morphology and strongly reducing the
HGF-induced migration. These findings suggest that ICOS-Fc could
also affect EMT in vivo and decrease the metastatic potential of
tumor cells.
To successfully metastasize (after the downregulation of cell-to-
cell junctions and the acquisition of a migratory phenotype), tumor
cells must invade the extracellular matrix and intravasate; they will
then disseminate and become sites of origin for future metastases.
Cell movement across the tissues plays a crucial role in several of
these steps. Thus, a major aim in modern cancer therapy strategies
is to counteract metastatic spreading by targeting the factors in-
volved in the migratory activity of tumor cells. This has been
mainly achieved using antagonists of the molecules involved in the
adhesion of these cells to the extracellular matrix (26), as well as
antagonists of proteases that facilitate cell migration by degrading
the extracellular matrix (27–29). Unfortunately, none of these
compounds has yet reached the market, primarily because of poor
in vivo antitumor activity, unsuitable therapeutic index, or the
rapid development of chemoresistance. This work suggests that
B7h may be a novel target for these therapies because ICOS-Fc
inhibits the migration of several tumor cell lines in vitro. This
effect is not ascribable to drug toxicity because the proliferation
and survival of tumor cells are not affected by ICOS-Fc. More-
over, this effect is specific; it is not detected in tumor cell lines
expressing low levels of B7h.
This underlines a potential pharmacological limitation of
ICOS-Fc, the efficacy of which is expected to be restricted to B7hhigh
tumors. It is intriguing that the migratory response to FCS
appeared to be weaker in the B7hlow than in the B7hhigh cell lines
and that the B7hlow B16-F10 cells displayed lower migratory ac-
tivity than their B7hhigh counterparts, which suggests that B7h may
play a direct role in cell migration. The antimetastatic effect of
ICOS-Fc is supported by our in vivo experiments showing that
treatment with ICOS-Fc inhibits the migration of both a human
(CF-PAC1 Luc) and a mouse (B16-F10) tumor cell line into the
lungs in mice. It is noteworthy that this effect was induced by both
the human and the mouse ICOS-Fc in the CF-PAC1 Luc human/
mouse model, which indicates that the effect was ascribable to the
triggering of both varieties of B7h on the tumor cells, as well as
the ECs. The human ICOS-Fc does not bind the mouse B7h, and the
mouse ICOS-Fc weakly binds the human B7h (data not shown).
These data strengthen those obtained from previous research
showing that ICOS-Fc inhibits tumor cell adhesion to ECs by acting
on both the tumor cells and the ECs (11). Moreover, in the B16-F10
model, treatment with ICOS-Fc increased the expression of IL-
17A and RORc, and decreased the expression of IL-10 and Foxp3;
this suggests that ICOS-Fc may also exert positive effects on the
antitumor immune response by increasing the Th17/Treg ratio.
This observation is in accordance with reports showing that the
triggering of B7h in immature mouse DCs induces partial matu-
ration with the prominent augmentation of IL-6 secretion (17), as
FIGURE 7. Effect of B7h triggering on B16-F10 cells in vivo. (A and B) Effect on metastasis in C57BL/6 mice injected in the tail vein with 106 B7hhigh
B16-F10 cells and treated daily with either the mouse ICOS-Fc (n = 3), human F119SICOS-Fc (n = 3), or the same volume of PBS (control group, n = 3). The
lung metastases were analyzed either after 3 d (on tissue sections stained with H&E) (A) or after 2 wk by counting the detectable tumor nodules on the lung
surface (B); (C) infiltrating cells from the 3-d experiment were harvested and used for the real-time PCR analysis of IL-17A, IL-10, RORc, and Foxp3
expression; the data are normalized for the expression in the control mice (control expression set at 100%). (D) Effect on b-Pix expression in s.c. tumors
treated with an intratumoral injection of either the mouse ICOS-Fc, human F119SICOS-Fc, or the same volume of PBS. The C57BL/6 mice were s.c. injected
with 106 B7hhigh B16-F10 cells, and the tumors were treated when they reached 4 mm in diameter. The b-Pix expression was evaluated via Western blot in
the lysates of the tumor tissue. The data are expressed as the mean 6 SEM and were obtained from three experiments (*p , 0.05, **p , 0.01).
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well as reports indicating that IL-6 supports the conversion of
Foxp3+CD4+ Tregs to Th17 cells (30). Moreover, we found that
B7h triggering in human DCs increases the secretion of IL-23
(which is involved in Th17 expansion and survival) and supports
Th17 cell activity (18). Finally, ICOS triggering in T cells (which
is blocked by ICOS-Fc) is involved in the differentiation of both
Tregs and Th17 cells (17, 31–33); however, its support of Treg
differentiation prevails in the tumor environment (34, 35).
The possibility that ICOS-Fc may also affect tumor angiogenesis
is suggested by the finding that it substantially inhibits the mi-
gration of vascular ECs. However, it does not inhibit EC prolif-
eration or angiogenesis, as determined via the tubulogenesis and
the sprouting assays, which indicates that the residual migratory
potential of ECs is sufficient for these in vitro assays. However, this
does not rule out the possibility that ICOS-Fc may be effective
in limiting conditions in vivo. The antiangiogenic potential of
ICOS-Fc is intriguing because the survival of the primary tumor
beyond a certain size requires neovascularization of the tumor
mass, and tumor-associated vessels represent a preferential path-
way for metastasization to distant sites. Thus, controlling tumor-
associated angiogenesis may limit cancer progression (21). How-
ever, clinical results from studies using individual antivascular
agents have been unsatisfactory and have required the combina-
torial use of conventional anticancer drugs and antivascular agents
(22). Therefore, novel antivascular agents targeting B7h would be
welcome in antitumor therapy.
In previous works, we demonstrated that B7h triggering inhibits
the activation of the ERK and p38 axis induced in ECs via various
proadhesive stimuli. This leads to cytoskeleton modifications with
the disruption of the VE-cadherin/b-catenin complex and the for-
mation of stress fibers involved in increasing the endothelial per-
meability and enabling the transendothelial migration of cancer cells
(11). However, this is not a general effect because it was not detected
in tumor cell lines (11) or DCs (18). In contrast, in DCs (18), ECs,
and tumor cells (Fig. 6), ICOS-Fc downregulates the expression
of b-Pix, which is a Rac-1 activator that is recruited by activated
integrins and is required for rapid nascent adhesion turnover.
Intriguingly, the downregulation of b-Pix expression is known to
prevent cell spreading and lamellipodial formation, and to increase
Rac1 activity (36, 37). Moreover, in ECs and tumor cells, B7h
triggering inhibits the phosphorylation of FAK, which is a key
mediator of signaling through integrins. The overexpression and
activation of FAK have been found in a variety of human cancers
and have been involved in cancer migration, invasion, EMT, and
angiogenesis (38). FAK signaling has also been shown to promote
angiogenesis in both embryonic development and tumor angio-
genesis, and the increased phosphorylation and activation of FAK
have been correlated with increased EC migration into wounded
monolayers (39). The signaling pathways activated by B7h are
presently unknown. In DCs, the engagement of B7.1 or B7.2 with
CTLA4-Ig leads to the STAT-1–mediated production of IDO and
decreased tryptophan levels (40, 41); however, it is unclear whether
a similar signaling pathway is also activated by B7h.
Upon extrapolating these data to physiological conditions, it may
be suggested that the physiological role of B7h-mediated signal-
ing is based on its effect on invasion, which is involved not only in
tumor progression (42), but also in tissue remodeling during
embryonic development, wound healing, angiogenesis, and im-
mune responses. In accordance with this possibility, the repair of
excisional wounds was dramatically delayed in mice deficient in
either ICOS or B7h; these mice showed decreased keratinocyte
migration, angiogenesis, granulation tissue formation, and dimin-
ished infiltration of T cells, macrophages, and neutrophils (43). One
possibility is that B7h+ cells, which are recruited from the blood
and the surrounding tissues for tissue defense and repair, are
arrested in the injured tissue via B7h interacting with the ICOS
that is expressed by the infiltrating T cells. Therefore, a defective
B7h–ICOS interaction may eventually affect the accumulation of
infiltrating cells in the injured tissue.
In conclusion, our data indicate that ICOS-Fcmay be an effective
antimetastasis drug acting on ECs and tumor cells both in vitro and
in vivo. Therefore, ICOS-Fc (which affects cancer cell migration
without severe toxic effects) may be a sound tool in cancer therapy
that acts on several aspects of tumor progression.
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FIGURE S1: ICOS-Fc does not affect HGF induced cells scatter in BHT-101.Cells were treated for 
24 h with or without HGF (50 ng/ml), ICOS-Fc (2 µg/ml) or F119SICOS-Fc (2 µg/ml). (A) Cells were 
photographed by phase contrast (left panel) or stained with Phalloidin-Alexa-Fluor 546 (red) / TO-
PRO 3 (blue) (right panel) and imaged by confocal microscopy. Scale bar 40 µm. (B) Percentage of 
disaggregated single cells (mean±SEM of 4 experiments); at least 100 cells were counted for each 
point (* P< 0.01 ). 
FIGURE S2: Effect of ICOS-Fc on B7hhigh and B7hlow B16-F10 cells in vitro. (A, D) 
Cytofluorimetric analysis of B7h expression performed as in Fig. 1. (B, E) Effect of ICOS-Fc on 
cell migration in the Boyden chamber assay performed as in Fig. 2. (C, F ) Effect of  ICOS-Fc on 
FAK phosphorylation (left panel) and β-Pix expression (right panel) performed as in Fig. 5. Data 
are expressed as mean±SEM from 3 independent experiments (** P<0.01, * P<0.05 versus the 
control). 
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